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ABSTRACT 
Diabetes mellitus (DM) imparts vascular and metabolic stressors that cause 
damage and dysfunction to the human nervous system. The disorder associated with this 
dysfunction is termed diabetic polyneuropathy (DPN). Although DPN has been 
associated with muscle weakness and atrophy, the extent of its impacts on the 
neuromuscular system is not well understood. The five studies presented in my thesis 
investigated how DPN affects the neuromuscular system in humans, from the motor 
neuron to skeletal muscle contractile properties, using a combination of 
electromyography (EMG), dynamometry and magnetic resonance imaging (MRI) 
techniques.  
The purpose of Studies 1 and 2 was to determine whether the neurogenic loss of 
motor units underlies the muscle weakness and atrophy associated with DPN, and to 
investigate how these changes may differ in an upper and lower limb muscle. I 
determined DPN patients feature reduced motor unit estimates (MUNEs) compared to 
controls, and progression of motor unit loss in DPN may follow a distal to proximal or 
nerve length-dependent pattern. 
The purpose of Study 3 was to assess the stability of neuromuscular transmission 
in patients with DPN compared with healthy controls, using a novel set of 
electrodiagnostic parameters obtained via quantitative EMG. I determined DPN patients 
have less stable neuromuscular transmission, and they feature intermittent conduction 
failure at a relatively low contraction intensity. 
The purpose of Study 4 was to investigate skeletal muscle contractile properties 
and morphology in DPN patients. I determined DPN patients possess slowed muscle, 
with greater proportional amounts of non-contractile intramuscular tissue compared to 
controls. 
The purpose of Study 5 was to explore the fatigability of DPN patients during a 
sustained maximal voluntary contraction (MVC). I determined DPN patients have less 
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endurance than controls, and their increased fatigability may be associated with 
neuromuscular transmission failure. 
 
Overall these foundational explorations greatly expand our knowledge of how 
DPN can impact the neuromuscular system in humans. Furthermore, the studies 
contained within my thesis may help direct further useful studies and strategies to 
understand, and direct clinical support in those with DPN. 
 
 
 
KEYWORDS 
Diabetic polyneuropathy (DPN); human; motor nervous system; muscle; weakness; 
motor unit; electromyography (EMG); fatigue; magnetic resonance imaging (MRI); 
dynamometry 
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Chapter 1  
1 General Introduction 
 
Voluntary movement is a fundamental attribute expressed by nearly all forms of 
animal life. In humans, similar to many animals, this voluntary movement is 
accomplished via activation and control of the neuromuscular system. Thus, given the 
understandable reverence humanity places on movement, it comes as no surprise that 
humans have been fascinated by the study of neuromuscular physiology for millennia. 
With utmost brevity, this fascination manifests within the ancient writings of Hippocrates 
and Galen; the musings of da Vinci and Vesalius during the European Renaissance; and 
through the seminal discoveries of Galvani
1
, Duchenne
2
, Adrian & Bronk
3,4
, Denny-
Brown
5
, Sherrington
6
, Henneman
7
 and others during the 18
th
, 19
th
 and 20
th
 centuries. In 
spite of the immense growth of our understanding, complete discernment of many 
workings within neuromuscular physiology remain elusive. Particular among these 
mysteries are questions concerning the impacts of disease on muscle and nerve. Deeper 
understanding of the impacts of these diseases may eventually lead to improved 
diagnostic methods and enhanced treatment options, as well as models of nature’s 
experiments to help understand basic physiology. Hence it has been observed, 
“Physiology is the stepchild of medicine. That is why Cinderella often turns out the 
queen.” (Martin H. Fischer) 
 
1.1 The Human Neuromuscular System and the Motor Unit  
The primary function of the neuromuscular system is to provide humans with the 
means for movement and locomotion. In parsimonious terms, the system is comprised of 
(1) α motor neurons which innervate, and thus control, (2) skeletal muscle fibres. Motor 
neurons are responsible for relaying signals, in the form of action potentials, from the 
central nervous system (i.e. the brain and spinal cord) to skeletal muscle which initiates 
2 
 
 
 
contraction. Muscle fibres are then responsible for contracting via the actomyosin 
complex, thus generating the force necessary for movement.  
Each individual α motor neuron and the muscle fibres that it innervates form the motor 
unit (Figure 1.1): the fundamental functional contractile unit in neuromuscular 
physiology
6
. The size of motor units varies greatly from unit to unit, and muscle to 
muscle, from dozens of muscle fibres per unit (e.g. external rectus) to thousands of 
muscle fibres per unit (e.g. medial gastrocnemius)
8
. The motor unit composition of a 
muscle is thought generally to reflect that muscle’s function9. For example muscles 
involved with fine, complex movements (i.e. hand muscles) are usually comprised of 
many, relatively smaller motor units. In contrast, muscles involved with gross limb 
movement (i.e. the knee extensors) usually consist of relatively fewer, larger motor 
units
8
. 
 
 
Figure 1.1 The motor unit.  
Two individual motor units are depicted. The α-motor neuron cell bodies are located in 
the ventral horn of the spinal cord. Neuron axons exit the ventral horn into the periphery 
and synapse with their respective muscle fibres. Each motor unit is composed of an 
individual α-motor neuron and all of the muscles fibres it innervates6. 
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Under most conditions, when contracting voluntarily, smaller motor units tend to 
be recruited prior to larger motor units, a concept coined the Henneman size 
principle
7,10,11
. The general result of this principle is that relatively smaller, weaker, 
slower, fatigue resistant muscle fibres are recruited first before larger, stronger, faster, 
less fatigue-resistant muscle fibres. This forms one important aspect of the orderly 
recruitment of muscle and is occasionally referred to as spatial summation
3,4,12,13
. In 
contrast, temporal summation refers to the modulation of motor unit firing rate whereby 
muscle force output is changed by increasing or decreasing the frequency at which motor 
neurons signal muscle to contract
3,4
. These two processes work concurrently and in 
concert with one another to allow for a high degree of smooth and graded control in 
muscle force generation in conjunction with motor drive and coordination from spinal 
and supraspinal levels.  
Of course, the neuromuscular system features far greater complexity than is 
outlined above and many questions remain unresolved. Investigating pathophysiological 
alterations to nerve and muscle due to aging or disease (e.g. diabetic neuropathy) can 
provide useful and unique avenues for further insight into basic neuromuscular 
physiology and the capacities and limitations of the system. 
 
1.2 Type 2 Diabetes and Diabetic Neuropathy 
Type 2 diabetes mellitus (DM) is a metabolic disorder marked by high blood 
sugar (hyperglycemia) associated with insulin resistance or a relative dearth of insulin
14
. 
In comparison, type 1 DM is an autoimmune mediated disorder leading to a total loss of 
insulin production due to the destruction of insulin-producing beta cells within the 
pancreas
14,15
. Type 2 DM accounts for approximately 90% of all cases of DM, and is 
closely associated with obesity, sedentarianism, and poor dietary habits
16
. Given its 
greater prevalence and burden upon society, the study of type 2 DM and its neuropathic 
complications will form the focus of this thesis. Thus, throughout this dissertation 
hereafter, “DM” shall refer to type 2 DM specifically, unless otherwise noted. 
Approximately 6% of the world’s adult population is living with DM16 and it is 
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recognized as a global health epidemic by the World Health Organization. Additionally, 
DM is closely associated with many complications including vascular disease, 
retinopathy, nephropathy, and of direct relevance to this dissertation, peripheral 
neuropathy
16,17
.   
Diabetic polyneuropathy (DPN) generally refers to nerve dysfunction as a 
complication of DM. It is estimated that 50% of patients with DM will develop DPN at 
some point in their lives
18
. In its broadest context, DPN can refer to any of a group of 
neuropathic conditions with relatively heterogeneous patterns of neurological 
involvement. However, two major subgroups of DPN have been proposed: typical DPN 
and atypical DPN
19
. Atypical DPNs are rarer and can feature acute, sub-acute or chronic 
onset of symptoms, with a monophasic or fluctuating course. Additionally, atypical DPNs 
often feature burning pain and hyperalgesia to touch, along with minimal sensory loss 
and motor dysfunction. In contrast, typical DPN is described as a chronic, symmetrical, 
length-dependent sensorimotor polyneuropathy
19,20
. Typical DPN features sensory (i.e. 
numbness and paresthesia) and motor (i.e. atrophy and weakness) dysfunction 
progressing in a length-dependent manner
19,20. “Length-dependent” refers to the length of 
sensory and motor neuron axons, meaning symptoms (i.e. numbness and weakness) 
typically manifest first in the feet, progressively moving into the legs and hands; with 
continued advancement in a distal to proximal pattern
19,21
. Epidemiological studies report 
typical DPN is the most common form of DPN, as its name indicates
19
. Throughout this 
dissertation, the term DPN shall refer to the typical, sensorimotor form of the disease.  
 
1.3 Pathophysiology of DPN 
 The precise mechanisms underlying the development of DPN are not entirely 
clear
21
. However, DPN is likely caused by diabetes-related metabolic or vascular 
disturbances that are not mutually exclusive, and may be interrelated or synergistic
21
. 
These mechanisms, briefly outlined below, lead to axonal loss via a dying-back, or 
retrograde degradation, as well as peripheral nerve demyelination
21
. 
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Vascular disease is a known complication associated with DM
22
. Indeed 
microangiopathy has been shown to develop early in DPN, and these abnormalities may 
directly relate to subsequent nerve dysfunction. More specifically, microangiopathy 
within the vasa nervorum (which provide the blood supply to peripheral nerves) may 
cause nerve dysfunction as a result of ischemic damage. Vasodilation is limited in DM 
due to disrupted nitric oxide signaling in blood vessels
23
. Additionally, DM is associated 
with increases in blood viscosity
24
, impaired oxygen release from blood to tissue
25
, and 
dysfunctional structural alterations of red blood cells
26
. Thus these combined changes 
may contribute to chronic hypoxia and ischemia resulting in nerve damage
21
. However, 
whether microangiopathy and the resultant hypoxia are the primary causes of DPN is the 
subject of debate. Whereas some studies have found decreases in nerve blood blow 
associated with DPN, others have actually found increases
27
 or no changes in nerve blood 
flow
28
, despite the clear development of impaired nerve function (see 
21
 for review). The 
reasons for these disparate findings may be related to technical differences in the way 
blood flow was measured, as well as key differences in the experimental model or 
population studied
21
.  
The other postulated mechanisms underlying DPN are related to a variety of 
metabolic and cellular signaling abnormalities that are consequences of DM and chronic 
hyperglycemia (see Figure 1.2). Peripheral nerves are especially vulnerable to 
hyperglycemic-mediated damage due to their reliance on GLUT-1 and -3 glucose 
transporters
29,30,31,32
. GLUT-1 and -3 transporters are insulin-independent and are 
dependent on extracellular blood glucose concentrations. Therefore, under diabetic 
conditions (i.e. hyperglycemia and insulin resistance) relatively large quantities of 
glucose will be transported into neural tissue. When intraneural glucose concentrations 
become too high, several pathways may become active leading to neural dysfunction or 
cell death. These cellular processes that may result in damage include: (1) increased 
reactive oxidative species (ROS) formation as a result of reverse mitochondrial electron 
flow due to excess NAD and FADH accumulation
33
; (2) excess sorbitol production 
leading to cellular osmotic stress
34
; (3) increased hexosamine pathway activation causing 
a chronic inflammatory response
35
. Additionally, the hyperglycemia-related increase in 
advanced glycated end-products (AGEs), caused by the reaction of glucose with various 
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fats and proteins, may impose an inflammatory-mediated stressor on neurons 
36
. Nerve 
cell stress in DM may also occur due to the dyslipidemia, for example through oxidized 
low density lipoproteins (oxyLDLs) or toxic (i.e. high) concentrations of intracellular fats 
which may act through mitochondrial-induced cell death or inappropriate lysosome 
activation, respectively
37,38
. Finally, impairments in nerve cell interaction with various 
neurotrophic and growth factors may play a role in the development of neuropathy and 
impaired regeneration. Deficiencies in insulin, insulin-like growth factor (IGF), brain 
derived growth factor (BDNF), and neurotrophin 3 and 4 (NT3, NT 4) signaling as a 
result of diabetes may play a role in the development and progression of DPN
39
. The 
aforementioned postulated mechanisms underlying DPN form a limited list and brief 
description that suit the purposes of this dissertation; more comprehensive discussions of 
this subject matter can be found elsewhere
21,40
.  
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Figure 1.2 Metabolic mechanisms of nerve damage in diabetic neuropathy  
Chronic hyperglycemia and hyperlipidemia in diabetes mellitus may activate multiple 
damaging mechanisms in neurons. Note: vascular causes potentially underlying diabetic 
neuropathy are not shown. Abbreviations: AGE, advanced glycation end product; GLUT, 
glucose transporter; LDL, low density lipoprotein; LDLR, LDL receptor; LOX1, 
oxidized LDL receptor 1; oxLDL, oxidized LDL; RAGE, receptor for advanced glycation 
end products. Adapted from: Vincent et al 2011
40
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1.4 Clinical Manifestations of DPN 
Confirmed clinical DPN is defined as: “an abnormal nerve conduction study and a 
symptom or symptoms or a sign or signs of sensorimotor polyneuropathy” that can be 
attributed to DM and no other cause of polyneuropathy
19,21
. Some of these signs, 
symptoms and abnormal nerve conduction studies are described briefly below, and 
reviewed elsewhere
21
. 
Patients with DPN typically present with sensory abnormalities, including 
numbness, paresthesia, hyperalgesia, or allodynia
19
. These symptoms usually first appear 
in the feet and may advance into the legs, hands and even more proximally over time and 
with increasing disease severity
19,41
. The distribution of sensory symptoms is sometimes 
referred to as “stocking and glove”, which reflects the length-dependent progression of 
the disease. In clinic, these sensory abnormalities are often assessed through physical 
neurological examination, quantitative sensory testing (QST), and Semmes-Weinstein 
monofilaments
19
. 
 Additionally DPN patients often present with dysfunction of the motor nervous, 
or neuromuscular system
42,43
. The earliest of these signs is usually atrophy of the extensor 
digitorum brevis (EDB) muscle in the foot; which may be followed by wasting and 
weakness of the ankle dorsiflexors
44,45
. This muscle weakness may lead to altered gait 
and foot posture, as well as other neuromuscular consequences outlined in greater detail 
in the next section of this dissertation
44
. Finally, DPN patients may also display a loss of 
reflexes at the ankle or knee
17
; foot ulceration
46
; and dysfunction of the autonomic 
nervous system, including distal anhidrosis, constipation, impotence, orthostatic 
intolerance, among other symptoms
47
. 
 Electrophysiological testing is an integral aspect of any clinical assessment of 
suspected DPN, and is considered to be the gold standard in DPN evaluation
19,21,48
. These 
measures, namely nerve conduction studies, have been shown to be clinically reliable and 
sensitive to the neurological changes associated with DPN. The elicitation of a sural 
nerve sensory nerve action potential (SNAP) that has a reduced amplitude (<6 µV) or is 
absent when recording from the posterior aspect of the ankle has proven to be the earliest 
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electrophysiological sign of DPN
51
. A prolonged peak sural nerve sensory nerve 
conduction latency (>4.9 ms) is another potential electrophysiological sign of DPN
49
. In 
more severe cases of DPN, abnormalities in fibular nerve motor nerve conduction 
velocities (MNCV; <40 m/s) or reduced compound muscle action potential (CMAP) 
amplitudes from the anterolateral compartment of the leg (i.e. tibialis anterior; <4.0 mV) 
are signs of detectable motor involvement
49
. In addition, other electromyographic-related 
measures have been used to evaluate nerve dysfunction in DPN such as motor unit 
number estimates (MUNE)
50
 and neuromuscular transmission stability (i.e. jitter)
51
 which 
will be discussed in further detail in this dissertation (Sections 1.5 and 1.9). Aside from 
their clinical relevance the aforementioned electrophysiological measures listed 
previously can provide detailed information regarding the status of the sensory and motor 
nervous systems in a minimally invasive manner which can prove invaluable in the 
context of scientific, physiological investigations.  
  
1.5 Neuromuscular Consequences of DPN 
 Although early and mild cases of DPN predominantly feature abnormalities of the 
sensory nervous system, it is clear stressors associated with DM may target motor 
neurons
42
 and thus DPN can be associated with substantial dysfunction of the 
neuromuscular system (see 
43
 for a brief review).  
DPN-related neuromuscular dysfunction may manifest in altered motor neuron 
properties including reduced firing rates
52
, increased firing rate variability
52
 and motor 
neuron excitability changes
53
. Additionally, animal studies have shown DPN can result in 
changes at the muscle-level including disrupted t-tubules
54
, dysfunctional ion pumps and 
channels
54–57
, and degenerated mitochondria
33,54
. However, perhaps the most obvious 
neuromuscular consequence of DPN is skeletal muscle atrophy and resultant 
weakness
45,58,59
. Loss of isometric strength in the ankle dorsi- and plantar flexors, as well 
as knee extensors has been previously reported in DPN patients
58,60,61
. A primary 
mechanism underlying this strength loss is muscle atrophy
62
. For example, as mentioned 
in the previous section, atrophy of EDB is a sensitive and early indicator of DPN
63
. 
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Additionally, magnetic resonance imaging (MRI) has been used to show substantial 
muscular atrophy in leg muscles of DPN patients, along with increased fatty infiltration 
of muscle
64
. The same study also reported decreased: plantar flexion strength; isokinetic 
power; as well as decreased strength or power per unit of muscle volume (i.e. decreased 
muscle quality)
64
. It remains unknown if the loss of power production is due to strength 
loss alone, or if a concomitant loss of muscle contractile velocity also occurs. The DPN-
related decrease in muscle quality could be due to increases in antagonist co-activation, 
reductions in myocellular contractile protein expression, disruption in Ca2+ handling, or 
intermittent neuromuscular transmission failure. 
It is not clear how DPN may affect neuromuscular fatigability. A previous study 
investigating type 1 DM found patients actually have greater relative muscular endurance 
versus healthy controls
61
. However, the majority of patients included in that previous 
study did not feature substantial motor involvement in their neuropathy and no measures 
of voluntary activation were made. In contrast, studies reporting on clinical populations 
other than DPN that involve dysfunction of physiological systems in common with DM 
and DPN have found increases in fatiguability. For example, it has been shown 
previously that individuals with metabolic disease without neuropathy (e.g. type 1 DM)
65
, 
vascular disease (e.g. chronic heart failure)
66
, or nerve disease (e.g. amyotrophic lateral 
sclerosis [ALS])
67
, fatigue more quickly than controls. Thus it remains to be determined 
how neuromuscular fatigue is impacted by DPN. 
 The neuromuscular consequences described previously can have major impacts, 
which are perhaps magnified by deficits in the sensory nervous system, in relation to 
functional status and quality of life. Weakness of the dorsi- and plantar flexors is 
associated with gait abnormalities and increases in fall risk
44,68
. Gait abnormalities can 
lead to damaged, malfunctioning ankle joints, as well as the development of ulcers
46,60
, 
which are closely associated with lower-limb amputation
69
. Increased fall risk in DPN 
patients is an especially important concern as patients with DM are at greater risk of 
injurious falls (e.g. hip fractures) compared to healthy controls
70
. Finally, these functional 
decrements may limit the patient’s ability to actively participate in exercise-based 
rehabilitation programs, which are an effective avenue to maintain glycemic control and 
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reduce DM-related disease severity
71
. Since neuromuscular consequences of DPN can 
lead to such unfortunate declines in functional ability and quality of life, their study is 
important and may lead to enhanced strategies of compensation.  
 
1.6 Motor unit number estimations (MUNE) in humans 
In humans, the loss of motor units has been acknowledged as a key physiological 
process underlying various neuromuscular diseases
72
 as well as contributing to functional 
declines of the NM system associated with natural adult aging
73
. Therefore developing 
methodologies for quantifying the number of functional motor units in a muscle in vivo 
has been of great interest in clinical neurophysiology. Standard electrophysiological 
measures such as motor nerve conduction studies (MNCS) and needle electromyography 
(EMG) serve as qualitative proxy measures of motor unit numbers; however they are not 
sensitive to mild degrees of motor unit loss, particularly following successful collateral 
reinnervation that may occur in some diseases and presumed to occur as part of adult 
aging
72,74
. 
The concept of the motor unit number estimate (MUNE) was developed to help 
address the limitations associated with standard clinical electrophysiological techniques 
in quantifying motor unit populations within a muscle. Due largely to improvements in 
computer processing capabilities, MUNE techniques have been greatly improved since 
their original inception in the 1970s
72,74
. Although MUNE actually refers to several 
different specific electrophysiological methodologies, each MUNE technique is 
conceptually similar in that it is based upon the ratio between the maximal compound 
muscle action potential (CMAP) divided by the mean surface motor unit potential 
(SMUP). The CMAP is representative of the maximal electrophysiological size of the 
entire motor unit pool within a muscle, and the mean SMUP is representative of the size 
of the average single constitutive motor unit. The primary difference between each 
MUNE technique is how the mean SMUP is derived.  
Since 1971 when MUNE was first reported
75
, different techniques have been 
developed. Each methodology features various strengths and limitations, and at present 
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no single MUNE technique is accepted as the ‘gold standard’72,74. Indeed, no gold 
standard exists even pertaining to the physical counting of motor units or motor axons 
due to technical limitations in histochemistry. Some common electrophysiological 
MUNE techniques include: (1) incremental stimulation, (2) multiple point stimulation, 
(3) statistical, (4) motor unit number index (MUNIX) and (5) spike triggered averaging 
(STA) with EMG decomposition. These techniques possess various inherent advantages 
and limitations which have been previously reviewed in the literature
72,74
 and, aside from 
the STA with EMG decomposition technique, will not be discussed within the confines of 
this thesis.  
 
1.7 Spike triggered averaging (STA) and STA with decomposition-based 
quantitative electromyography (DQEMG) MUNE 
 Spike triggered averaging (STA) MUNE combines simultaneous collection of 
needle and surface EMG in a given muscle during voluntary contractions
76
. During a 
low-level voluntary contraction, the EMG operator positions the needle electrode so that 
only the single motor unit of interest is being recorded. This needle-detected motor unit 
potential (MUP) is then used as a trigger to time lock the response from the same motor 
unit being recorded at the surface electrode. This process is repeated until sufficient 
(approximately 20) single surface motor unit potentials (SMUP) have been recorded to 
provide a representative mean
76
. The mean SMUP is then divided into the maximal 
CMAP to provide a MUNE, similar to other techniques. This technique has been 
improved upon with the inclusion of EMG decomposition software which allows for 
decomposition-enhanced STA (DE-STA). DE-STA MUNE is based upon the same 
premise as traditional STA MUNE, however it is much more efficient and allows the 
investigator to sample from a wider range of the motor unit recruitment profile of a 
muscle
77–79
. This means DE-STA can record motor units that are recruited at higher 
intensities compared to traditional STA, which is generally limited to recording low-
threshold motor units. Thus DE-STA may provide a more representative sample of motor 
unit size compared to STA without decomposition. DE-STA involves the application of 
decomposition algorithms to the EMG interference pattern, allowing the software to 
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decompose the signal into its individual, constituent MUP trains (MUPTs)
77
. This allows 
a greater number of individual motor units to be sampled simultaneously, during higher 
intensity contractions. Another advantage of this MUNE technique is that it allows for the 
collection of needle EMG data that may provide other useful information regarding the 
physiological status of the neuromuscular system including: motor unit firing rates, 
neuromuscular transmission stability (i.e. jitter and jiggle), and transmission failure (via 
% blocking). A common software used to perform DE-STA is decomposition based 
quantitative EMG (DQEMG)
77,79,80
, which will be described in greater detail in a 
subsequent section (Section 1.9). 
 
1.8 Clinical usage of MUNE 
 The MUNE methods previously outlined have been applied in various clinical 
models of human neurological or neuromuscular disease. ALS has been a frequent target 
for the application of MUNEs given this disease involves directly large and rapid loss of 
motor neurons
81,82,83
. In the United States, the Food and Drug Administration (FDA) has 
not yet accepted MUNE as a primary endpoint measure in  ALS clinical trials because the 
clinical meaning of MUNE has not been sufficiently established
84
. However, MUNE 
results in ALS clinical trials have been corroborated by other standard clinical 
measures
82
. Moreover, in ALS, MUNE has proven to be more sensitive than strength 
testing in predicting the onset of ALS-associated symptoms
85
. Beyond ALS, MUNE has 
been used to detect motor unit losses in spinal muscle atrophy
86
, Charcot Marie Tooth 
neuropathy
87
, stroke-related hemiparetic muscle
88
 and, most relevant to this dissertation, 
diabetic polyneuropathy
50
. Additionally, MUNE techniques have been used multiple 
times in the literature to examine how the neuromuscular system changes with adult 
aging
73,89,90
. 
 The lone previous study using MUNE more than 35 years ago in human diabetic 
neuropathy found significantly fewer motor units in DPN patients compared with age-
matched controls in the extensor digitorum brevis (EDB) muscle
50
. EDB was likely 
selected for study due to its known involvement in DPN, especially given the length-
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dependent progression of the disease. MUNE results in DPN patients were positively 
correlated with a decrease in motor nerve conduction velocities, a standard measure of 
neuromuscular dysfunction associated with DPN. Additionally, Hansen and Ballantyne
50
 
reported MUNEs were negatively related to: age, duration of diabetes and MUP size. 
This study helped establish the potential clinical utility of MUNE in examining patients 
with DPN, and was the first to electrophysiologically show DPN was related to a loss of 
motor units. However, studying EDB in the context of MUNEs and DPN has important 
limitations. The functional status (e.g. strength) of EDB is difficult to assess; moreover 
EDB has relatively limited functional importance in day-to-day activities of living 
compared to other limb muscles. Additionally, when examining EDB it may be difficult 
to definitely attribute motor unit loss to the neuronal impacts of diabetes per se, or 
mechanical damage induced via altered gait and sensory and proprioception dysfunctions. 
Furthermore, in DPN, it remains unclear how data acquired via MUNE may integrate 
with other complementary measures (i.e. muscle strength, muscle morphology) in 
providing comprehensive information regarding the impacts of DPN on the 
neuromuscular system in humans. 
 
1.9 Decomposition-based quantitative electromyography (DQEMG) 
Quantitative assessment of motor unit action potentials (MUAPs) from individual 
motor units can provide useful and interesting information for the physiological appraisal 
of the neuromuscular system. One method that is used to accomplish this assessment is 
through using the computer software decomposition-based quantitative EMG 
(DQEMG)
78,91,92
. DQEMG software combines intramuscular EMG and surface EMG 
with a series of algorithms that can decompose a complex EMG pattern into its 
individual, constituent motor unit action potential trains (MUAPTs)
77,78
. Subsequently, 
DQEMG software provides more detailed information for each MUAPT including: firing 
rate, firing rate variability, size, shape, and stability. Additionally, DQEMG can be used 
to derive a MUNE via the DE-STA method, as described previously (Section 1.7)
78,79,93
. 
Further details regarding DQEMG are subsequently presented. 
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DQEMG typically involves the collection of both micro and macro signals
92
. 
Micro signals are derived via intramuscular, needle EMG electrodes which provide 
selective, detailed spatial and temporal information regarding individual motor units. 
Macro signals are usually collected via surface electrodes which provide information 
regarding overall size and spatial distribution of single motor units. Needle EMG data can 
be acquired via concentric, monopolar or single fibre needle electrodes during sustained, 
isometric voluntary contractions, typically of 30 seconds in duration. For the purposes of 
this brief description, discussion will be limited to data acquired via concentric needle 
electrode, although the general principles for each needle-type are the same.  
The aforementioned micro signal, collected during low to moderate level muscle 
contractions, originally consists of a complex EMG interference pattern from multiple 
motor units. This EMG pattern is decomposed into its constituent individual MUAPTs 
using a series of algorithms which classify and cluster individual MUAPs based on 
MUAP shape, firing rate, and firing rate variability. The macro (surface EMG) signal is 
analyzed in temporal alignment with the decomposed micro signal. This is performed by 
using each individual MUAP as a trigger which locks to a 100 ms epoch of the macro 
signal. This method allows for the derivation of surface motor unit potentials (SMUPs), 
which correspond to the relative size of individual motor units within a muscle, and are 
used to calculate a MUNE as described previously (Section 1.6). MUNEs calculated 
using DQEMG software have been reported with high degrees of intra- and inter-rater 
reliability
79,94
. It is noteworthy that contraction intensity has been shown to have a 
marked effect on DQEMG-derived MUNEs
93,95
. Studies performed in the first dorsal 
interosseous (FDI)
93
 and tibialis anterior (TA)
73
 have found with increasing contraction 
intensities, from 10%-50% MVC, mean SMUPs increase resulting in decreased MUNEs. 
McNeil et al (2005) concluded, in the TA, a contraction intensity of 25% MVC includes 
recruitment of the majority of low- and high-threshold motor units, and thus provides the 
most representative MUNE compared to other contraction intensities
73
.  
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1.10 Analysis of individual motor unit action potential trains (MUAPTs) 
In addition to providing CMAPs, SMUPs and MUNEs, DQEMG can provide 
detailed information regarding the temporal, spatial and morphological characteristics of 
individual needle-detected MUPs
78,92
. Some of these parameters include: MU firing rates, 
MU firing rate variability, MUP size (amplitude, area), MUP shape and complexity 
(turns, phases), MUP density (fibre count) and MUP stability (jitter, jiggle, % blocking). 
Increases in MUP size and complexity are electrophysiological signs of enlarged, 
collaterally reinnervated motor units, which are associated with various disease 
processes
96
 as well as adult aging
76,97,98
. These parameters are commonly included in a 
clinical, intramuscular needle EMG assessment. With major involvement of the 
neuromuscular system in DPN, abnormal findings indicative of skeletal muscle 
denervation have been reported
50,51,99
.  
MUP stability refers to the integrity of neuromuscular transmission, which can be 
examined in detail through the assessment of the degree of variability in the shape of 
consecutively detected MUPs
100
. The two key properties related to MUP shape variability 
are termed jitter and jiggle
100,101
. Jitter refers to the variability of the time intervals 
between pairs of individual muscle fibre potentials from a single MUP, and jiggle refers 
to the variability in overall MUP shape from one MUP discharge to the next (see Figure 
4.1). Increases in both jitter and jiggle have been reported under conditions of 
neuromuscular transmission disturbance and can reflect early axonal denervation
51,102,103
. 
Specific to DPN, a previous study using single fibre electromyography (SFEMG) found 
increased jitter in the tibialis anterior (TA) of patients with DPN, however jiggle was not 
reported
51
. Additionally, increased fibre density (fibre count) in patients with DPN 
compared to controls was observed, which is indicative of reinnervation similar to the 
interpretation of enlarged, more complicated MUPs
51
.  
A limitation associated with traditional MUP morphological parameters (e.g. size, 
complexity) as well as traditional jitter and jiggle, is they can be difficult to assess at 
voluntary contraction levels greater than very light (approximately 5-10% of MVC). This 
is due to increases in EMG signal intensity and complexity that may lead to 
electrophysiological contamination of single MUPT analysis. Thus most clinical needle 
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EMG studies are performed at minimal contraction intensities, often using SFEMG. This 
constrains most clinical needle EMG assessments to relatively few and exclusively low 
threshold motor units, limiting the scope of data obtained. One potential solution to this 
issue involves the development of near fibre (NF) MUP parameters that are obtained via 
a high-pass filtered MUP template, which therefore focuses on the electrophysiological 
contributions of muscle fibres that are nearest (within ~350 µm) to the needle electrode 
centre of detection
104
. Filtering the EMG signal in this way reduces contributions from 
electrophysiological signals located greater than ~350 µm away from the needle detection 
surface, and thus this analysis may prove more robust than traditional MUP analysis, 
especially during MUNE protocols which require sustained, moderate level (25% MVC) 
contractions. Some NF parameters of interest include: NF count (a measure of fibre 
density), NF jiggle (which can be used to assess the neuromuscular transmission 
variability of the near fibers), NF dispersion (which measures the temporal dispersion of 
the near fiber contributions) and maximum NF interval (which is the maximum time 
interval between temporally adjacent near fiber contributions to a NF MUP). At present, 
no study has reported these measures in patients with neuropathy therefore their utility 
remains poorly understood.  
Thus, DQEMG provides a unique and convenient platform to combine MUNE 
and needle-detected MUP analysis measures to gain a more detailed understanding of 
pathological alterations to the neuromuscular system imposed by DPN. Further study 
using DQEMG software is warranted to determine how changes in neuromuscular 
transmission stability and neuromuscular remodeling may relate to one another, as well 
as other aspects of functional capacity and disease severity in patients with DPN.  
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1.11 Purposes and Hypotheses 
 Broadly stated, the primary purpose of the studies described herein (Chapters 2, 3, 
4, 5, & 6) was to investigate the physiological impacts of DPN on the neuromuscular 
system in humans. More specific objectives and hypotheses are as follows: 
 
1. Purpose: To determine if the loss of strength reported in patients with DPN is related to 
a loss of motor units, as quantified using DQEMG (Chapter 2). 
a) It was hypothesized that DPN patients would have fewer motor units 
compared to controls, and MUNEs would be positively associated with 
strength. 
2. Purpose: To determine if a length-dependency exists regarding the DPN-related loss of 
motor units in humans (Chapter 3). 
a) It was hypothesized that MUNE of the TA would be more greatly 
affected by DPN than FDI. 
3. Purpose: To determine how DPN affects the stability of neuromuscular transmission 
using the electrophysiological parameters jiggle, jitter and percent blocking (Chapter 4). 
a) It was hypothesized that patients with DPN would feature a greater 
degree of neuromuscular transmission instability (i.e. greater jiggle, jitter 
and % blocking) compared to healthy controls. 
4. Purpose: To assess the effect of DPN on dorsiflexor muscle contractile properties, 
including contractile speed and muscle morphology, in association with DPN-related 
denervation (Chapter 5)  
a) It was hypothesized DPN patients would have weaker, slower muscles 
with greater proportions of non-contractile intramuscular tissue that would 
be negatively correlated with MUNE. 
19 
 
 
 
5. Purpose: To examine the neuromuscular fatigability of patients with DPN using 
sustained isometric contractions and identify possible mechanisms underlying differences 
from controls (Chapter 6). 
a) It was hypothesized DPN patients would be relatively more resistant to 
fatigue due to slowed muscle properties and the less absolute strength. 
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Chapter 2  
2 Motor unit loss and weakness in association with diabetic 
neuropathy in humans
1
 
2.1 Introduction 
The most common form of diabetic neuropathy is a length dependent symmetrical 
neuropathy with predominant involvement of sensory fibres
1
. In more severe forms there 
is progressive involvement of motor fibres
2
. Animal models show that relative to the 
sensory nervous system, motor axons are more resistant to the effects of diabetes mellitus 
(DM)
3
. Nonetheless these models indicate motor axons are targeted by DM and undergo 
degeneration
4
.  In humans, motor axon or motor unit (MU) loss as a complication of DM 
has been quantified in the extensor digitorum brevis (EDB)
5
. However, in intrinsic foot 
muscles such as the EDB it may be difficult to differentiate between axonal loss caused 
by physical trauma versus damage caused by biochemical stressors associated with 
diabetes. Furthermore, investigating MU loss in more functional muscles (e.g. tibialis 
anterior) allows for the assessment of other relevant clinical and physiological properties 
such as strength and fatiguability. Thus the purpose of this study was to estimate the 
number of functioning MUs in the tibialis anterior, using an electrophysiological method, 
in a group of patient with DM in comparison to age and sex matched controls. 
 
                                                 
1
 A version of this chapter has been published. Used with permission from John Wiley 
and Sons, Inc. 
 
Allen, M.D., Choi, I.H., Kimpinski, K., Doherty, T.J., Rice, C.L. Motor unit loss and 
weakness in association with diabetic neuropathy in humans. Muscle Nerve, 48(2):298-
300, 2013.  
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2.2 Materials and Methods 
Participants  
Six patients (4 men and 2 women; age, 63 ± 16.1 years) were recruited for this 
study. All patients met criteria for the diagnosis of DM and had clinical and 
electrophysiological features of confirmed diabetic polyneuropathy (DPN)
2
. Additionally, 
all patients had a thorough history and clinical examination to exclude other causes of 
nerve injury (i.e. compressive mononeuropathies or L5-S1 radiculopathies). Six healthy, 
age and sex-matched controls (4 men and 2 women; age, 62 ± 16.3 years) were recruited 
from the community. The study was approved by the local university’s research ethics 
board. Informed, oral and written consent was obtained from all participants prior to 
testing.  
Motor Unit Number Estimates (MUNE) and Dorsiflexor Strength  
To assess dorsiflexion strength, participants were seated in a custom isometric 
dynamometer. Surface electromyography (EMG) was collected from the tibialis anterior 
using self-adhering Ag-AgCl electrodes. Intramuscular EMG signals were recorded via a 
disposable concentric needle electrode inserted into the TA, 5-10 mm proximal to the 
active surface electrode.  
All EMG data were acquired using customized software on a Neuroscan Comperio 
system (Neurosoft, El Paso, TX). The algorithms used for decomposition-based 
quantitative EMG (DQEMG) and decomposition-enhanced spike-triggered averaging 
(DE-STA) have been described in detail elsewhere
6,7
. In brief, the surface and 
intramuscular EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz, 
respectively. Surface electrodes (Marquette Medical Systems, Jupiter, FL) were applied 
to the TA muscle using standard methods and the maximum CMAP for the TA muscle 
was obtained by supra-maximal stimulation of the fibular nerve, just distal to the fibular 
head, with a hand held stimulating electrode. Next, three maximal voluntary dorsiflexion 
contractions (MVCs) were performed.  Subsequently, participants matched a target line 
of 25% MVC for all isometric contractions because this contraction intensity has been 
31 
 
 
 
shown to be the most effective intensity for obtaining a representative motor unit number 
estimation (MUNE) in the tibialis anterior (TA)
8
. Surface and concentric needle (Model 
N53153; Teca, Hawthorne, NY) EMG were collected simultaneously while participants 
sustained a steady target torque for each contraction for ~30 s. These contractions were 
repeated until at least 20 suitable trains of motor unit potentials (MUPs) and their 
respective surface-motor unit potentials (S-MUPs) were collected.  
Decomposed EMG signals were reviewed off-line to determine the acceptability 
of the needle-detected MUP trains and their corresponding S-MUPs.  A computer 
algorithm aligned the negative onset markers for all accepted S-MUPs and created a 
mean S-MUP template based upon their data-point by data-point average. A MUNE was 
derived by dividing the negative-peak amplitude of the CMAP by the negative peak 
amplitude of the mean S-MUP
9
.   
Torque signals were collected and sampled online at 500 Hz using Spike2 
software (Cambridge Electronic Design, Cambridge, UK) and analyzed off-line to 
determine voluntary isometric torques (strength). 
Statistics 
 Group CMAP, MUNE and isometric dorsiflexion strength data were compared 
using a one way ANOVA. Group mean S-MUP data were not normally distributed, thus 
these data were compared using a Kruskal-Wallis one way analysis of variance by ranks. 
All data are presented as group means ± standard deviations. Significance was set at p ≤ 
0.05.  
2.3 Results 
All results all presented in Table 2.1. Control (n=6) and DPN (n=6) groups were age 
and sex matched (p>0.05). DPN patients were found to be ~60% weaker in isometric 
dorsiflexion strength (Nm) versus controls (p<0.05). DPN patients possessed 
significantly reduced (~40%) CMAP negative peak amplitudes (mV) and enlarged S-
MUP (~50%) negative peak amplitudes (µV) (p<0.05).  These changes resulted in ~60% 
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fewer MUs based on MUNE in DPN patients when compared to controls (p<0.05). DPN 
patients had  mean motor unit firing rates of 10.2 ± 1.5 pulses per second; controls had 
mean motor unit firing rates of 12.1 ± 0.9 (p<0.05). During the 25% MVC contractions 
DPN patients produced 29.0 ± 3.6% of maximal RMS EMG; controls produced 24.5 ± 
6.4% of maximal RMS EMG (p>0.05). 
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Measure Control (6) DPN Patient (6) % Difference 
Age    62 ± 16.3    63 ± 16.1  1.6% 
Dorsiflexion Strength (Nm) 39.0 ± 10.6 15.9 ± 4.0* 59.3% 
TA CMAP NP Amplitude (mV)  6.2 ± 1.3   3.9 ± 0.9* 38.1% 
TA S-MUP NP Amplitude (µV)       57 ± 19 109 ± 47* 47.4% 
TA MUNE (#)      111 ± 22   45 ± 27* 59.1% 
Nerve Conduction Studies    
Sural Nerve SNAP Amplitude (µV) - 1.6 ± 0
#
 - 
Sural Nerve CV (m/s) - 32.4 ± 0
#
 - 
Fibular Nerve CV (m/s) - 37.6 ± 5.8  - 
Tibial Nerve CMAP Amplitude 
(mV) 
-  1.6 ± 1.7 - 
Tibial Nerve CV (m/s) - 33.9 ± 2.9 - 
Table 2.1 Strength and motor unit number estimates of the tibialis anterior in controls 
and patients with diabetic polyneuropathy 
Nerve conduction study data presented in the patient group are outside of normal ranges. 
DPN = diabetic polyneuropathy; Nm = Newton*metre; TA = tibialis anterior; CMAP = 
compound muscle action potential; NP = negative peak; mS-MUP = mean surface motor 
unit potential; MUNE = motor unit number estimate; SNAP = sensory nerve action 
potential; CV = conduction velocity. * denotes significant difference between groups, 
p<0.05; 
#
 sural nerve responses were absent in all patients except one 
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2.4 Discussion  
 DM imposes unique, chronic forms of damage and degeneration to the peripheral 
nervous system. Whilst damage to the sensory nervous system is often observed 
clinically, much less is known about the long-term effect of DM on the motor nervous 
system. Our results provide new evidence in humans of MU loss with DM, in association 
with significant decreases in strength, using DQEMG-derived MUNE.  
Using various electrophysiological MUNE techniques, MU loss has been 
previously documented in other diseases affecting the nervous system
8
 and in DM in an 
intrinsic foot muscle
5
. MU loss and associated muscular weakness as a result of DM has 
not been directly quantified in the TA in humans despite the inclusion of related clinical 
signs such as atrophy, weakness, and reduced CMAPs in the description of patients with 
DPN
9
. Our findings indicate the weakness, muscular atrophy, and increased fatigue 
reported in DPN patients may be partially accounted for by a loss of MUs. However, 
MUNE does not allow for the differentiation between distal axonal retraction versus 
motor neuron death.  
In rodent models of chronic experimental diabetes, motor neurons undergo distal, 
axonal dropout, whereby motor neurons gradually withdraw their terminals from distal 
innervation of their associated muscle
3
. Additionally it has been suggested that smaller 
MUs are preferentially targeted or there is a general enlargement of surviving MUs 
through compensatory sprouting
3
. Our results of pathologically enlarged S-MUPs within 
the patient group also indicate an ongoing process of denervation and collateral 
reinnervation in DM patients
6,10
. However, the observation of reduced strength in the DM 
group indicate the process of denervation is outpacing collateral reinnervation, leading 
not only to a reduction in MUs but also to probable atrophy of muscle tissue and 
concomitant loss of strength
11
.  
The TA was selected for investigation in the present study due to the distal to 
centripetal progression of diabetic neuropathy
12
 and its functional relevance in mobility, 
balance and association with fall-risk
13
. Given the pattern of the development of 
weakness in patients with diabetic neuropathy it seems likely that MUs would be 
35 
 
 
 
preserved in more proximal limb muscles, such as the quadriceps or biceps brachii, 
although this remains to be determined
12,14
. 
The results from the present study indicate DQEMG-derived MUNE may have 
some clinical utility in predicting functional impairment, tracking DM progression and 
disease management. This may be particularly useful in individuals whose diabetic 
neuropathy features a detectable motor component (i.e. muscle wasting, reduced CMAP, 
weakness) using standard clinical measures (i.e. manual muscle testing, motor nerve 
conduction studies). Additionally, it remains to be determined how MU loss in DM 
patients relates to other relevant clinical and functional measures. 
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Chapter 3  
3 Length dependent loss of motor axons and altered motor unit 
properties in human diabetic polyneuropathy
2
  
3.1 Introduction  
Diabetic polyneuropathy (DPN) is a generalized disorder of the peripheral 
nervous system caused by metabolic and vascular stressors associated with diabetes 
mellitus (DM). The pathophysiology underlying this nervous system dysfunction may be 
due to a combination of various metabolic and vascular factors
1
, and is correlated with 
disease duration and quality of serum glucose control  (e.g. as indicated by HbA1c 
levels)
2,3
. In the early stages of DPN, patients often present with predominant 
involvement of the sensory nervous system and no clinical impairment in motor function 
is detectable
4,5
. Regardless of the underlying causes, DPN commonly develops as a 
length-dependent, or progressive centripetal degeneration of peripheral nerve axons
6
. 
This manner of disease progression typically leads to development of length dependent 
neurological complications first in the feet, followed by the legs and hands.  
Although motor neurons may be more resistant than sensory axons to the 
dysfunction and degeneration associated with diabetes mellitus
7,8,9
, studies in animal and 
human models nonetheless have shown that the motor system is affected
3,10–13
. Indeed, 
whereas sensory dysfunction can lead to injury resulting from lack of sensation, 
ulceration and amputation; dysfunction of the motor nervous system is associated with 
muscle atrophy and weakness
14,15
. Muscle weakness may therefore contribute to the 
higher risk of developing physical disability in patients with diabetes
16
. 
                                                 
2
 A version of this chapter has been published. Used with permission from Elsevier, Inc. 
 
Allen, M.D., Kimpinski, K., Doherty, T.J., Rice, C.L. Length dependent loss of motor 
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Muscular atrophy and weakness associated with DM may be partially a result of 
motor unit or motor axon loss. Electrophysiologically-derived motor unit number 
estimates (MUNEs) in human patients with DPN have been shown to be significantly 
reduced in one distal muscle of the lower limb, specifically an intrinsic foot muscle, the 
extensor digitorum brevis (EDB)
10
 and, in preliminary findings, in the tibialis anterior 
(TA)
13
. In EDB, these pathological changes in motor unit number and properties were 
correlated with age and disease duration
10
. Motor unit loss has been reported concurrent 
with significant muscular weakness when compared with age and sex-matched human 
controls
13
. In addition to reduced MUNEs, changes in motor neuron properties have been 
reported in patients with DPN. Abnormal single-fiber electromyography recordings 
(increased jitter) have been found in DPN patients, suggestive of reinnervation of the 
motor system, which correlated with glycemic control
3
. Also, previous studies indicate 
patients with DM show lower mean motor unit discharge rates versus controls and greater 
variability in discharge rates of action potential trains during sustained low level 
contractions
17
. These findings may be related to changes in recruitment strategy due to 
neuromuscular remodeling and altered excitability of motor units
18
. However it is not 
known how these results may compare to potential changes in motor unit numbers of 
more proximal or upper limb muscles, or how they relate more broadly to indicators of 
disease severity, such as glycemic control.  
Decomposition-based quantitative electromyography (DQEMG) is an 
electrophysiological technique based on surface and intramuscular EMG, in conjunction 
with dedicated computer algorithms used to decompose complex EMG signals
19,20
.  This 
technique can be used to provide reliable MUNEs, as well as other valuable information 
concerning motor unit properties in humans, including motor unit size, complexity, 
stability, recruitment order, and rate coding strategies
21–23
. Although this useful technique 
has been applied to study various clinical and special populations, including amyotrophic 
lateral sclerosis
21
, compressive neuropathies
24
, knee osteoarthritis
23
, and adult aging
25
 it 
has not been fully employed in the investigation of diabetic neuropathy (Chapter 2).   
 The purpose of the present study was to estimate the number of motor units and 
assess their electrophysiological properties in an upper (first dorsal interosseus [FDI]) 
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and lower limb (TA) muscle of patients with DPN using DQEMG. We sought to compare 
how motor unit numbers and their properties were affected by DPN and whether changes 
in these properties were related. Additionally, the associations between these different 
neuromuscular properties with functional parameters (e.g. strength) and measures of 
serum glucose control (e.g. HbA1c levels) were investigated across muscles. We 
hypothesized DPN patients would feature significantly reduced MUNEs, and enlarged 
motor units in both TA and FDI when compared with age matched controls. Additionally, 
we hypothesized these differences would be more pronounced in the TA versus the FDI 
due to the centripetal nature of DPN disease progression. Finally, we hypothesized 
negative relationships would exist between MUNEs and parameters of disease severity. 
 
3.2 Methods 
3.2.1 Participants 
Twelve patients (7 men, 5 women; ages 32-78 years) with DPN were recruited. 
They met the criteria for diagnosis of type 2 non-insulin dependent DM with clinical and 
electrophysiological features of confirmed DPN
8
. Additionally, they had a thorough 
history, and clinical and electrophysiological examination by an experienced neurologist 
with specialized training in neuromuscular disease to exclude other causes of nerve injury 
(i.e., other polyneuropathies, compressive mononeuropathies, radiculopathies). Patients 
with any neurological, metabolic or vascular diseases other than related to DM or DPN 
were excluded. Twelve healthy, age and sex-matched controls (7 men, 5 women; ages 29-
77 years) were recruited from the community. Control participants were screened by 
physicians (neurologists) to ensure they met inclusion criteria. The study was approved 
by the local university research ethics board. Informed oral and written consent was 
obtained from all participants prior to testing. 
3.2.2 DQEMG and Strength Assessment of Tibialis Anterior  
Participants were seated in a custom isometric dynamometer designed to measure 
plantar and dorsiflexion at the ankle joint
26
. In the dynamometer, the right ankle was 
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positioned at 30° of plantar flexion, with both knee and hip angles maintained at 90°. A 
C-shaped brace was secured directly on the distal aspect of the right thigh to minimize 
movement at the hip joint during contractions. Inelastic Velcro straps were placed over 
the dorsum of the foot to secure the foot to the dynamometer
22
. 
All testing was performed on the right (dominant) leg.  Participants performed 
three dorsiflexion maximal voluntary contractions (MVCs), with at least 3 min of rest 
between attempts. Each MVC was held for approximately 3 seconds. Participants were 
provided with real time visual feedback of their torque and verbally encouraged. 
Voluntary activation during the 2
nd
 and 3
rd
 MVC attempts was assessed using the 
interpolated twitch technique
27
. This technique involves supramaximal percutaneous 
electrical stimulation of the fibular nerve just distal to the fibular head. The amplitude of 
the interpolated torque electrically evoked from a single 100us stimulus during the 
plateau of the MVC was compared with a single (100μs) resting twitch evoked ~1s 
following the MVC.  Voluntary activation was calculated as a percent using the following 
equation: [1- (interpolated twitch /resting twitch)] x 100. The peak torque of the three 
MVC attempts was taken as the maximal torque for the participant. All torque signals 
were collected and sampled online at 500 Hz using Spike2 software (Version 7.11; 
Cambridge Electronic Design Ltd., Cambridge, United Kingdom) and analyzed off-line 
to determine voluntary isometric torques (strength). 
Surface electromyography (EMG) was collected from the TA using self-adhering 
Ag-AgCl electrodes (1 cm x 3 cm). The active electrode was placed over the TA motor 
point, approximately 7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior 
border of the tibia. This placement was adjusted to maximize the TA compound muscle 
action potential (CMAP) amplitude as necessary. The reference electrode was placed 
over the distal tendon of the TA. A ground electrode was placed over the patella. 
Decomposition-based quantitative electromyography (DQEMG) data were 
acquired using decomposition enhanced spike triggered averaging (DE-STA) software, 
described in detail elsewhere
19,28
. Intramuscular EMG signals were recorded via a 
disposable concentric needle electrode (Model N53153; Teca Corp., Hawthorne, NY) 
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inserted into the TA, 5-10 mm distal to the active surface electrode.  The surface and 
intramuscular EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz, 
respectively. Surface EMG was sampled at 3 kHz; intramuscular EMG was sampled at 30 
kHz. To evoke the maximum CMAP a bar electrode held distal to the fibular head 
delivered supramaximal electrical stimuli to the common fibular nerve.  Subsequently, 
participants matched a target line of 25% MVC, visible on a computer monitor, for all 
isometric dorsiflexion contractions during which the intramuscular needle electrode was 
inserted and manipulated in the muscle. This contraction intensity has been shown to be 
the most effective intensity for obtaining a representative motor unit number estimation 
(MUNE) in the tibialis anterior (TA)
22
. Surface and intramuscular EMG were collected 
while participants sustained a steady target torque for each contraction held for ~30 s. 
Between contractions, the concentric needle electrode was repositioned in order to obtain 
to sample from different motor units. These procedures were repeated until at least 20 
suitable trains of motor unit potentials (MUPs) and their respective surface-motor unit 
potentials (S-MUPs) were collected.  
Decomposed EMG signals were reviewed off-line to determine the acceptability 
of the needle-detected MUP trains and their corresponding S-MUPs.  A computer 
algorithm aligned the negative onset markers for all accepted S-MUPs and created a 
mean S-MUP template based upon their data-point by data-point average. All MUP and 
S-MUP markers were subsequently reviewed visually by the operator. A MUNE was 
derived by dividing the negative-peak amplitude of the CMAP by the negative peak 
amplitude of the mean S-MUP
29
.  
In addition to providing MUNEs, the DQEMG software measures firing rates 
(Hz) of individual motor unit action potential trains (MUAPTs), and provides overall 
mean firing rates per participant at a relative target level of contraction. Finally, the 
DQEMG system allows for the measurement of properties of needle detected-MUPs, 
including MUP amplitude, area, duration, and area to amplitude ratio (AAR). The 
calculation of the MU size index (SI [SI = 2 x log(amp) + area/amp]), a stable measure 
useful in the detection of neurogenic processes, was also performed
30
. All markers were 
automatically placed by the DQEMG software and were subsequently inspected manually 
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and adjusted where appropriate. The DQEMG technique described has been shown to 
possess similar test-retest values within individuals
31
, and high degrees of intra- and 
inter-rater reliability in control and clinical populations
32,33
.  
3.2.3 DQEMG of First Dorsal Interosseus 
 For the FDI, participants were seated in a straight-back chair with their feet on the 
floor. The participant’s forearm and hand were secured in a custom-built apparatus 
designed to isolate the second (index) digit during isometric abduction contractions
34
. 
This apparatus was designed to minimize any movement in the wrist and hand, while 
allowing for isolated index finger abduction (FDI contraction) through the 
immobilization of the wrist, thumb and digits three to five with Velcro straps. Torque 
data was not recorded for the FDI. 
Surface EMG was collected using self-adhering Ag-AgCl electrodes (1 cm by 2.5 
cm); the active electrode was placed over the motor point of the FDI muscle and the 
reference electrode was placed over the second metacarpal phalangeal joint. A ground 
electrode was applied to the medial aspect of the wrist, distal to the stimulation site. To 
obtain a maximal FDI CMAP supramaximal stimulation was applied to the ulnar nerve at 
the wrist (~7 cm proximal to the active electrode). 
 Participants performed three index finger abduction maximal voluntary 
contractions (MVCs), with at least 3 min of rest between attempts. Each MVC was held 
for approximately 3 seconds during which the participant was verbally encouraged. 
Visual and auditory feedback were provided to the participant via surface EMG activity, 
and maximal RMS EMG activity was recorded during these MVCs. The intensity of 
subsequent contractions was based on a percentage (25%) of relative maximal RMS 
activity (% MVC-RMS)
28,29
. 
 DQEMG data were acquired from the FDI using similar equipment, filter and 
amplification parameters to the protocol in the TA (described above). The concentric 
needle electrode was inserted into the FDI 2-5 mm distal or proximal to the active 
electrode. Participants performed ~30 s FDI contractions, while matching a target line of 
25% MVC-RMS, during which surface and intramuscular EMG were collected. These 
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procedures were repeated until at least 20 suitable trains of MUPs and their respective S-
MUPs were collected. Decomposed EMG signals of the FDI were analyzed using the 
same methodology used in the TA (described above). 
3.2.4 Statistics 
Mean values ± standard deviations are presented in the text.  Normally distributed 
data were analyzed using a one-way ANOVA; the level of significance was set at P ≤ 
0.05. When a significant main effect was detected, Tukey’s post-hoc test was performed. 
Non-normally distributed data were analyzed using a Kruskal-Wallis one-way ANOVA 
on ranks, with Dunn’s Method used as the post-hoc test. Effect sizes for comparisons 
between groups are presented as Cohen’s d. Relationships between variables were testing 
using Pearson’s Product Moment Correlation. Data analyses were performed using 
SigmaPlot software (Version 12.2; Systat Software, Chicago, Illinois, US). 
 
3.3 Results 
3.3.1 Participant Characteristics 
Participant characteristics are presented in Table 3.1. No significant differences 
were detected for age or height (p>0.05) between groups. DPN patients had significantly 
greater body mass (p<0.05) and BMI (p<0.05) than controls. Maximum ankle 
dorsiflexion strength was 40% lower in the DPN group versus controls (p<0.05), with no 
group differences for voluntary activation (p>0.05). Data characterizing the clinical 
history and status of the DPN patient group are presented in Table 3.2. In both groups, 
mean TA and FDI CMAP amplitudes were above our clinic’s lower limit of normal35, 
which are 4.0 mV and 10 mV, respectively.   
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 Control (n = 12) DPN Patient (n = 12) 
Anthropometric Parameters   
Male/Female 7/5 7/5 
Age (years) 63.8 ± 15.5 65.8 ± 15.4 
Height (m) 1.8 ± 0.1 1.7 ± 0.1 
Weight (kg) 73.8 ± 6.1 83.1 ± 7.4* 
BMI (kg/m
2
) 24.4 ± 3.1 28.9 ± 3.7* 
   
Dorsiflexion Properties   
Dorsiflexion MVC (Nm) 34.1 ± 9.5 22.3 ± 7.2* 
Voluntary Activation (%) 98.3 ± 1.9 97.6 ± 2.1 
 
Table 3.1 Participant Characteristics 
MVC – maximal voluntary contraction. * Denotes significant difference between groups 
(p<0.05). 
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 Range or Limit of 
Normal 
DPN Patients 
Diabetic Characteristics   
Duration of Diabetes (years) - 14.1 ± 11.2 
Duration of DPN (years) - 9.2 ± 8.1 
HbA1c (%) <6.0 7.4 ± 1.4 
Triglycerides (mmol/L) 0.77-1.7 1.9 ± 1.3 
Cholesterol (mmol/L) 3.0-5.0 4.1 ± 0.3 
HDL Cholesterol (mmol/L) 0.9-2.0 1.3 ± 0.5 
LDL Cholesterol (mmol/L) 2.0-3.0 2.1 ± 0.8 
Total Cholesterol:HDL Ratio <5.0 3.9 ± 0.9 
   
Nerve Conduction Studies   
Sural Nerve SNAP Amplitude 
(µV)  
>5 1.3 ± 2.5
#
 
TA NP CMAP amplitude (mV)  >4.0 5.0 ± 1.7 
Fibular nerve CV (m/s) >40.0 41.4 ± 10.4 
FDI CMAP amplitude (mV) >10.0 10.3 ± 2.7 
Ulnar nerve CV (m/s) >53.0 49.2 ± 3.4 
 
Table 3.2 Clinical characteristics of DPN patient group 
 
SNAP – sensory nerve action potential; TA – tibialis anterior; NP - negative peak; CMAP 
– compound muscle action potential; CV – conduction velocity; FDI – first dorsal 
interosseous. 
# 
SNAP responses were absent in 10 out of 12 patients. 
 
 
 
3.3.2 Decomposition-based Quantitative Electromyography Measures  
Results from DQEMG of the TA and FDI are presented in Tables 3.3 & 3.4. In 
both muscles, DPN patients featured ~25% greater duration for mean needle-detected 
motor unit potentials (NMUPs) than controls (p<0.05), however, mean NMUP amplitude 
(peak-to-peak amplitude) and area to amplitude ratios (AAR) were not different between 
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groups (p>0.05). In examining NMUP complexity, groups did not differ in the number of 
phases (p>0.05), although the DPN patient group featured ~25% more turns than controls 
in both muscles (p<0.05). In the TA and FDI, the DPN patient group had lower mean 
firing rates during the sustained, submaximal contractions compared to controls (p<0.05). 
Motor unit size index and % RMS EMG were not different between groups in either 
muscle (p>0.05). 
When examining the TA, DPN patients were found to have ~40% larger mean 
surface motor unit potentials (S-MUP) than controls (p<0.05). Maximal compound 
muscle action potentials (CMAP) (negative peak-amplitude) were significantly smaller 
(~30%) in DPN patients compared to controls (p<0.05). Additionally, the DPN patient 
group featured a ~45% lower MUNE compared to the control group (p<0.05) (Figure 
3.1). 
In the FDI, SMUP amplitudes were not different between groups (p>0.05). 
Maximal CMAP (negative peak-amplitude) were significantly smaller (~20%) in DPN 
patients compared to controls (p<0.05). Finally, the DPN patient group featured a ~30% 
lower MUNE compared to the control group (p<0.05) (Figure 3.1). In both TA and FDI, 
individual MUNE data for DPN patients and controls are illustrated in Figure 3.2. 
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 Control DPN Patient Effect Size 
N-MUP Parameters    
Peak-to-peak voltage 
(µV) 
803.0 ± 145.0 1056.0 ± 468.0 0.88 
Duration (ms) 8.4 ± 1.54 10.8 ± 1.6* 1.72 
AAR (ms) 1.6 ± 0.3 1.7 ± 0.3 0.32 
Phases (#) 2.9 ± 0.2 3.1 ± 0.3 0.62 
Turns (#) 3.3 ± 0.6 4.1 ± 0.7* 0.91 
    
S-MUP Parameters    
Negative peak 
amplitude (µV) 
77.0 ± 20.0 116.0 ± 61.0* 0.98 
    
Other    
Mean Firing Rate (Hz) 12.2 ± 1.7 10.1 ± 1.2* 1.34 
% RMS EMG 20.7 ± 6.1 23.3 ± 4.3 1.02 
Motor Unit Size Index 1.3 ± 0.3 1.5 ± 0.6 0.71 
    
MUNE    
CMAP (mV) 6.8 ± 1.1 5.0 ± 1.7* 2.12 
SMUP (µV) 77.0 ± 20.0 116.0 ± 61.0* 0.98 
MUNE (#) 99.0 ± 19.0 54.0 ± 25.0* 2.40 
 
Table 3.3 Decomposition-based quantitative electromyography of tibialis anterior 
 
N-MUP – needle detected motor unit potential; AAR – area to amplitude ratio; RMS 
EMG – root mean squared electromyography; CMAP – compound muscle action 
potential; SMUP – surface detected motor unit potential; MUNE – motor unit number 
estimation. Effect size presented as Cohen’s D. CMAP and SMUP data are presented as 
negative peak amplitudes. * Denotes significant difference between groups (p<0.05). 
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 Control DPN Patient Effect Size 
N-MUP Parameters    
Peak-to-peak voltage 
(µV) 
839.0 ± 124.0 846.0 ± 218.0 0.23 
Duration (ms) 8.0 ± 0.74 9.9 ± 1.6* 2.04 
AAR (ms) 1.5 ± 0.2 1.6 ± 0.2 0.17 
Phases (#) 2.7 ± 0.2 2.8 ± 0.2 0.63 
Turns (#) 2.6 ± 0.2 3.4 ± 0.5* 1.67 
    
S-MUP Parameters    
Negative peak 
amplitude (µV) 
133.0 ± 30.0 157.0 ± 54.0 0.24 
    
Other    
Mean Firing Rate (Hz) 14.8 ± 2.2     12.4 ± 1.9 1.03 
% RMS EMG 20.7 ± 1.6 22.6 ± 3.32 1.17 
Motor Unit Size Index 0.9 ± 0.3 1.1 ± 0.5 0.29 
    
MUNE    
CMAP 12.7 ± 1.6 10.3 ± 2.7* 1.07 
SMUP 133.0 ± 30.0 157.0 ± 54.0 0.24 
MUNE 107.0 ± 33.0 73.0 ± 18.0* 0.96 
Table 3.4 Decomposition-based quantitative electromyography of first dorsal 
interosseous 
 
N-MUP – needle detected motor unit potential; AAR – area to amplitude ratio; RMS 
EMG – root mean squared electromyography; CMAP – compound muscle action 
potential; SMUP – surface detected motor unit potential; MUNE – motor unit number 
estimation. Effect size presented as Cohen’s D. CMAP and SMUP data are presented as 
negative peak amplitudes. * Denotes significant difference between groups (p<0.05). 
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Figure 3.1 Comparison of relative differences between DPN patients and controls in key 
electrophysiological variables between tibialis anterior (TA) and first dorsal interosseous 
(FDI). All relative differences between DPN patients and controls were significant, 
excluding FDI mSMUP.  
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Figure 3.2 Motor unit number estimates in diabetic neuropathy 
Motor unit number estimates in the tibialis anterior (panel A) and first dorsal interosseous 
(panel B) in DPN patients and age-matched controls. Group means are represented by 
enlarged symbols and feature standard deviation error bars. 
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Figure 3.3 Relationship between muscle action potential size and motor unit number estimates  
Relationship between compound muscle action potential (CMAP) amplitude and motor unit number estimates (MUNEs) in the tibialis 
anterior of DPN patients (black squares) and controls (grey circles). Dotted line represents lower limit of normal (4.0 mV) for CMAP 
amplitude. Group means are represented by enlarged symbols and feature standard deviation error bars.
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3.3.3 Tibialis Anterior versus First Dorsal Interosseus Motor Unit Properties  
In patients with DPN, the TA has undergone greater motor unit loss in 
comparison to the FDI (see effect sizes in Tables 3.3, 3.4). Patients with DPN featured a 
~45% lower MUNE in the TA, versus a ~30% lower MUNE in FDI. CMAPs were ~30% 
smaller in the TA versus ~20% smaller in FDI. Furthermore, in the TA, DPN patients 
were found to have mean SMUPs enlarged by ~40% whereas in FDI there were no 
differences. 
3.3.4 Disease Severity, Age, Strength and Motor Unit Number Estimates 
 Within the DPN patient group, in either muscle, no significant relationships were 
found between MUNEs and: HbA1c levels, blood lipid profiles, duration of DM, duration 
of DPN, or age (p>0.05). TA MUNE and dorsiflexion strength were found to be 
positively related to one another (r = 0.79; r
2
 = 0.62; p<0.05) within the DPN group.   
 
3.4 Discussion  
This study has demonstrated that patients with DPN have fewer motor axons, 
which may be related to a loss of MUs, in both distal lower (TA) and upper limb (FDI) 
muscles compared to healthy, age-matched controls. Neuromuscular properties of the TA 
were more severely affected by DPN than FDI in terms of degree of motor unit loss and 
motor unit remodeling. The number of motor units in the TA was found to be 
significantly positively related to dorsiflexion strength in the DPN patient group. Using 
DQEMG, patients with DPN were found to have more complex motor units and lower 
mean motor unit firing rates compared to controls at similar levels of contractile intensity. 
Finally, in the DPN group, no significant relationships were found between motor unit 
loss and disease severity, disease duration or age in either muscle. 
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3.4.1 DPN-Related Motor Axon Loss and DQEMG-Derived MUNE 
 In the present study, the observed motor axon loss associated with DPN in the TA 
and FDI is consistent with findings previously reported in extensor digitorum brevis
10
, 
and preliminary findings reported in the TA of a small group of DPN patients
13
. The 
reduced MUNEs in DPN patients are likely primarily due to distal axonal retraction of 
motor neurons from their associated muscle fibres and concurrent inadequacy of 
compensatory collateral reinnervation, rather than cell death of motor neurons at the 
perikaryal level
7
. Using a rodent model of experimental diabetes, it has been found that 
although motor neurons are resistant to immutable loss, indeed, they gradually withdraw 
their terminals from distal innervation of skeletal muscle
7
. A key difference between the 
present study and the report by Hansen and Ballantyne
10
 is that they used a modified 
version of the incremental MUNE technique, whereas we have employed DE-STA. The 
results from the incremental technique can be affected by several important factors  
including the effects of ‘alternation’; the instability caused by neuropathy; and the 
assumption that MUs electrically stimulated at low intensities are representative of the 
entire MU pool
36
, which may overestimate the total number of functioning motor units. 
DQEMG-derived MUNE accounts for these limitations through its use of voluntary 
contractions and algorithms designed to compensate for neuromuscular instability in 
detecting single MUPs
19
. Additionally, at 25% of maximal contractile intensity, the 
majority of MUs are recruited in both FDI and TA
37,38
. Also, the MUNE technique in the 
present study has the added benefit of providing data pertaining to needle detected-
MUPs
19
. Although all subjects tolerated the needle component of the assessment very 
well, the reliance on needle-electrode insertion with this technique may be uncomfortable 
for some DPN patients, especially those with symptoms of painful diabetic neuropathy. It 
is also important to note this MUNE protocol has been shown to have high degrees of 
intra- and inter-rater reliability
32,33
, and produces similar test-retest values within 
subjects, thus supporting its potential utility in following patients longitudinally
31,39
. 
Finally, it should be noted that DQEMG-derived MUNE is especially useful for studying 
more proximal muscles (e.g. TA, soleus, trapezius) versus some other MUNE 
techniques
13,33,40
.  
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In addition to technical differences noted above, there are functional differences 
between the TA and EDB that may limit a direct comparison. In older adults, it is not 
uncommon to observe reduced CMAP amplitudes in fibular motor nerve conduction 
when recording from EDB, but not from the TA of the same individuals. As an intrinsic 
muscle on the dorsum of the foot, the EDB may be more susceptible to lifelong 
mechanical damage regardless of DM, but unlike the TA, relevant functional 
impairments of the EDB may not affect important lower limb functions related to 
locomotion, postural stability and the risk of falls
41
. 
3.4.2 Length-Dependent Motor Axon Loss in DPN 
  The degree of motor unit loss in EDB, TA and FDI is variable and the observed 
pattern appears to reflect the length-dependent nature of DPN disease progression. In 
EDB, a more distally located muscle than FDI or TA, a previous study reported ~63% 
fewer motor units in DPN patients compared to controls
10
. In comparison, the present 
study found reduced MUNEs in DPN patients of ~50% and ~30% in the TA and FDI 
respectively (Figure 3.1). In this context, interpretation of our results with the prior study 
must be done with caution because the DPN patients studied by Hansen and Ballantyne
10
 
featured a shorter mean duration of DM compared to the present study (11.7 vs 16.1 
years). Assuming that for any patient a greater loss of motor units occurs with longer 
disease duration, it seems plausible the greater relative loss of motor units in EDB is a 
reflection of the pattern (peripheral to central) of disease progression rather than an 
artifact of inherent differences between DPN patient populations, or due to different 
MUNE techniques as mentioned above. Furthermore, greater differences in other 
electrophysiological parameters, including maximal CMAP amplitudes and mean SMUP 
amplitudes, in the TA versus the FDI fits the general pattern of DPN progression.  
These findings highlight that in human DPN, reductions in axonal loss and 
presumably motor unit numbers follow the same length-dependent pattern of progression 
as other clinical signs and symptoms (i.e. sensory abnormalities, weakness, muscle 
atrophy, autonomic dysfunction)
1,8
. Furthermore, the significant and strong positive 
relationship
42
 between TA MUNE and dorsiflexion strength (r = 0.79) may indicate that a 
loss of MUs is an important factor in dorsiflexor weakness. In human adult aging, loss of 
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motor neurons has been purported as an important but often overlooked factor related to 
muscle atrophy and associated loss of strength (i.e. sarcopenia)
43,44
. Since innervation is 
necessary for the maintenance of muscle mass, and thus strength, it seems likely the 
motor unit loss reported in DPN patients in the present study is a key factor leading to the 
concomitant loss of strength. Indeed, previous studies have noted a positive relationship 
between MUNEs and strength in clinical and special populations including post-polio 
syndrome
45
, amyotrophic lateral sclerosis
46
, Charcot-Marie-Tooth disease
47
 and adult 
aging
25
. Additionally, in a rodent model of DPN, motor unit loss has been documented in 
the early stages of DPN prior to the manifestation of standard electrophysiological, 
behavioral or clinical signs including strength loss
12
. As weakness of the TA is associated 
with increased postural instability and greater likelihood of injurious falls
41
, early 
detection of motor unit loss in DPN patients could prove useful in the prescription and 
adoption of preventative or compensatory interventions (e.g. aggressive glycemic control, 
strength training, pharmacological interventions).  
In addition to motor axon loss, the present study provides indirect evidence of 
neuromuscular remodeling and collateral reinnervation via significantly greater needle-
detected MUP durations; greater MUP complexity (i.e. turns), and greater mean SMUP 
amplitudes in the TA of DPN patients compared to controls
25
 (Tables 3.3 and 3.4). These 
findings in the TA of DPN patients may reflect the ongoing process of distal, axonal loss 
of α-motor neurons resulting in denervation of their muscles fibres, and compensatory 
collateral reinnervation of those orphaned muscle fibres by neighboring α-motor neurons 
that remain intact and functional. This process has been documented in animal models of 
DM following nerve crush injury
48
, and leads to the development of larger, more 
complex individual motor units, a result that is detectable via MUPs with more turns and 
larger average SMUPs. In early DPN, this process may preserve muscle fibres and 
maximal CMAP amplitudes
48
. This result stands in contrast to our findings in the FDI in 
which no differences were found in mean SMUP size between DPN patients and controls. 
This may be due to FDI undergoing a lesser degree of neuromuscular remodeling and 
collateral reinnervation as TA in the DPN patient group as indicated by less substantial 
losses in MU numbers.  
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3.4.3 DQEMG Compared to Standard Electrodiagnostics 
The mean CMAPs in the TA (5.0 mV) and FDI (10.3 mV) of the DPN patient 
groups were greater than the lower limits of normal used in our EMG clinic (4.0 mV and 
10 mV, respectively)
35
. Based on this electrodiagnostic criterion alone, as a group, the 
DPN patients would not be considered to have undergone significant motor axonal loss 
(Figure 3.3). At this time, no standardized lower limits of normal exist for TA and FDI 
MUNEs. However, DPN patients featured substantially fewer MUs versus controls, and 
these differences were greater than the differences reported in CMAP amplitudes, 
particularly in the TA (ΔTA: MUNE ~45%, CMAP ~30%; ΔFDI MUNE ~30%, CMAP 
ΔFDI ~20%). Given MUNE takes into account the process of neuromuscular remodeling 
and collateral reinnervation via the mean SMUP, MUNE may provide a more sensitive 
measure of motor unit loss in comparison to nerve conduction studies alone. In addition, 
standard needle EMG studies would also be insensitive to this extent of axonal loss. 
Whereas clear differences were found in MUNEs between groups, differences in some 
needle detected MUP parameters, such as AAR, size index and number of phases, were 
not apparent (Tables 3.3 and 3.4). Thus, our results support the potential inclusion of 
MUNE as a useful tool in identifying patients in the early stages of motor-involved DPN, 
allowing for earlier detection and intervention. 
 In addition to motor axon loss and neuromuscular remodelling, our findings 
illustrate a decrease (~15% ) in motor unit firing rates in DPN patients compared to 
controls at similar contractile intensities (approximately 25%MVC). This result 
corroborates a similar finding in the vastus lateralis of type 2 DM patients during low 
intensity, ramped knee extension contractions
17
. They attributed this finding of 
neurophysiological adaptation to a slowing of inherent muscle contractile properties 
which has been reported in diabetic rodent skeletal muscle
49
. Additionally, the decreased 
firing rates observed in DPN patients may reflect changes in intrinsic properties of α-
motor neurons related to excitability. In humans, excitability increases in motor neurons 
as a result of Na+/K+ pump dysfunction were reported to be associated with DPN
50
. This 
could result in changes in recruitment patterns, specifically a greater reliance on 
recruitment of additional motor units, rather than firing rate increases, as a means of 
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grading force output. Furthermore, given the enlargement of motor units found in the TA 
of DPN patients, presumably fewer motor units would be necessary at lower relative 
firing rates to produce a similar relative level of force output. Our results support this 
notion given the lower recruitment and firing rate indices (Tables 3.3 and 3.4) found in 
both TA and FDI of DPN patients compared to controls.  
3.4.4 Motor Axon Loss and Disease Severity 
We did not find any significant relationships between MUNEs and disease 
duration or disease severity of DM (e.g. HbA1c levels). This is most likely due to the 
modest sample size of the present study and a result of the complex interaction of the 
various factors that could drive axonal and MU losses observed in this sample of patients. 
In insulin-dependent DM , HbA1c levels have been identified as one of the strongest 
predictors of the development and severity of other signs and symptoms (e.g. numbness, 
electrophysiological measures) associated with DPN, and therefore the lack of 
relationship between MUNE and HbA1c levels is somewhat surprising
2,3
. Previous 
reports featuring substantially larger sample sizes have found significant relationships 
between motor dysfunction and neuromuscular remodeling with glycemic control
2,3
. 
Specifically, Bril and colleagues
3
 found a positive relationship between increased single-
fibre EMG jitter, a marker of neuromuscular remodeling, and glycemic control.  
Additionally, significant negative relationships between DM disease duration and 
MUNE, as well as age and MUNE has been reported; however they did not examine the 
role of disease severity, as marked by hyperglycemia or dyslipidemia, in motor unit 
loss
10
.  Furthermore, it is important to note HbA1c values recorded at the time of 
inclusion in this study only reflect glycemic control for approximately the previous six 
months. Thus the patient’s history beyond this six month window is unaccounted for 
which could pervasively influence neuromuscular integrity.  Additionally, some recent 
reports suggest that glycemic control in type 2 diabetics may be less important than 
vascular factors in relation to the development and severity of DPN
51,52
. Conceivably, the 
duration of diabetes
10
, the severity of diabetes, genetic predisposition, age
25
 and physical 
activity patterns
53
 could all affect MUNE in DPN patients.  
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3.4.5 Conclusions 
Regardless of these potential relationships, our study demonstrates significant 
reduction of MUNE in the TA and FDI in association with DPN. The magnitude of motor 
unit loss appears to be muscle dependent, and follows a length-dependent pattern. 
Needle-detected motor unit properties are also altered in DPN patients, specifically mean 
firing rates and MUP turns. Finally, our study may lend support to the use of DQEMG as 
a potential measure that is sensitive to changes not detected by standard nerve conduction 
studies associated with DPN. The DQEMG-derived MUNE technique described in the 
present study is particularly useful in studying more proximal muscles in comparison to 
other MUNE methods. The use of DQEMG could be incorporated into larger studies to 
help identify DPN patients in the early stages of neuromuscular degeneration allowing for 
earlier, and perhaps more effective intervention. 
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Chapter 4  
4 Increased neuromuscular transmission instability and motor unit 
remodeling with diabetic neuropathy as assessed using novel near 
fibre motor unit potential parameters
3
  
4.1 Introduction  
Diabetic polyneuropathy (DPN) is a progressive neuropathic disorder 
characterized by distal axonal loss
1
 and impaired regeneration
2
. Early signs and 
symptoms may be predominantly sensory in nature
3
, however there is known 
involvement of the motor system, including loss of motor axons or motor units
4–7
 which 
has been associated with muscle weakness
6
. Electrophysiologically, the demyelinating 
component of this neuropathy can be evaluated through nerve conduction studies (NCS), 
however NCS provide limited information regarding axonal properties and no 
information with regard to collateral reinnervation (axonal regeneration).  
Standard concentric needle electromyography (NEMG) can provide more detailed 
information regarding the denervation-reinnervation process underlying DPN
8
. This is 
accomplished via the detection of spontaneous activity, polyphasic motor unit potentials 
(MUPs), and also the quantification of MUP amplitude, duration, and number of turns, as 
well as MU recruitment pattern
8
. Furthermore, the integrity of neuromuscular 
transmission can be examined in greater detail through the assessment of the degree of 
variability in the shape of consecutively detected MUPs
9
. Two key properties related to 
MUP shape variability are termed jitter and jiggle
9,10
. Jitter refers to the variability of the 
time intervals between pairs of individual muscle fibre potentials from a single MUP, and 
jiggle refers to the variability in overall MUP shape from one MUP discharge to the next. 
                                                 
3
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Increases in both jitter and jiggle have been reported under conditions of neuromuscular 
transmission disturbance and can reflect early axonal denervation
5,11,12
. Additionally, 
increases in MUP instability (and thus jitter and jiggle) can be caused by variability in 
muscle fibre action potential velocity, a finding present in various myopathies
13–15
. 
Specific to DPN, a previous study using single fibre electromyography (SFEMG) found 
increased jitter in the tibialis anterior (TA) of patients with DPN, however jiggle was not 
reported
5
. Additionally, increased fibre density in patients with DPN compared to 
controls was observed, which is indicative of reinnervation presumably to compensate for 
prior denervation (motor unit remodeling)
5
. It is not known how jitter and jiggle may 
relate to functional parameters such as strength or fatigue, however they may share a 
negative association as the disturbances that lead to increased neuromuscular instability 
may also be a factor related to a decrease in strength. 
Novel parameters of near fiber (NF) MUPs have been developed.  A NF MUP is 
calculated by high-pass filtering a MUP template waveform, and therefore is primarily 
comprised of contributions from fibers that are close to the needle detection surface
16,17
. 
NF MUP parameters include: NF count (which, as described in Stashuk 1999
17
, is a 
measure of fiber density), NF jiggle (which can be used to assess the neuromuscular 
transmission variability of the near fibers), NF dispersion (which measures the temporal 
dispersion of the near fiber contributions) and maximum NF interval (which is the 
maximum time interval between consecutive near fiber contributions to a NF MUP). NF 
MUP parameters theoretically can provide similar types of information as traditional 
MUP analysis (i.e. metrics of motor unit size (MUP amplitude, duration or area), fiber 
contribution dispersion (MUP # of phases or turns), and neuromuscular transmission 
instability (MUP jiggle)). However, because NF MUP parameters are dependent on the 
configuration and activity of the subset of motor unit fibers that are close (within ~350 
µm) to the needle detection surface
17–20
 they can potentially provide more robust and 
detailed information concerning neuromuscular transmission variability and motor unit 
remodeling in comparison to conventional MUP parameters.  This is particularly relevant 
when the MUPs and NF MUPs analyzed were extracted from a moderately complex 
interference pattern using electromyographic (EMG) signal decomposition methods (see 
Methods 4.2.3). At present, no study has reported these NF MUP parameter values for 
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patients with neuropathy, although it is expected that the general characteristics 
associated with neuropathic MUPs (increased size, complexity, and instability) will also 
be evident in neuropathic NF MUPs.  
All of the aforementioned MUP and NF MUP parameters are obtained using a 
concentric needle-electrode and decomposition-based quantitative electromyography 
(DQEMG) software
16,17
. DQEMG also provides data pertaining to motor unit firing rates 
and firing rate variability, as well as relative motor unit size, via surface motor unit 
potentials (SMUPs)
7,21,22
. In addition, if a maximal compound muscle action potential 
(CMAP) waveform is appropriately recorded, DQEMG can be used to calculate a motor 
unit number estimate (MUNE), which can provide further insight regarding the 
denervation of a muscle
7,21,22
. 
The present study was designed to assess the effects of DPN on standard MUP 
and novel NF MUP parameters including NF jiggle, NF dispersion and maximum NF 
interval, compared to age and sex-matched controls. We compared results from the novel 
NF MUP parameters to standard MUP parameters including number of turns, area and 
traditional jiggle. Additionally we related measures of neuromuscular transmission 
variability and motor unit remodeling to dorsiflexion strength. Finally, we examined how 
changes in individual motor unit size, due to the DPN-associated denervation-
reinnervation process, are related to NF MUP stability during sustained, low-level 
isometric contractions in patients with DPN. We hypothesized the following: (i) DPN 
patients would possess motor units with greater mean NF fiber count, NF jiggle, NF 
dispersion, and maximal NF interval; (ii) NF fiber count, NF jiggle and NF dispersion 
would be negatively related to dorsiflexion strength; and (iii) positive relationships would 
exist between standard parameters of MUP size and NF fibre count, NF jiggle and NF 
dispersion. 
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4.2 Methods 
4.2.1 Participants 
Twelve patients (7 men, 5 women; ages 32-78 years) with DPN were recruited. 
They met the criteria for diagnosis of type 2 (non-insulin dependent) diabetes mellitus 
(DM) with clinical and electrophysiological characteristics of confirmed DPN
23
. 
Additionally, patients received a thorough consultation and electrophysiological 
examination by an experienced neurologist with specialized training in neuromuscular 
disease to exclude other causes of nerve injury (i.e., other polyneuropathies, compressive 
mononeuropathies or radiculopathies). Patients with any neurological, metabolic or 
vascular diseases other than related to DM or DPN were excluded. Twelve healthy, age 
and sex-matched controls (7 men, 5 women; ages 29-77 years) were recruited from the 
community. Control participants were screened by physicians (neurologists) to ensure 
they met inclusion criteria. The study was approved by the local university research 
ethics board. Informed oral and written consent was obtained from all participants prior 
to testing. 
4.2.2 Tibialis Anterior DQEMG Data Acquisition 
For the present investigation, the TA was selected due to its known involvement 
in DPN
6,7
 and its high-degree of accessibility for needle EMG study. Participants were 
seated in a custom isometric dynamometer designed to measure plantar and dorsiflexion 
at the ankle joint
24
. In the dynamometer, the right ankle was positioned at 30° of plantar 
flexion, with both knee and hip angles maintained at 90°. A C-shaped brace was secured 
directly on the distal aspect of the right thigh to minimize movement at the hip joint 
during contractions. Inelastic Velcro straps were placed over the dorsum of the foot to 
secure the foot to the dynamometer
25
. 
All testing was performed on the right (dominant) leg.  Participants performed 
three dorsiflexion maximal voluntary contractions (MVCs), with at least 3 min of rest 
between attempts. Each MVC was held for approximately 3 seconds. Participants were 
provided with real time visual feedback of their torque and verbally encouraged. 
Voluntary activation during the 2
nd
 and 3
rd
 MVC attempts was assessed using the 
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interpolated twitch technique (ITT)
26
. This technique involves supramaximal 
percutaneous electrical stimulation of the fibular nerve just distal to the fibular head. The 
amplitude of the interpolated torque electrically evoked from a single 100 µs stimulus 
during the plateau of the MVC was compared with a single (100μs) resting twitch evoked 
~1s following the MVC.  Voluntary activation was calculated as a percent using the 
following equation: [1- (interpolated twitch /resting twitch)] x 100. The ITT allows the 
operator to ensure the participant is providing a maximal voluntary effort during their 
MVC. The peak torque of the three MVC attempts was taken as the maximal torque for 
the participant. All torque signals were collected and sampled online at 500 Hz using 
Spike2 software (Version 7.11; Cambridge Electronic Design Ltd., Cambridge, United 
Kingdom) and analyzed off-line to determine voluntary isometric torques (strength). 
Surface EMG signals were recorded from the TA using self-adhering Ag-AgCl 
electrodes (1 cm x 3 cm). The active electrode was placed over the TA motor point, 
approximately 7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior border of 
the tibia. This placement was adjusted as needed to maximize the TA CMAP 
amplitude. The reference electrode was placed over the distal tendon of the TA. A ground 
electrode was placed over the patella. 
DQEMG EMG data were acquired using the protocol described in detail 
elsewhere
16,27
. Intramuscular EMG signals were recorded via a disposable concentric 
needle electrode (Model N53153; Teca Corp., Hawthorne, NY) inserted into the TA, 5-10 
mm distal to the active surface electrode.  The surface and intramuscular EMG signals 
were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz, respectively. Surface EMG 
signals were sampled at 3 kHz; intramuscular EMG signals were sampled at 30 kHz. To 
evoke the maximum CMAP a bar electrode held distal to the fibular head delivered 
supramaximal electrical stimuli to the common fibular nerve. Subsequently, participants 
matched a target line of 25% MVC, visible on a computer monitor, for all isometric 
dorsiflexion contractions. Prior to engaging in these contractions, the intramuscular 
needle electrode was inserted and manipulated in the muscle. This contraction intensity 
has been shown to be the most effective intensity for obtaining a representative MUNE in 
the tibialis anterior (TA)
25
. Surface and intramuscular EMG signals were recorded during 
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a sustained 25% MVC contraction, which was held for ~30 seconds. Between 
contractions, the concentric needle electrode was repositioned in order to sample different 
motor units. These procedures were repeated until at least 20 suitable MUP trains and 
their respective surface-motor unit potentials (S-MUPs) were acquired.  
4.2.3 Tibialis Anterior Decomposition-based Quantitative Electromyography 
Analysis 
Decomposed intramuscular EMG signals were reviewed off-line to determine the 
acceptability of the extracted MUP trains and their corresponding S-MUPs.  MUP trains 
were inspected visually to ensure that their MUP occurrence patterns were consistent 
with the expected activity of a single motor unit (consistent firing pattern and 
interdischarge coefficient of variation of < 0.3).  Invalid MUP trains and their associated 
S-MUPs were excluded from further analyses. The DQEMG algorithms estimate a MUP 
and S-MUP template waveform. For these waveforms DQEMG automatically places 
markers related to onset, end, negative peak and positive peak positions. All MUP and S-
MUP markers were subsequently reviewed visually by the operator. A MUNE was 
derived by dividing the negative-peak amplitude of the maximal CMAP by the negative 
peak amplitude of the mean S-MUP
21,22
. These MUNE results have been previously 
reported
7
. 
The DQEMG algorithms also provide measures of the overall needle EMG signal 
intensity (measured in pulses per second), mean firing rates (Hz) of individual motor 
units based on their extracted MUP trains, and an overall mean firing rate per participant 
at a relative target level of contraction (25% of MVC). Additionally, the DQEMG system 
automatically calculates standard parameters of the MUP template, including peak-to-
peak amplitude, area, duration and traditional jiggle. For the assessment of MUP stability, 
used to reflect neuromuscular transmission variability, MUPs that represent the isolated 
activity of a single motor unit are automatically selected by the DQEMG algorithms.  The 
sets of automatically selected isolated MUPs were manually inspected and any MUPs 
found to be significantly contaminated by the activity of other motor units were removed 
and replaced. The DQEMG technique described has been shown to possess similar test-
retest values within individuals
28
, and high degrees of intra- and inter-rater reliability in 
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control and clinical populations
29,30
. The investigator was blinded to the status of the 
participant (DPN patient vs control) during off-line analysis. 
4.2.4 Novel Near Fibre Motor Unit Potential Parameters 
4.2.4.1 Near Fibre MUP Template 
 The MUP template provided by the DQEMG algorithms is high-pass filtered 
using a second ordered low-pass differentiator
17,31
. The second order filter equation is:  
xt = yt+2 – yt+1 – yt + yt-1  
Where yt is the sampled raw signal and xt is the sampled filtered signal
31
.  Due to 
the spatial low-pass filtering properties of volume conduction, the resulting near fibre 
MUP template waveform, or NF MUP, is primarily comprised of contributions from 
fibres that are ‘near’ (within ~350 µm) to the detection surface of the needle electrode. 
The NF MUP can be used to focus on characteristics of the near fibres and is 
defined as a MUP contributed to by the fibers that are close to the detection surface of the 
needle electrode. In contrast, a NF contribution is the specific contribution of an 
individual NF (an individual muscle fibre) to a NF MUP. The temporal relationships of 
the near fibre contributions may be more easily determined than relationships among all 
contributing fibres as would be the case when analyzing MUPs collected using only 
traditional Butterworth filtering. This is due to the spatial filtering used to create NF 
MUPs, which filters out more distant volume conducted MU activity that could 
potentially reduce the ability to detect individual muscle fibre.  As such, by focusing on 
the near fibre contributions measures of the temporal dispersion of these near fibre 
contributions can be obtained. These measures in turn can be used to reflect the relative 
conduction times of the muscle fibre action potentials to the detection surface of the 
electrode.  Assuming similar conduction velocities across the fibres of a motor unit which 
may not be true in disease, the temporal dispersion of NF contributions can therefore 
reflect the relative conduction distances of the axonal and muscle fibre action potentials. 
With presumed similar conduction distances along the muscle fibres, temporal dispersion 
can reflect the degree of axonal sprouting in the motor unit and provide evidence of 
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reinnervation. Figure 4.1 displays a MUP and its associated NF MUP as well as 
important aspects of the NF MUP parameters described below.  
4.2.4.2 Near Fibre Parameters 
Near fibre duration (NF Dur) is the time between the onset and end positions of 
the near fibre MUP.  The NF MUP onset and end positions are calculated by applying the 
same criteria used to calculate the MUP onset and end positions. Near fibre area (NF 
Area) is the sum of the absolute area under the curve of the NF MUP between the onset 
and end positions multiplied by the sampling interval (i.e. 1/ (sampling rate)).  
Near fibre count (NF fiber count) is the number of detected near fiber 
contributions to the NF MUP. A positive turn detected in the NF MUP with sufficient 
symmetry and amplitude is considered a distinct near fiber contribution. The NF fiber 
count reflects the density of fibers in the motor unit.  
Near fibre dispersion (NF dispersion) can be used to assess reinnervation, and is 
the time interval between the first and last detected fiber contribution to the NF MUP.  
The maximum near fibre interval (max NF Interval) is the maximum time 
between consecutive detected near fiber contributions. Large max NF interval values may 
indicate long reinnervating axonal sprouts.  Large max NF intervals values may relate to 
traditionally identified satellite potentials.  
Near fibre jiggle (NF jiggle) is a statistic that measures the variability of 
consecutive isolated NF MUPs of a MUP train. The statistic is the same as introduced by 
Stalberg applied to the MUPs of a MUP train
10
.  The NF MUPs of a MUP train are 
created by high-pass filtering each MUP using the same second ordered low-pass 
differentiator used to create the NF MUP template. Isolated NF MUPs are selected as 
described previously
17
.         
Near fibre jitter refers to the mean consecutive difference value measured for a 
pair of detected distinct fiber contributions within a NF MUP across the NF MUP 
train
10,17
. Suitable muscle fibre pair tracking was confirmed by visual inspection. In 
72 
 
 
 
addition, % blocking was assessed for all pairs of detected fiber contributions across the 
sets of isolated NF MUPs. % blocking is indicative of the rate at which an individual 
muscle fibre fails to propagate an action potential following the activation of its motor 
neuron. This is measured by counting the number of intermittent absences of an 
individual NF contribution to the NF MUPs of the set of isolated NF MUPs analyzed
10
. 
4.2.5 Inter-Rater Reliability of DQEMG NF Jiggle Analysis 
To provide an assessment of the inherent variability of DQEMG-derived NF 
jiggle, a second examiner performed the DQEMG NF MUP analysis described above on 
a pseudo-random subset of the collected data (6 controls, 6 DPN patients). A reliability 
assessment of NF jiggle was appropriate as there is some subjective decision-making 
regarding the inclusion and exclusion of NF MUPs for stability analysis due to signal 
contamination from adjacent motor units. Data analysis by each examiner was performed 
independently, and examiners were blinded to participant status during analysis. Each 
rater remained blind to the results of the other examiner until data collection and 
respective analyses were complete for all participants. 
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Figure 4.1 Electromyographic tracings of motor unit potential and near fibre motor unit 
potential  
Electromyographic tracings from decomposition based quantitative electromyography 
(DQEMG) of a sample (A) motor unit potential (MUP), and (B) the corresponding near 
fibre (NF) MUP. On the NF MUP tracing (B), numbers 1, 2, 3 and 4 represent NF 
contributions, providing the NF fibre count. NF dispersion is calculated as the duration 
between 1 and 4. Maximal NF interval is calculated as the duration between 2 and 3. 
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4.2.6 Statistics 
Mean values ± standard deviations are presented in the text.  Normally distributed 
data were analyzed using a one-way ANOVA; the level of significance was set at P ≤ 
0.05. Normality was assessed using a Shapiro-Wilk test. Non-normally distributed data 
were analyzed using a Kruskal-Wallis one-way ANOVA on ranks. Relationships among 
variables were tested using Pearson’s Product Moment Correlation. To represent the 
degree of differences between groups, effect sizes between group MUP and NF MUP 
parameter values were calculated using Cohen’s D. Relative inter-rater reliability was 
tested using a Model 2 (two-way random, absolute agreement) single measure intra-class 
correlation coefficient (ICC). ICC point estimates were considered ‘poor’ (<0.50), 
‘moderate’ (0.50 – 0.75) or ‘good’ (>0.75)32. Data analyses were performed using 
SigmaPlot software (Version 12.2; Systat Software, Chicago, Illinois, US) excluding the 
ICC calculation which was performed using SPSS (Version 20.0; SPSS, Chicago, 
Illinois, US). 
 
4.3 Results 
Participant characteristics are presented in Table 4.1. No significant differences 
were detected for age (p>0.05) or height (p>0.05) between groups. DPN patients had 
significantly greater body mass (p<0.05) and BMI (p<0.05) than controls. Data 
characterizing the clinical history and status of the DPN patient group are also presented 
in Table 4.1.  
Dorsiflexion strength and standard MUP parameters and MUNE values
7
 are 
presented in Table 4.2. The DPN patients had smaller CMAPs compared to controls (6.8 
vs 5.0 mV; p<0.05), however the mean CMAP value for the patient group was not below 
our clinical laboratory’s lower limit of normal (4.0 mV). DPN patients had fewer motor 
units (-45%) and were weaker (-35%) than controls (p<0.05), but no group differences 
were detected with respect to traditional jiggle (p>0.05). Both DPN patients and controls 
were able to achieve near-maximal (>95%) voluntary activation during MVCs as 
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assessed using the ITT. Finally, the DPN group had larger (+47% MUP area) MUPs with 
significantly more turns (+21%) compared to controls (p<0.05).  
NF MUP parameter values are presented in Table 4.3. DPN patients had greater: 
NF area (+40%), NF duration (+24%), NF dispersion (+38%) and maximal NF interval 
(+22%) compared to controls (p<0.05). Additionally, NF jiggle was found to be greater 
in DPN patients versus controls (+21%; p<0.05), and NF jiggle was found to have a 
‘good’ level of inter-rater reliability (ICC = 0.81). In comparison with controls, DPN 
patients had increased NF fibre counts (+31%) and greater NF jitter values (+34%; 
p<0.05). In comparing how DPN patients differed from controls in standard MUP 
parameters and NF MUP parameters, differences in NF MUP parameters tended to have 
greater effect sizes (Tables 4.2 and 4.3). The largest magnitude of effects were found for 
NF fibre count and max NF interval (d = 1.76 and 1.51, respectively; Table 4.3). In 
comparison, most standard MUP parameters had effect sizes less than 1.0 (Table 4.2). 
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Anthropometric Parameters Control (n = 12) DPN Patient (n = 12) 
Male/Female 7/5 7/5 
Age (years) 63.8 ± 15.5 65.8 ± 15.4 
Height (m) 1.8 ± 0.1 1.7 ± 0.1 
Weight (kg) 73.8 ± 6.1 83.1 ± 7.4* 
BMI (kg/m
2
) 24.4 ± 3.1 28.9 ± 3.7* 
   
Diabetic Characteristics Range or Limit of Normal  
Duration of Diabetes (years) - 14.1 ± 11.2 
Duration of DPN (years) - 9.2 ± 8.1 
HbA1c (%) <6.0 7.4 ± 1.4 
   
Nerve Conduction Studies Range or Limit of Normal  
Sural Nerve SNAP Amplitude 
(µV)  
>5 1.3 ± 2.3
#
 
TA CMAP amplitude (mV)  >4.0 5.0 ± 1.7 
Fibular nerve CV (m/s) >40.0 41.4 ± 10.4 
Table 4.1 Participant Characteristics 
* Denotes significant difference between groups (p<0.05). 
SNAP – sensory nerve action potential; TA – tibialis anterior; CMAP – compound 
muscle action potential; CV – conduction velocity; DPN – diabetic polyneuropathy. # 
SNAP responses were absent in 10 out of 12 patients. 
 
  
 
 
 
 
 
77 
 
 
 
 
Parameter Controls (n=12) DPN Patients (n=12) % Difference Effect Size 
Dorsiflexion MVC Strength (Nm) 34.1 ± 9.5 22.3 ± 7.2* -35% 1.39 
%MVC RMS EMG 23.2 ± 4.2 25.2 ± 3.8   
EMG Intensity (pps) 74.3 ± 20.2 55.6 ± 19.2* -25% 0.94 
Mean MU FR (Hz) at 25% MVC 12.10 ± 1.80 10.2 ± 1.2* -15% 1.24 
MUP Vpp (µV) 810.4 ± 217.0 1164.3 ± 493.0* +43% 0.92 
MUP Duration (ms) 12.3 ± 2.1 14.4 ± 2.2* +17% 0.97 
MUP Area (µVms) 1436.5 ± 503.6 2117.5 ± 991.1* +47% 0.86 
AAR (ms) 1.77 ± 0.22 1.8 ± 0.3   
Shape Width (ms) 0.7 ± 0.1 0.7 ± 0.1   
Turns (#) 4.2 ± 0.7 5.1 ± 0.9* +21% 1.11 
Traditional Jiggle (%) 36.4 ± 21.0 25.4 ± 20.7   
CMAP (mV) 6.8 ± 0.9 5.0 ± 1.7* -26% 1.32 
mSMUP (µV) 77.0 ± 20.0 116.0 ± 61.0* +51% 0.85 
MUNE (#) 99 ± 19 54 ± 25* -45% 2.02 
Table 4.2 Tibialis Anterior Strength, MUP and MUNE Parameters  
 
* Denotes significant difference between groups (p<0.05). Effect size calculated as Cohen’s D. MVC – maximal voluntary 
contraction; RMS – root mean squared; EMG – electromyography; pps – pulses per second; MU – motor unit; MUP – motor unit 
potential; Vpp – peak to peak voltage; AAR – area to amplitude ratio; CMAP – compound muscle action potential; mSMUP – mean 
surface motor unit potential; MUNE – motor unit number estimate; DPN – diabetic polyneuropathy 
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Parameter Controls (n=12) DPN Patients 
(n=12) 
% Difference Effect 
Size 
# of MUPTs 23.4 ± 1.6 26.4 ± 3.4 +13% 1.13 
Contractions (#) 4.4 ± 0.5 6.2 ± 2.5 +42% 0.99 
NF Area (kV/s
2
ms) 6.9 ± 1.8 9.7 ± 3.0* +40% 1.13 
NF Duration (ms) 3.8 ± 0.7 4.7 ± 0.9* +24% 1.12 
NF Dispersion (ms) 1.7 ± 0.4 2.4 ± 0.9* +38% 1.01 
Max NF Interval (ms) 1.0 ± 0.2 1.3 ± 0.2* +22% 1.51 
NF Fibre Count (#) 2.5 ± 0.4 3.3 ± 0.5* +31% 1.76 
NF Jiggle (%) 33.8 ± 3.7 40.9 ± 6.3* +21% 1.18 
NF Jitter (µs) 37.6 ± 9.0 50.6 ± 14.2* +34% 1.09 
% of MUPTs w/ 
blocking 
0.0 ± 0.0 17.1 ± 7.9* +17% 3.06 
% Blocking 0.0 ± 0.0 3.7 ± 1.3* +4% 4.02 
Table 4.3 Neuromuscular Transmission Stability and Near Fibre Parameters 
 
* Denotes significant difference between groups (p<0.05). Effect size calculated as 
Cohen’s D. 
MUPT – motor unit potential train; NF – near fibre; DPN – diabetic polyneuropathy 
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NF MUP size parameters were positively related to MUP area, the conceptually 
analogous standard MUP size parameter. NF area was positively related to MUP area in 
both controls (r = 0.67; p<0.05) and DPN patients (r = 0.55; p<0.05). NF duration was 
positively related to MUP area in controls (r = 0.45; p<0.05) and DPN patients (r = 0.35; 
p<0.05).  Also, in both controls (r = 0.64; p<0.05) and DPN patients (r = 0.81; p<0.05), 
NF dispersion (a measure of fiber contribution dispersion) was positively associated with 
MUP area.  
NF MUPs with greater numbers of fibre contributions tended to be larger in size. 
This is supported by the result that NF area was positively related (controls, r = 0.60; 
DPN patients, r = 0.51; p<0.05) with the number of distinct muscle fibres detected within 
that NF MUP (NF count) (Figure 4.2). Furthermore, NF jiggle was not related to MUP 
area (p>0.05), indicating acute neuromuscular instability was not associated with a 
traditional metric of motor unit size. However, NF jiggle was positively associated with 
NF fibre count (Figure 4.3; r = 0.46; p<0.05).  
NF dispersion, but not stability, was associated with whole muscle denervation. 
Specifically, NF jiggle values were not significantly related to dorsiflexion strength or 
TA MUNE values (p>0.05) (Figure 4.4A and 4C; p>0.05); whereas, in DPN patients, NF 
dispersion was negatively related to MUNE (Figure 4.4D; r = -0.63; p<0.05) but not 
strength (Figure 4.4B; p>0.05). Finally, no significant relationships were found between 
NF MUP parameters and duration of DM (p>0.05), duration of DPN (p>0.05) or 
glycemic control values (HbA1c levels) (p>0.05). 
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Figure 4.2 Relationship between near fibre (NF) fibre count and NF motor unit potential 
area 
Relationship between near fibre (NF) fibre count and NF Area in the tibialis anterior of 
controls (grey circles; r = 0.60 [grey line]) and diabetic polyneuropathy (DPN) patients 
(black circles; r = 0.51 [black line]). In both groups, NF motor unit potentials (MUPs) 
with greater NF fibre counts had larger NF MUP areas.  
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Figure 4.3 Relationship between near fibre (NF) fibre count and NF jiggle 
Relationship between near fibre (NF) fibre count and NF Jiggle in the tibialis anterior of 
controls (grey circles) and diabetic polyneuropathy (DPN) patients (black circles; r = 
0.46). In DPN patients, increased fibre counts were associated with increased NF 
instability (black line). No relationship was detected between these variables in controls 
(grey line). 
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Figure 4.4 Relationships between tibialis anterior health, strength and neuromuscular transmission stability 
Relationships between (A) dorsiflexion maximal voluntary contraction (MVC) strength and NF Jiggle; (B) dorsiflexion MVC strength 
and NF dispersion; (C) motor unit number estimates and near fibre (NF) Jiggle; and (D) motor unit number estimates and NF 
dispersion (DPN r = -0.63) in controls (grey circles) and diabetic polyneuropathy (DPN) patients (black circles). Relationships for 
control participants are denoted by grey lines; relationships for DPN patients are denoted by black lines.
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4.4 Discussion 
The main findings of this study were: (1) patients with DPN had larger (NF area, 
NF duration), more complex (NF dispersion, NF fibre count) and less stable NF MUPs 
(NF jiggle, NF jitter), compared to controls; (2) NF dispersion was positively related to 
whole muscle denervation (MUNE) but not strength, whereas NF MUP stability (NF 
jiggle) was not related to either strength or whole muscle denervation; (3) NF MUPs with 
a greater number of distinguishable near fibre contributions tended to be less stable, 
although no relationship was found between NF jiggle and NF area; (4) NF parameters 
were not significantly related to metrics of disease duration or glycemic control. 
4.4.1 Near Fibre versus Traditional MUP Parameters in Diabetic Polyneuropathy 
In the present study, patients with DPN had clear evidence of DM and DPN 
through their clinical assessment, elevated glycosylated hemoglobin (HbA1c) levels and 
reduced or absent sural sensory nerve action potential amplitudes (SNAPs) (Table 4.1). 
Our traditional MUP (Table 4.2) and NF MUP (Table 4.3) results show increased 
neuromuscular transmission instability and fibre density in patients with DPN.  Although 
this finding is consistent with a prior report that used traditional single-fibre EMG
5
, the 
present study extends these observations by using novel quantitative concentric needle-
derived EMG measures (NF MUP parameters).   
In the present study, traditional jiggle was not different between groups (p>0.05) 
whereas NF jiggle was significantly greater in patients with DPN compared to controls 
(Table 4.3; p<0.05). These divergent findings in two metrics purported to assess the same 
variable (i.e. neuromuscular transmission instability) support the idea that when 
analyzing intramuscular EMG signals detected using concentric needle electrodes during 
moderate level (25% MVC) contractions, NF MUP parameters may be more robust than 
standard MUP parameters
17
. Traditional jitter measured using concentric needle detected 
MUPs have been reported before in other neuropathic conditions
33,34
, and its advantages 
over SFEMG have been outlined
34
. However, our study appears to be the first to perform 
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this technique with DQEMG software, to present concentric needle acquired jiggle data, 
and to report NF MUP parameters in a chronic neuropathic condition.  
The lack of any significant differences in traditional jiggle values between groups 
in this study is surprising given our other results showing increased NF MUP instability 
(NF jiggle) in DPN patients (Table 4.3), and the conclusions of previous investigations
5
. 
However, one possible contributing factor to explain our finding may be the different 
degrees of intensity of MUPs detected during the sustained voluntary contractions in 
controls compared to patients with DPN (75 vs 55 pps respectively; Table 4.2). As a 
consequence of their neuropathy, individuals in the DPN group have significantly 
enlarged and fewer MUs compared to controls (Table 4.2)
7
. Thus, during a sustained 
dorsiflexion contraction at 25% MVC, DPN patients are activating fewer MUs, and those 
activated are discharging at lower firing rates (Table 4.2) leading to less intense 
electromyographic interference pattern activity (-25% less pps; Table 4.2). The reduced 
firing rates in DPN patients may reflect the slowing of muscle contractile properties
35
 or 
preferential loss of fast motor units
35
. These group differences in recruitment patterns are 
influential when examining MUP raster plots for stability analysis, as higher amounts of 
electrophysiological ‘contamination’ from nearby MUs is apparent in the control data 
versus that of the DPN patient group. This drives the traditional jiggle values artificially 
higher in controls such that they may not reflect the true amount of neuromuscular 
transmission instability. Compared to traditional jiggle, NF jiggle may be less affected by 
this contamination as the focus is placed on MUs with fibers near (within ~350 µm) the 
electrode detection surface, with minimal contributions from more distal fibres. This 
technical limitation could be reduced by using lower voluntary contractile intensities
5,10
 
or low-frequency, evoked contractions
33
. However performing contractions at 25% of 
MVC provides two important advantages. Firstly, this contractile intensity includes a 
greater, more representative sample of MUs from the muscle being examined, thus 
allowing for a more comprehensive assessment of the muscle’s entire motor unit pool. In 
contrast, other methods of measuring neuromuscular transmission instability have been 
limited to low threshold motor units, at relatively low firing rates
5,9
. Secondly, 
performing the protocol at 25% of MVC when using DQEMG allows for the 
simultaneous calculation of a valid MUNE
25
, which is another important and useful 
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measure related to neuromuscular health
36,6,7
. Indeed, reduced MUNEs in the DPN group 
had one of the largest effect sizes across all parameters (Table 4.2), supporting the 
inclusion of MUNEs as a useful clinical indicator. The specific MUNE results presented 
in this study have been reported and discussed previously
7
.  
In comparing NF MUP parameters, other than NF jiggle, with their respective 
analogous traditional MUP parameters there is a stronger degree of correlation. NF area 
and NF duration were significantly positively related to MUP area and MUP duration, 
respectively. This indicates these NF MUP parameters are positively associated with 
traditional metrics representing MU size. Additionally, NF area was positively related to 
NF fibre count which indicates the NF MUP size is partially determined by the number of 
near muscle fibres innervated by that particular motor unit (Figure 4.2). Similar to a 
previous report in DPN examining traditional jitter, we found increased NF jitter in DPN 
patients compared to controls (Table 4.3)
5
. It is important to note when comparing the 
traditional MUP and NF MUP parameter results for the present study that the apparent 
ability to discriminate between controls and DPN patients is greater using the NF MUP 
parameters. Specifically, the majority of the NF MUP parameters had greater effects sizes 
than standard MUP parameters (Tables 4.2 and 4.3). Indeed, the two parameters with the 
largest effect sizes were NF fibre count (d = 1.76) and max NF interval (d = 1.51). Thus, 
NF MUP parameters may prove more useful than standard MUP parameters in 
distinguishing neuropathic from non-neuropathic MUs, however further study is required. 
4.4.2 Physiological Interpretation and Clinical Relevance of Near Fibre MUP 
Parameters 
 Our data showing increased NF jiggle and NF jitter in DPN patients relative to 
controls may be reflective of pathological alterations in neuromuscular action potential 
propagation, or neuromuscular transmission instability, due to DPN (Table 4.3). 
Increased NF jiggle and NF jitter values primarily reflect the denervation-reinnervation 
process acutely
10
. Specifically, increased neuromuscular transmission instability is 
thought to occur in association with partial loss of innervation by a damaged motor axon, 
or incomplete reinnervation occurring between orphaned muscle fibres and their adopted 
axonal sprout during the process of collateral reinnervation
10
. In this instance, the concept 
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of acute reinnervation is contrasted by chronic reinnervation in which mature 
neuromuscular junctions have formed, and neuromuscular transmission variability has 
recovered. Additionally, our data show an increased amount of neuromuscular 
transmission failure (i.e. % blocking) in DPN patients compared to controls (Table 4.3). 
A previous study in DPN using SFEMG did not include blocking as a measured 
parameter
5
. Indeed, a greater contraction intensity would be more likely to challenge the 
neuromuscular system and induce neuromuscular transmission failure
37
. This intermittent 
transmission failure reflects the underlying dysfunction in processes related to 
neuromuscular transmission, and would also directly lead to increases in NF jiggle and 
NF jitter. However, it is unclear how potential dysfunction occurring at the site of distal 
axonal branches; the neuromuscular junction; muscle fibre action potential propagation; 
or some combination thereof, contribute to increased instability. Previous studies, mainly 
relying upon animal models, provide evidence that DPN-related neuromuscular 
instability could be due to a range of factors including: nerve demyelination and reduced 
axonal calibre
38
; axon terminal dysfunction
39
; ion channel alterations
39–41
; or structural 
changes at the muscle fibre
39,42
, among other possible mechanisms. Any of these putative 
changes within the neuromuscular system could differentially affect muscle fibre action 
potential conduction velocity
43
, consequently affecting MUP shape stability. Assuming 
these diabetes-related neuromuscular changes would not occur uniformly, nor have a 
consistent effect on action potential propagation across terminal axon branches or muscle 
fibres within a single motor unit, they could result in increased NF jiggle and NF jitter. In 
comparison, our results showing increased NF dispersion, max NF interval and NF fibre 
count in DPN are most likely representative of prior compensatory reinnervation that has 
occurred following muscle fibre denervation
4,7
. 
We did not find any relationships between neuromuscular transmission instability 
(NF jiggle) and whole muscle denervation (MUNE) or muscle strength (Figures 4.4C and 
4.4A; p>0.05). NF jiggle and MUNE may not have been related to one another as they 
reflect different aspects of the denervation-reinnervation process. Whereas increased NF 
jiggle may indicate acute, or on-going, denervation or reinnervation, a decreased MUNE 
represents denervation that is complete. Therefore it may be possible that individuals who 
have lost many motor units may possess fewer, enlarged, but relatively stable motor 
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units. Indeed, no significant relationship was found between NF jiggle and MUP area 
(p>0.05). Notwithstanding, there was a tendency for MUPs with greater numbers of 
distinguishable near fibre contributions to be less stable than their counterparts with 
fewer distinguishable near fibre contributions (Figure 4.3). This occurs perhaps because a 
motor unit that is sprouting axons to reinnervate denervated fibres will have a greater 
chance of having immature or nascent neuromuscular junctions which in turn will be 
unstable and lead to higher jitter and therefore contribute to higher jiggle. NF jiggle and 
strength did not correlate as increased neuromuscular transmission instability does not 
necessitate concurrent muscle atrophy or functional decrement. In contrast, in the DPN 
patients, NF dispersion was negatively related to MUNE (Figure 4.4D). This is likely due 
to increased NF dispersion representing prior motor unit remodeling that occurs 
following denervation (or a decrease in MUNE). Given these relationships, our results 
indicate the assessment of NF jiggle may be most useful in identifying patients in the 
early stages of neuromuscular pathology, prior to the development of detectable motor 
unit loss or decreases in strength. 
Our NF MUP stability parameters were not significantly related to the duration of 
DM or DPN, or glycemic control as expressed by HbA1c values. This is in contrast to 
one previous finding in which traditional jitter, derived from SFEMG, correlated 
positively with HbA1c
5
. The difference in findings may be attributed partially to the 
complex, multi-factorial nature of DPN. Some factors that may interact and effect 
neuromuscular transmission instability include: disease duration, disease severity, 
glycemic control
5
, adult aging, physical activity history, and natural biological variability. 
The effects and importance of these, and other factors, likely will require studies with 
greater numbers of participants.  
4.4.3 Conclusions 
We have demonstrated concentric needle-derived DQEMG can be used to detect 
increased neuromuscular transmission instability and motor unit remodeling in patients 
with DPN. Additionally, in a chronic neuropathic condition, we present NF MUP 
parameters and support their inclusion as potentially useful metrics concerning 
neuromuscular stability and motor unit remodeling relative to controls. Indeed, NF MUP 
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parameters may have enhanced clinical utility in detecting neuropathic abnormalities 
compared to standard MUP parameters. Our results show NF MUPs with greater 
numbers of distinct near fibre contributions are less stable. Changes in neuromuscular 
transmission instability do not appear to closely associate with whole muscle 
denervation; perhaps as a result of the development of stable motor axon-muscle fibre 
synapses as the collateral reinnervation process progresses. The presence of 
neuromuscular transmission blocking in DPN patients may have consequences 
concerning neuromuscular function under conditions that stress the capacity of the 
system, such as fatiguing contractions. Finally, NF jiggle may be useful in identifying 
patients in the early stages of neuromuscular disease, prior to the loss of motor units or 
onset of muscle weakness. 
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Chapter 5  
5 Skeletal muscle morphology and contractile function in relation to 
muscle denervation in diabetic neuropathy
4
  
5.1 Introduction  
Diabetes mellitus (DM) and its common complication, diabetic polyneuropathy 
(DPN) are associated with changes in the neuromuscular system and motor dysfunction
1
. 
Motor dysfunction as a result of DPN can manifest broadly as muscle atrophy, weakness, 
and increased susceptibility to fatigue
2–6
. These changes may be due to a combination of 
DM-induced alterations to the α-motor neuron, neuromuscular junction, and skeletal 
muscle fibres
7,8
. Despite many studies conducted using diabetic animal models, relatively 
few have attempted to directly quantify neuromuscular and motor unit properties in 
humans with DPN. Thus the current study was aimed at investigating alterations in 
contractile properties and morphology of skeletal muscle in patients with DPN in 
association with changes in motor unit properties and denervation. 
 In rodent models of DM, weakness, as measured through induced tetanic 
stimulation, has been attributed partially to muscle atrophy, particularly in fast-twitch 
fibres
9
. However, reduction in strength persists when muscle is compared relative to 
weight
9
 or cross-sectional area
10
. Studies investigating DPN in humans have reported 
length-dependent atrophy of skeletal muscle using magnetic resonance imaging (MRI) 
and dual energy x-ray absorptiometry (DXA) imaging techniques, in association with 
weakness
3,4,11
. Strength loss in DPN has also been linked to excess fat infiltration of 
skeletal muscle
12
 and preferential loss of type II muscle fibres related perhaps to their 
selective denervation
13
. Other studies using experimental rodent models of DPN report 
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distal motor axon or neuromuscular junction deficits, as well as excitation-contraction 
uncoupling and disruption of Ca
2+
 handling as contributing factors to strength loss
7,14,15
. 
Thus, there is no consensus on which factors, or combination of key factors explains DM 
or DPN-associated weakness in humans or rodents. In humans with DPN, a potential 
unexplored source and complication of muscle weakness may be due to increased 
antagonist coactivation. In other neurological disorders (i.e. stroke, muscular dystrophy, 
Parkinson’s disease), increased levels of coactivation have been reported to contribute to 
muscle weakness
16,17
 which may occur as a compensatory strategy to maintain joint 
stability. In addition to weakness, reductions in ankle plantar and dorsiflexion isokinetic 
muscle power
12
 and rate of torque development
13
 have been reported in DPN patients
12,13
. 
These changes have been associated with decrements to balance and physical function. 
To date, the relationships between muscle morphological changes and reduction in rate of 
torque development with a quantification of denervation, or motor unit loss, have not 
been explored in DPN patients.  
Whereas a loss of power production in DPN patients may be accounted for partly 
by a loss in strength, a reduction in contractile velocity could also play an important role. 
Studies investigating neuromuscular function in healthy adult aging have explored this 
link
18
. In diabetic rodent skeletal muscle, reduced contractile speed of muscle fibres has 
been shown
9,10,15,19
, however these studies have utilized rodent models of diabetes, and 
mechanically skinned single-muscle fibre preparations, and thus the translation of these 
results to humans is unclear. A study in the tibialis anterior (TA) of humans reported no 
differences in evoked contractile properties between patients with DM and controls
20
, but 
it is important to note the patient group studied featured DM, and not DPN. The presence 
of DPN could reflect a longer duration or more severe history of DM, and indeed DPN 
can result directly in greater muscle atrophy, weakness and neuromuscular remodeling 
than DM alone
21,22
. Indeed, DPN has been associated with reduced motor unit number 
estimates (MUNEs)
23,24
, although how this chronic process of muscular denervation may 
affect muscle morphology has not been comprehensively explored. 
Additionally, the potential slowing of muscle contractile properties has been 
purported to be associated with reduced motor unit (MU) firing rates
25
. Previous 
95 
 
 
 
investigations in rodent and human muscle have found muscle fibre contractile velocities 
match the firing rate properties of the motor neurons supplying their innervation
26,27
. This 
has been reported for some muscles in humans in relation to adult aging, including the 
TA
28
. It is conceivable that the lower maximal motor unit firing rates reported in DPN 
patients may be linked with slowed contractile properties relative to controls. However, 
although contractile slowing has been reported numerous times in rodent models of DM 
and DPN, this slowing has not been shown in humans with DPN. 
The purpose of this study was to assess the neuromuscular contractile properties of the 
TA in patients with DPN in comparison to age and sex-matched controls. The TA was 
selected because it is generally observed to be affected by DPN earlier and to a greater 
extent than more proximal muscles
29
, and it has a more important functional role in 
everyday tasks compared to more distal muscles (i.e. intrinsic muscles of the feet). Our 
specific objectives were three fold: (1) to investigate evoked twitch and voluntary 
contractile properties of dorsiflexors, including antagonist (plantar flexor) co-activation; 
(2) to determine peak TA muscle cross-sectional area (CSA), normalized strength 
(strength per unit of muscle tissue) and relative contractile and non-contractile tissue; (3) 
and to determine the relationship of the morphological measures stated above as they 
relate to TA denervation. We hypothesized patients with DPN would have slowed 
contractile properties compared to controls. Conjunctly, we hypothesized slowed 
contractile properties in DPN patients would be positively associated with lower mean 
firing rates (relative to controls) in TA motor units during a sustained, low intensity 
dorsiflexion contraction. We hypothesized patients with DPN would be weaker and 
demonstrate lower maximal rates of torque development during maximal isometric 
voluntary contractions (MVCs), and that these decrements would be positively related to 
increased antagonist co-activation. Additionally, we hypothesized DPN patients would 
possess smaller TA CSAs with greater relative amounts of non-contractile tissue which 
would be negatively related to the number of functioning motor units estimated in the 
TA. 
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5.2 Methods 
5.2.1 Participants 
With ethical approval from the local university’s Research Ethics Board, 
informed oral and written consent was obtained from twelve patients (7 men, 5 women; 
ages 32-78 years) with DPN. These patients met the criteria for diagnosis of type 2 non-
insulin dependent DM with clinical and electrophysiological features of confirmed 
DPN
30
. The majority of DPN patients were being treated with medications pertaining to 
glycemic control (i.e. metformin and/or insulin) and antihypertensives. Additionally, they 
had a thorough history, and clinical and electrophysiological examination by an 
experienced neurologist with specialized training in neuromuscular disease to exclude 
other causes of nerve injury and or neuropathy (i.e., compressive mononeuropathies or 
radiculopathies), and other neurological, metabolic or vascular conditions unrelated to 
DM or DPN. To provide electrophysiological evidence of neuropathy all DPN patients 
underwent motor nerve conduction studies of the fibular nerve while recording from the 
TA, as well as sensory nerve conduction studies of the sural nerve while recording from 
the ankle. Data regarding blood lipid profiles and glycemic control were obtained through 
chart review. The DPN patient group was compared with twelve healthy, age and sex-
matched controls (7 men, 5 women; ages 29-77 years) who were recruited from the 
community. Control participants were recreationally active, living independently in the 
community, free from medications and were screened by physicians (neurologists) to 
ensure they met inclusion criteria.  
5.2.2 Evoked Contractile Properties and Strength of Tibialis Anterior  
To assess voluntary and electrically stimulated properties of the TA, participants 
were seated in a custom isometric dorsiflexion dynamometer
31
. The right ankle was 
positioned at 30° of plantar flexion, while both knee and hip angles were maintained at 
90°. Movement at the hip was minimized by securing a padded, C-shaped brace to the 
distal aspect of the right thigh. Inelastic straps were wrapped over the dorsum of the foot 
to secure the foot to the dynamometer
2,23,32
. 
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All testing was performed on the right (dominant) leg. Maximal evoked twitch 
and compound muscle action potential (CMAP) responses of the TA were obtained by 
supramaximal, percutaneous electrical stimulation of the fibular nerve just distal to the 
fibular head. Stimulation was performed through a bar stimulating electrode using single, 
100 µs square wave pulses via a constant-voltage electrical stimulator (Digitimer 
stimulator, model DS7AH; Digitimer Ltd., Welwyn Garden City, UK). Supramaximal 
dorsiflexion twitches were evoked prior to the assessment of voluntary strength. 
Participants performed three dorsiflexion maximal voluntary contractions (MVCs), with 
at least 3 min of rest between attempts. Participants were instructed to contract as hard 
and fast as possible to ensure maximal torque, and rate of torque development were 
achieved. Each MVC was held for approximately 3-4 seconds. Participants were 
provided with real time visual feedback of their torque on a computer monitor and were 
verbally encouraged throughout the contraction. Voluntary activation during the 2
nd
 and 
3
rd
 MVC attempts was assessed using the interpolated twitch technique
33
. This technique 
involves supramaximal electrical stimulation of the fibular nerve before, during and after 
a voluntary MVC. The amplitude of the interpolated torque electrically evoked from a 
single 100µs stimulus during the plateau of the MVC was compared with a single 
(100μs) resting twitch evoked ~1s following the MVC.  Voluntary activation was 
calculated as a percent using the following equation: [1- (interpolated twitch /resting 
twitch)] x 100.  The twitch evoked following the MVC was used to evaluate post-
activation potentiation (PAP) torque. The peak torque of the three MVC attempts was 
taken as the maximal torque for the participant. All torque signals were collected and 
sampled online at 500 Hz using Spike2 software (Version 7.11; Cambridge Electronic 
Design Ltd., Cambridge, United Kingdom) and analyzed off-line to determine voluntary 
isometric torques (strength) and voluntary rate of torque development (RTD) (Nm/sec). 
Surface electromyography (EMG) was collected from the TA and soleus (SOL) 
using self-adhering Ag-AgCl electrodes (1 cm x 3 cm; GE Healthcare, Helsinki, 
Finland). For the TA, the active electrode was placed over the motor point, approximately 
7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior border of the tibia; 
whereas the reference electrode was placed over the distal tendon of the TA. For the 
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SOL, the active electrode was placed 2 cm below the gastrocnemii border, along the 
longitudinal axis over the soleus; whereas the reference electrode was placed over the 
distal tendon of the triceps surae. Electrode placement was adjusted to maximize the TA 
and SOL compound muscle action potential (CMAP) negative peak amplitudes as 
necessary. Two ground electrodes were placed over the patella. Electrically evoked 
CMAPs were elicited from the SOL using a bar electrode held in the distal portion of the 
popliteal fossa between the origins of the heads of the gastrocnemius to stimulate the 
tibial nerve. Surface EMG signals were preamplified (x100), amplified (x2), bandpass 
filtered (10 Hz to 1 kHz), converted by a 12-bit analog-to-digital converter (Power 1401, 
Cambridge Electronic Design, Cambridge, UK), and sampled online at 2,000 Hz. To 
calculate the level of coactivation, a 0.5 second period of EMG was analyzed from the 
SOL corresponding to the point of peak torque during a dorsiflexion MVC. The mean 
root mean square (RMS) of this EMG signal was calculated and normalized to the 
maximal SOL CMAP (% antagonist coactivation = [mean MVC SOL RMS EMG/peak 
RMS SOL CMAP] x 100).  
5.2.3 Decomposition-based Quantitative Electromyography (DQEMG) of Tibialis 
Anterior 
To obtain motor unit number estimates (MUNE) and mean MU firing rates in the 
TA, decomposition-based quantitative electromyography (DQEMG) data were acquired 
using decomposition enhanced spike triggered averaging (DE-STA) software, described 
in detail elsewhere
34
. Intramuscular EMG signals were recorded via a disposable 
concentric needle electrode (Model N53153; Teca Corp., Hawthorne, NY) inserted into 
the TA, 5-10 mm distal to the active surface electrode.  The surface and intramuscular 
EMG signals were bandpass filtered at 5 Hz to 1 kHz and 10 Hz to 10 kHz, respectively. 
Surface EMG was sampled at 3 kHz; intramuscular EMG was sampled at 30 kHz. 
Participants matched a target line of 25% MVC, visible on a computer monitor, for all 
isometric dorsiflexion contractions while the intramuscular needle electrode was inserted 
and manipulated in the muscle. This contraction intensity has been shown to be the most 
effective intensity for obtaining a representative motor unit number estimation (MUNE) 
in the tibialis anterior (TA) based on the limitations of the technique
32
. Surface and 
intramuscular EMG were collected while participants sustained a steady target torque for 
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each contraction held for ~30 s. Between contractions, the concentric needle electrode 
was repositioned in order to obtain a sample from different motor units. These procedures 
were repeated until at least 20 suitable trains of motor unit potentials (MUPs) and their 
respective surface-motor unit potentials (S-MUPs) were collected.  
Decomposed EMG signals were reviewed off-line to determine the acceptability 
of the needle-detected MUP trains and their corresponding S-MUPs.  A computer 
algorithm aligned the negative onset markers for all accepted S-MUPs and created a 
mean S-MUP template based upon their data-point by data-point average. All MUP and 
S-MUP markers were subsequently reviewed visually by the operator. A MUNE was 
derived by dividing the negative-peak amplitude of the CMAP by the negative peak 
amplitude of the mean S-MUP
23
 (MUNE = [CMAP/mean S-MUP). In addition to 
MUNEs, the DQEMG software measures firing rates (Hz) of individual motor unit action 
potential trains (MUAPTs), and provides overall mean firing rates per participant at a 
relative target level of contraction. The investigator was blinded to the status of the 
participant during off-line analysis. 
5.2.4 Magnetic Resonance Imaging of Dorsiflexors 
Magnetic resonance images were acquired via serial axial plane in a 3.0 Telsa 
magnet (Verio MRI, Siemens; Erlangen, Germany).  Proton density images were 
acquired using the following parameters:  1500ms repetition time (TR), 14ms echo time 
(TE), 256x192 matrix, 243x325mm field of view, 5mm slice thickness with slice 
separation of 2mm. Participants were inserted into the magnet bore feet first, in the 
supine position, with the motor point on their right TA isocentred to the bore of the 
magnet.  To ensure minimal movement the feet and knees were strapped together using 
inelastic, Velcro straps. The entire musculature of the leg from the tibial plateau to the 
malleoli was imaged. 
From the images, total TA CSAs were calculated pixel-wise using a combination 
of manual and semi-automated techniques with open-source OsiriX image processing 
software (version 4.1, Geneva, Switzerland).  Muscle CSAs were measured at the slice 
with the largest CSA.  Analysis began proximally from the first slice, in which the TA 
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appeared to the most distal slice containing the TA. A region of interest (ROI) was 
manually outlined on the dorsiflexor compartment with the brush tool and repeated every 
five slices; missing ROIs on the skipped slices were automatically interpolated.  With the 
TA outlined, all pixels outside the ROIs were set to zero.  To quantify the contractile only 
tissue, a three-dimensional threshold-growing tool was used to ensure only muscular 
tissue was included in the ROIs (excluding non-contractile tissue and septal spaces). Any 
errors produced by the automatic generation were corrected manually.  The software 
calculated muscle CSA and volume for the ROIs. Sample images of a leg of a control 
participant and DPN patient are depicted in Figure 5.1. The investigator was blinded to 
the status of the participant during off-line analysis. Previous research has shown a high 
degree of intra- (ICC=0.997) and inter-rater reliability (ICC=0.997) with this analysis 
technique
35
. Normalized strength was calculated by relating MVC torque values to TA 
CSA (Nm/cm
2
). 
 
 
 
Figure 5.1 Sample magnetic resonance imaging (MRI) images  
Sample MRI images of age-matched (~65 year old) male control (A) and diabetic 
polyneuropathy (DPN) patient (B) leg. The anterior compartment of the leg is outlined in 
white. Note: the greater amounts of intramuscular fatty infiltration and non-contractile 
tissue found in the DPN patient leg compared to the control leg (also see Table 5.3).             
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5.2.5 Statistics 
Mean values ± standard deviations are presented in the text.  Normally distributed 
data were analyzed using a one-way ANOVA (group); the level of significance was set at 
p ≤ 0.05. Normality was assessed using the Shapiro-Wilk normality test; the only variable 
found to have a non-normal distribution was mean SMUPs. Non-normally distributed 
data were analyzed using a Kruskal-Wallis one-way ANOVA on ranks. Relationships 
among variables of interest were testing using Pearson’s Product Moment Correlation. 
Data analyses were performed using SigmaPlot software (Version 12.2; Systat Software, 
Chicago, Illinois, US). 
 
5.3 Results 
5.3.1 Participant Characteristics 
Participant characteristics are presented in Table 5.1. No significant differences 
were detected for age (p=0.42) or height (p=0.29) between groups. DPN patients had 
significantly greater body mass (p=0.008) and BMI (p=0.02) than controls. Data 
characterizing the clinical history and status of the DPN patient group are also presented 
in Table 5.1.  
5.3.2 Dorsiflexor Contractile Properties 
 Dorsiflexor contractile properties are presented in Table 5.2. DPN patient MVCs 
were 35% lower with 48% slower rates of maximal voluntary RTD compared to controls 
(p=0.0001), although these differences did not appear to be due to any differences in 
voluntary activation (p=0.57). DPN patients featured weaker and slower evoked twitch 
responses as evidenced by lesser peak twitch torque (~35%; p=0.02), lesser average rate 
of twitch rise (~40%; p=0.01), greater half-relaxation time (~35%; p=0.001) and 
greater twitch contraction duration (~22%; p= 0.003). Additionally, the twitch response 
of DPN patients potentiated significantly less (~40%; p=0.01) following a 3 second 
MVC compared to controls. 
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Anthropometric Parameters Controls (n = 12) DPN Patients (n = 12) 
Male/Female 7/5 7/5 
Age (years) 64.5 ± 14.7 65.6 ± 14.6 
Height (m) 1.8 ± 0.1 1.7 ± 0.1 
Weight (kg) 73.8 ± 6.1 83.1 ± 7.4* 
BMI (kg/m
2
) 24.4 ± 3.1 28.9 ± 3.7* 
   
Diabetic Characteristics Range or Limit of Normal DPN Patients (n = 12) 
Duration of Diabetes (years) - 14.1 ± 11.2 
Duration of DPN (years) - 9.2 ± 8.1 
HbA1c (%) <6.0 7.4 ± 1.4 
Triglycerides (mmol/L) 0.77-1.7 1.9 ± 1.3 
Cholesterol (mmol/L) 3.0-5.0 4.1 ± 0.3 
HDL Cholesterol (mmol/L) 0.9-2.0 1.3 ± 0.5 
LDL Cholesterol (mmol/L) 2.0-3.0 2.1 ± 0.8 
Total Cholesterol:HDL Ratio <5.0 3.9 ± 0.9 
   
Nerve Conduction Studies Range or Limit of Normal DPN Patients (n = 12) 
Sural Nerve SNAP Amplitude 
(µV)  
>5 1.3 ± 2.5
#
 
TA CMAP amplitude (mV)  >4.0 5.0 ± 1.7 
Fibular nerve CV (m/s) >40.0 41.4 ± 10.4 
FDI CMAP amplitude (mV) >10.0 10.3 ± 2.7 
Ulnar nerve CV (m/s) >53.0 49.2 ± 3.4 
Table 5.1 Participant Characteristics 
 
SNAP – sensory nerve action potential; TA – tibialis anterior; CMAP – compound 
muscle action potential; CV – conduction velocity. # SNAP responses were absent in 10 
out of 12 patients. * Denotes significant difference between groups (p<0.05). 
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Muscle Property Control (n = 12) DPN (n = 12) % Difference 
MVC (Nm) 34.1 ± 9.5 22.3 ± 7.2* -34.6% 
Maximal MVC RTD (Nm/s) 180.5 ± 49.9 93.9 ± 33.1*  -47.9% 
Voluntary Activation (%) 98.3 ± 1.9 97.6 ± 2.1 - 
Peak twitch tension (Nm) 5.4 ± 1.9 3.5 ± 1.3* -35.2% 
Twitch average rate of rise 
(Nm/ms) 
0.05 ± 0.01 0.03 ± 0.01* -40.0% 
Time to peak tension (ms) 105.3 ± 17.1 113.6 ± 25.6 - 
Half relaxation time (ms) 121.8 ± 16.6 164.3 ± 32.1* +34.8% 
Twitch Rate of Relaxation 
(Nm/ms) 
0.04 ± 0.01 0.02  ± 0.01* -50.0% 
Twitch contraction duration 
TPT + HRT (ms) 
227.1 ± 24.6 277.9 ± 43.9* +22.0% 
Potentiated twitch tension 
(Nm) 
8.8 ± 2.7 4.8 ± 1.5* -45.5% 
% Potentiation 65.4 ± 22.1 39.7 ± 17.3* -39.3% 
Table 5.2 Dorsiflexion (tibialis anterior) contractile properties in controls and patients 
with diabetic polyneuropathy (DPN) 
 
MVC – maximal voluntary contraction; RTD – rate of torque development. * Denotes 
significant difference between groups (p<0.05). 
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5.3.3 Tibialis Anterior Cross-Sectional Area and Normalized Strength 
Both groups featured similar peak absolute TA total size (p=0.21), contractile 
tissue (p=0.18), and non-contractile tissue (p=0.14; Table 5.3). However, as a relative 
percentage of total size, DPN patients featured 5% less contractile tissue and 5% more 
non-contractile tissue (p=0.0003). When normalized to total TA CSA DPN patients were 
30% weaker than controls, although total TA CSA contains both contractile and non-
contractile tissue (p=0.008; Figure 5.2). However, DPN patients were also found to be 
weaker when strength was normalized to maximal TA contractile tissue CSA alone 
(p=0.03; Figure 5.2). 
 
 
 
 
Tibialis Anterior Parameter Control (n = 12) DPN (n = 12) % Difference 
Total CSA (cm
2
) 10.3 ± 2.3 9.5 ± 2.4 - 
Contractile tissue CSA (cm
2
) 9.6 ± 2.0 8.3 ± 2.2 - 
Contractile tissue CSA (%) 93.2 ± 2.8 87.8 ± 4.3* -4.8% 
Non-contractile CSA (cm
2
) 0.8 ± 0.4 1.1 ± 0.4 - 
Non-contractile CSA (%) 7.7 ± 2.8 12.2 ± 4.5* +74.3% 
Strength normalized to total 
CSA (Nm/cm
2
) 
3.5 ± 0.8 2.5 ± 0.9* -28.6% 
Strength normalized to 
contractile CSA (Nm/cm
2
) 
3.8 ± 0.6 2.8 ± 0.9* -26.3% 
Table 5.3 Tibialis anterior cross-sectional area and normalized dorsiflexion strength 
 
CSA – cross sectional area; DPN – diabetic polyneuropathy. * Denotes significant 
difference between groups (p<0.05). 
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5.3.4 Relationships between Muscular Denervation, Function and Morphology 
 DPN patients featured 25% smaller TA CMAPs (p=0.002), 50% larger mSMUPs 
(p=0.03), and 45% reduced MUNEs (p=0.0001) when compared to controls (Table 5.4). 
Between groups, no differences were found in antagonist co-activation during MVCs 
(p=0.07). In DPN patients, TA MUNEs were negatively related to the proportion of TA 
non-contractile tissue (p=0.007, r=0.72; Figure 5.3); whereas no significant relationships 
were found between TA MUNEs and contractile/non-contractile tissue in the control 
group (p=0.10, r=0.49; Figure 5.3). A significant negative relationship was found 
between dorsiflexion twitch half-relaxation time and tibialis anterior MUNEs in the DPN 
patient group (p=0.04; r = -0.61), but no significant relationship was found in the control 
group (p=0.32, r = -0.31) (Figure 5.4). In the DPN patient group, a negative relationship 
was found between antagonist co-activation and dorsiflexion MVC strength (p=0.03, r = -
0.64) but not RTD (p=0.24, r = -0.36). During 25%MVC dorsiflexion contractions, mean 
TA firing rates were significantly lower in patients with DPN (10 vs 12 Hz; p=0.009). 
Finally, within the patient group, mean firing rates were negatively correlated with twitch 
half relaxation time (p=0.009, r = -0.77), whereas no significant relationship was found 
within the control group (p=0.29, r = -0.36). 
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Electrophysiological 
Parameter 
Control (n = 12) DPN (n = 12) % Difference 
TA CMAP NP (mV) 6.8 ± 0.9 5.0 ± 1.7* -26.5% 
TA mSMUP NP (µV) 77.0 ± 20.0 116.0 ± 61.0* +50.6% 
TA MUNE (#) 99.0 ± 19.0 54.0 ± 25.0* -45.5% 
Mean TA Firing Rate at 
25%MVC (Hz) 
12.2 ± 1.7 10.1 ± 1.2* -17.2% 
MVC % Antagonist (Plantar 
Flexor) Coactivation 
2.7 ± 0.9 4.4 ± 2.4 - 
 
Table 5.4 Needle and surface electromyography of tibialis anterior and plantar flexors 
 
CMAP – compound muscle action potential; NP – negative peak amplitude; mSMUP – 
mean surface detected motor unit potential; MUNE – motor unit number estimation; 
MVC – maximal voluntary contraction; DPN – diabetic polyneuropathy. * Denotes 
significant difference between groups (p<0.05). 
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Figure 5.2 Dorsiflexion specific strength  
Dorsiflexion strength normalized to total tibialis anterior (TA) cross-sectional area (CSA) 
in controls (solid grey) and diabetic polyneuropathy (DPN) patients (solid black) and TA 
contractile tissue CSA in controls (striped grey) and diabetic polyneuropathy (DPN) 
patients (striped black). * denotes significant difference between groups (p<0.05). 
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Figure 5.3 Relationships between relative tibialis anterior (TA) non-contractile tissue 
with TA motor unit number estimations (MUNE) 
Controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols). 
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Figure 5.4 Relationships between dorsiflexion twitch half-relaxation time and tibialis 
anterior (TA) motor unit number estimates (MUNE) 
Controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols). 
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5.4 Discussion 
 The main findings of this study were: (1) patients with DPN had significantly 
weaker and slowed evoked and voluntary contractile properties of the dorsiflexors; (2) no 
differences between groups were found in antagonist co-activation during voluntary 
contractions; (3) DPN patients featured less dorsiflexion post-activation potentiation; (4) 
DPN patients had less relative contractile tissue and greater relative non-contractile tissue 
in the TA than controls; (5) compared to controls, DPN patients featured less specific 
strength when torque was related to total TA CSA or contractile TA tissue CSA; (6) 
MUNEs were positively related to relative TA contractile tissue CSA (and negatively 
related to TA non-contractile tissue CSA) in DPN patients, but not controls. 
 In the present study, our patient group featured clear evidence of DM and DPN 
through elevated glycosylated hemoglobin (HbA1c) levels and reduced or absent sural 
nerve sensory nerve action potential amplitudes (SNAPs) (Table 5.1). The slowed 
dorsiflexor contractile properties in patients with DPN are consistent with previous 
findings reported in rodent models of experimental diabetes
9,10,15,19
. This contractile 
slowing is evidenced by a decreased twitch average rate of rise (-40%), prolonged evoked 
half relaxation times (+35%) and contraction durations (+22%), as well as decreased 
maximal RTD during voluntary MVCs (-50%) (Table 5.3). In addition to slowing, DPN 
patients featured ~40% less post-activation potentiation (PAP) compared to controls 
(Table 5.3). Our results may be due to a variety of non-mutually exclusive factors, both 
myogenic and neurogenic in nature, and these factors may be directly related to 
mechanisms underlying decreases in strength and muscle quality. 
5.4.1 Muscle Strength, Quality and Denervation 
In humans, it has been well established that DM and DPN are associated with a 
loss of muscle mass and strength
2,11,36,37
. Indeed, our DPN group featured ~35% weaker 
dorsiflexion strength than the control group (Table 5.2). In DPN, this weakness is related 
to the severity of the neuropathy and is thought to be caused by motor axonal 
degeneration and subsequent muscle fibre atrophy
2,24
. In addition to the present study, 
previous reports have shown patients with DM have reduced muscle quality (torque per 
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unit of muscle) when compared to healthy controls (Figure 5.2)
11,37
. Thus, the present 
study importantly extends and focuses these previous findings by investigating patients 
with DPN, and relating neurogenic changes (i.e. motor axon or motor unit loss) with 
changes to muscle morphology. From our results a greater loss of motor units is 
associated with greater proportions of non-contractile intramuscular tissue (r = -0.72) and 
proportional loss of contractile tissue (r = 0.72) in patients with DPN (Figure 5.3). This 
process may be caused by the diabetes-induced denervation of muscle fibres and 
insufficiency of surviving motor neurons in providing collateral reinnervation, thus 
failing to rescue these orphaned muscle fibres
23,24,38
. If denervated muscle fibres fail to 
acquire a new source of innervation, they may atrophy, die and subsequently the vacated 
space may be replaced by intramuscular fat deposits or other non-contractile tissue
39–41
. 
Based on our results, strength and muscle quality differences cannot be attributed 
to differences in voluntary activation of the TA, as both groups were able to activate their 
muscle similarly, and near maximally (>95%). Additionally, no differences were found 
between groups for antagonist co-activation during voluntary MVCs (Table 5.4). 
However within the DPN group, there was a significant negative relationship (r = -0.64) 
between antagonist co-activation % and strength, thus perhaps with greater disease 
severity antagonist co-activation may become more pronounced to help stabilize the 
ankle joint during contraction. Alternatively, this pattern of weakness and increased co-
activation may be related to a loss of proprioception associated with DPN
42
. In either 
case, changes in agonist-antagonist co-activation in DPN patients seem comparable to 
contraction strategies used in other patient populations with neurological disorders such 
as stroke, muscular dystrophy and Parkinson’s disease16,17. Finally, myocellular gene 
expression of key contractile and regulatory proteins are markedly reduced in diabetes, 
particularly in the absence of insulin (and presumably established insulin resistance as 
occurs in type 2 DM)
43
. Some of these down-regulated genes control the synthesis of 
myosin heavy chain polypeptide, myosin light chain, actin, troponin, tropomyosin and 
calmodulin proteins 
43
. In a single myocyte, reduced transcription of these genes could 
result in less contractile (e.g. actin, myosin) and contractile-supporting proteins (e.g. 
troponin, tropomyosin), potentially resulting in less tension produced per muscle fibre. 
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5.4.2 Muscle Contractile Slowing and DPN 
 Conflicting results have been reported from studies that have explored the impacts 
of diabetes on muscle fibre type composition, which is important pertaining to contractile 
speed and post-activation potentiation (PAP). Using an experimental animal model of 
diabetes, one investigation showed slow oxidative muscle fibres were least affected by 
DM, whereas fast oxidative and fast glycolytic muscle fibres were reduced in proportion 
and size
44
. In contrast, using human cross-sectional studies, patients with non-insulin-
dependent DM (type 2 DM) have been reported to possess lower proportions of type I 
muscle fibres and greater proportions of type II fibres (especially type IIb) in skeletal 
muscle (vastus lateralis) compared to healthy controls
45,46
. It is important to note that the 
animal model of experimental diabetes
44
 represented type 1 DM in humans, whereas the 
muscle fibre composition studies in humans investigated patients with type 2 DM. Thus 
the latter may better reflect the physiological status of the patients included in the present 
study, who had type 2 DM. Given this information, faster contractile properties might be 
expected to accompany DM, contrary to the results presented in this study. However, it is 
possible changes in excitation-contraction (EC) coupling and Ca
2+ 
handling supersede the 
effects of muscle fibre type and MHC expression on contractile speed, or they are 
competing factors which are differently expressed depending on the muscle or disease 
severity. Indeed, it is important to note the durations of diabetes in the studies that tested 
human vastus lateralis (VL) muscles
45,46
 are unknown, and the VL is a relatively 
proximal muscle that may be less affected (versus TA) by the length-dependent 
neurogenic changes associated with DPN.  The muscle fibre compositions in the patients 
included in those prior studies with more recent disease onset may be more a reflection of 
the risk of development of DM as opposed to the effects of DM on potential muscle fibre 
type changes
47
. Additionally, studies investigating muscle fibre composition and DM 
have not explored the impacts of DPN on this relationship.  
 
Although motor unit or axon loss is a feature of DPN
2,23,24,38
 it is not known 
whether there is a preferential loss of larger, faster (type 2) motor units. If type 2 motor 
units are lost preferentially, this could drive the observed slowing of muscle contractile 
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properties via the collateral reinnervation of orphaned muscle fibres by slow, type 1 
motor neurons. Subsequently, these reinnervated muscle fibres acquire the characteristics 
of their new parent motor neuron
48
. Indeed, there is some evidence to suggest this may be 
the case in DPN. For example, our results show a negative relationship between MUNEs 
and dorsiflexion twitch half-relaxation time (r = -0.61). This relationship could reflect a 
slowing of muscle properties due to a preferential loss of faster motor units associated 
with muscular denervation (Figure 5.4). The significantly lesser degree of PAP in 
muscles from DPN patients reported in this study may also reflect a greater proportional 
loss of fast, type 2 motor units because muscle potentiation is known to be heavily 
influenced by fibre type composition
49
. Also, motor unit firing rates are reduced in DM 
and DPN patients at a given contractile intensity in both the TA (Table 5.4)
23
 and vastus 
lateralis
25
 which may indicate a preferential loss of faster motor units, or slowing of the 
firing rates of surviving motor units. This process matches the contractile slowing 
reported in the present study and corroborates findings in healthy development and 
aging
27,28
. Additionally, within the DPN group, prolonged twitch half-relaxation times 
were negatively associated with decreases in mean firing rates (r
 
= -0.77), however it is 
not known if one alteration is necessarily dependent on the other. 
Changes in EC coupling and Ca
2+
 handling may partially be responsible for 
slowing of contractile properties of patients with DPN. It has been reported previously 
that baseline myocellular Ca
2+
 levels are elevated in diabetic rats
50
. Even relatively minor 
increases in myocellular Ca
2+
 concentrations have been demonstrated to cause attenuation 
in the rate of Ca
2+ 
release from the sarcoplasmic reticulum (SR) during contraction
51,52
, 
and therefore a lower rate of SR Ca
2+
 release could directly lead to a decrease in RTD in 
evoked or voluntary contractions. Additionally, muscles from diabetic rodents may 
possess elevated SR Ca
2+
 ATPase activity levels and increased microsomal Ca
2+
 uptake 
capacity
53
. This increased sequesterization and reuptake of Ca
2+
 may impose further 
limitations on Ca
2+
 interaction with the actin-myosin contractile complex, resulting in the 
reduced RTD in the muscles of the DPN group compared with controls found in our 
study. However, increased reuptake of Ca
2+
 by the sarcoplasmic reticulum would 
presumably result in an increased rate of relaxation, which is contrary to the results 
reported in the present study.  
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 Additional considerations regarding the reported reductions in strength and 
slowed contractile properties in patients with DPN include alterations in muscle 
architecture and tendon mechanical properties. Whereas aspects of muscle architecture, 
such as pennation angle, fascicle length and sarcomere number and orientation, were not 
directly measured in this study, the increased proportion of non-contractile tissue in the 
TA of DPN patients may reflect broader architectural changes. Heterogeneous 
development of intramuscular non-contractile tissue and fatty infiltration
12
 may not only 
reduce muscle CSA, but it may also disrupt normal fascicular organization. Structurally, 
an important determinant of whole muscle contractile speed is the number of sarcomeres 
in series
54
, and fascicular disruption via non-contractile tissue could result in contractile 
slowing. With regard to tendon mechanical properties, previous studies have found the 
tendons of DM and DPN patients appear to show signs similar to those undergoing 
accelerated aging
55,56
. Specifically, these changes include altered tendon fibril shape, 
increases in fibril packing density, and increased tendon stiffness
55,57
. However, these 
DM-related changes in tendon properties are unlikely to lead to a slowed or weaker 
contractile response as a stiffer tendon would be conducive to a faster RTD. Slowed 
contractile properties as a result of DPN may be related to important functional 
decrements in conjunction with strength loss; specifically impaired muscle power 
generation. As power is a function of both muscle torque generating capacity and 
contractile velocity, a decrease in either or both aspects will lead to reductions in power. 
Indeed, previous reports show patients with DM feature a loss of isokinetic power 
generation relative to controls, and the degree of power loss is greater than reductions in 
torque generating capacity
12,36
. Additionally, this loss of power in DPN patients may be 
more important than strength loss alone in terms of functional consequences in dynamic 
muscle activities and the onset of physical disability
58
. Finally, one possible confound 
related to our findings regarding contractile slowing is the potential difference between 
groups in physical activity levels. A previous study has shown that with adult aging, more 
sedentary individuals demonstrate greater contractile slowing than those who are more 
physically active
59
. We do not report a direct quantification of physical activity history of 
our participants, however both our controls and nearly all of our DPN patients were 
living independently in the community with no mobility issues (2 DPN patients had 
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impaired mobility and utilized a wheelchair or a cane). We do not believe there were 
substantive differences in everyday physical activity levels between the two groups. 
Thus, whereas a lesser engagement in physical activity may be responsible for some of 
the slowing observed in our patient group, we believe the primary reason underlying the 
reported contractile differences is due to DPN itself, not reduced physical activity levels. 
5.4.3 Summary 
 The present study reports contractile slowing, loss of muscle CSA, loss of 
strength and reduced contractile quality of lower limb muscles in association with DPN 
in humans. We propose these neuromuscular alterations may be caused by a combination 
of factors related to both myogenic and neurogenic changes that are known to occur with 
DPN. However, the relationships between muscle morphology and contractile slowing 
with denervation (MUNE) suggests changes in muscle properties may be secondary to 
neurogenic processes. With regards to functional consequences, these findings may 
represent key underlying mechanisms leading to DPN-related impairments in gait
11,60
, 
impaired balance and increased fall risk
61,62
, and reduced walking speed
62
. 
 
 
 
 
 
 
 
 
 
 
116 
 
 
 
References 
1. Andersen, H. Motor dysfunction in diabetes. Diabetes Metab. Res. Rev. 28, 89–92 
(2012). 
2. Allen, M.D., Choi, I.H., Kimpinski, K., Doherty, T.J. & Rice, C.L. Motor unit loss 
and weakness in association with diabetic neuropathy in humans. Muscle Nerve 
48, 298–300 (2013). 
3. Andersen, H., Gadeberg, P. C., Brock, B. & Jakobsen, J. Muscular atrophy in 
diabetic neuropathy: a stereological magnetic resonance imaging study. 
Diabetologia 40, 1062–9 (1997). 
4. Greenman, R., Khaodhiar, L. & Lima, C. Foot small muscle atrophy is present 
before the detection of clinical neuropathy. Diabetes 28, 1425-30 (2005). 
5. Regensteiner, J.G., Bauer, T.A., Reusch, J.E., Brandenburg, S.L., Sippel, J.M., 
Vogelsong, A.M., Smith, S., Wolfel, E.E., Eckel, R.H., and Hiatt, W.R. Abnormal 
oxygen uptake kinetic responses in women with type II diabetes mellitus skeletal 
muscle contracting at moderate intensity J. Appl. Physiol. 85, 310–17 (1998). 
6. Regensteiner, J., Sippel, J., McFarling, E.T., Wolfel, E.E., Hiatt, W.R. Effects of 
non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. 
Sci. Sport. Exerc. 27(6): 875-81 (1995).  
7. Cameron, N.E., Cotter, M.A., & Robertson, S. Changes in skeletal muscle 
contractile properties in streptozocin-induced diabetic rats and role of polyol 
pathway and hypoinsulinemia. Diabetes 39, 460–5 (1990). 
8. Fahim, M.A., Hasan, M.Y. & Alshuaib, W.B. Early morphological remodeling of 
neuromuscular junction in a murine model of diabetes. J. Appl. Physiol. 89, 2235–
40 (2000). 
9. Cotter, M., Cameron, N.E., Lean, D.R. & Robertson, S. Effects of long-term 
streptozotocin diabetes on the contractile and histochemical properties of rat 
muscles. Q. J. Exp. Physiol. 74, 65–74 (1989). 
10. Stephenson, G., O’Callaghan, A. & Stephenson, D. Single-fiber study of 
contractile and biochemical properties of skeletal muscles in streptozotocin-
induced diabetic rats. Diabetes 43, (1994). 
11. Volpato, S., Bianchi, L. & Lauretani, F. Role of muscle mass and muscle quality in 
the association between diabetes and gait speed. Diabetes 35, 1672-1679 (2012).   
12. Hilton, T. N., Tuttle, L. J., Bohnert, K. L., Mueller, M. J. & Sinacore, D. R. 
Excessive adipose tissue infiltration in skeletal muscle in individuals with obesity, 
diabetes mellitus, and peripheral neuropathy: association with performance and 
function. Phys. Ther. 88, 1336–44 (2008). 
117 
 
 
 
13. Gutierrez, E. & Helber, M. Dealva, D., Ashton-Miller, J.A., Richardson, J.K. Mild 
diabetic neuropathy affects ankle motor function. Clin. Biomech. 16, 522–528 
(2001). 
14. Fahim, M.A. el-Sabban, F., & Davidson, N. Muscle contractility decrement and 
correlated morphology during the pathogenesis of streptozotocin-diabetic mice. 
Anat Rec. 244, 240–244 (1998). 
15. Lesniewski, L.A., Miller, T.A. & Armstrong, R.B. Mechanisms of force loss in 
diabetic mouse skeletal muscle. Muscle Nerve 28, 493–500 (2003). 
16. Busse, M.E., Wiles, C.M. & van Deursen, R.W.M. Co-activation: its association 
with weakness and specific neurological pathology. J. Neuroeng. Rehabil. 3, 26 
(2006). 
17. Lamontagne, A., Malouin, F., Richards, C.L. & Dumas, F. Mechanisms of 
disturbed motor control in ankle weakness during gait after stroke. Gait Posture 
15, 244–55 (2002). 
18. McNeil, C.J., Vandervoort, A.A. & Rice, C.L. Peripheral impairments cause a 
progressive age-related loss of strength and velocity-dependent power in the 
dorsiflexors. J. Appl. Physiol. 102, 1962–8 (2007). 
19. Paulus, S.F. & Grossie, J. Skeletal muscle in alloxan diabetes. A comparison of 
isometric contractions in fast and slow muscle. Diabetes 32, 1035–9 (1983). 
20. Singh-Peters, L.A., Jones, G.R., Kenno, K.A. & Jakobi, J.M. Strength and 
Contractile Properties Are Similar Between Persons With Type 2 Diabetes and 
Age-,Weight-, Gender- and Physical Activity matched Controls. Can. J. Diabetes 
31, 357–364 (2007). 
21. Boulton, A.J. & Ward, J.D. Diabetic neuropathies and pain. Clin Endocrinol 
Metab 15, 917–931 (1986). 
22. Bril, V., Werb, M.R., Greene, D.A. & Sima, A.A.F. Single-fiber electromyography 
in diabetic peripheral polyneuropathy. Muscle Nerve 19, 2–9 (1996). 
23. Allen, M.D., Kimpinski, K., Doherty, T.J. & Rice, C.L. Length dependent loss of 
motor axons and altered motor unit properties in human diabetic polyneuropathy. 
Clin. Neurophysiol. 125, 836–43 (2014). 
24. Hansen, S. & Ballantyne, J.P. Axonal dysfunction in the neuropathy of diabetes 
mellitus: a quantitative electrophysiological study. J. Neurol. Neurosurg. 
Psychiatry 40, 555–64 (1977). 
25. Watanabe, K. Gazzoni, M., Holobar, A., Miyamoto, T., Fukuda, K., Merletti, R., 
Moritani, T. Motor unit firing pattern of vastus lateralis muscle in type 2 diabetes 
mellitus patients. Muscle Nerve 48, 806–13 (2013). 
118 
 
 
 
 
26. Gardiner, P.F. & Kernell, D. The “fastness” of rat motoneurones: time-course of 
afterhyperpolarization in relation to axonal conduction velocity and muscle unit 
contractile speed. Pflügers Arch. Eur. J. Physiol. 415, 762–766 (1990). 
27. Vrbová, G., Navarrete, R. & Lowrie, M. Matching of muscle properties and 
motoneurone firing patterns during early stages of development. J. Exp. Biol. 115, 
113–23 (1985). 
28. Connelly, D.M., Rice, C.L., Roos, M.R. & Vandervoort, A.A. Motor unit firing 
rates and contractile properties in tibialis anterior of young and old men. J. Appl. 
Physiol. 87, 843–52 (1999). 
29. Said, G., Slama, G., & Selva, J. Progressive centripetal degeneration of axons in 
small fibre diabetic polyneuropathy. Brain. 106, 791–807 
30. Dyck, P. J. and the Toronto Expert Panel on Diabetic Neuropathy. Diabetic 
polyneuropathies : update on research definition , diagnostic criteria and estimation 
of severity. Diabetes Metab Res Rev. 27, 620–628 (2011).  
31. Marsh, E., Sale, D., McComas, A.J. & Quinlan, J. Influence of joint position on 
ankle dorsiflexion in humans. J. Appl. Physiol. 51, 160–7 (1981). 
32. McNeil, C.J., Doherty, T.J., Stashuk, D.W. & Rice, C.L. The effect of contraction 
intensity on motor unit number estimates of the tibialis anterior. Clin. 
Neurophysiol. 116, 1342–7 (2005). 
33. Todd, G., Gormon, R.B. & Gandevia, S.C. Measurement of voluntary activation of 
fresh and fatigued human muscles using transcranial magnetic stimulation. Muscle 
Nerve 29, 834-842 (2004).  
34. Stashuk, D.W. Decomposition and quantitative analysis of clinical 
electromyographic signals. Med. Eng. Phys. 21, 389–404 (1999). 
35. Berger, M.J., McKenzie, C.A, Chess, D.G., Goela, A. & Doherty, T.J. Quadriceps 
neuromuscular function and self-reported functional ability in knee osteoarthritis. 
J. Appl. Physiol. 113, 255–62 (2012). 
36. Andersen, H. & Poulsen, P. Isokinetic muscle strength in long-term IDDM patients 
in relation to diabetic complications. Diabetes 45, (1996). 
37. Park, S.W., Goodpaster, B.H., Strotmeyer, E.S., Rekeneire, N., Harris, T.B., 
Schwartz, A.V., Tylavsky, F.A., Newman, A.B. Decreased muscle strength and 
quality in older adults with type 2 diabetes: the health, aging, and body 
composition study. Diabetes 55, 1813–8 (2006). 
119 
 
 
 
38. Ramji, N., Toth, C., Kennedy, J. & Zochodne, D.W. Does diabetes mellitus target 
motor neurons? Neurobiol. Dis. 26, 301–11 (2007). 
39. Doherty, T.J., Vandervoort, A.A., Taylor, A.W. & Brown, W.F. Effects of motor 
unit losses on strength in older men and women. J. Appl. Physiol. 74, 868–74 
(1993). 
40. Lexell, J. Human aging, muscle mass, and fiber type composition. Journals of 
Gerontology, 50, 11-16 (1995). 
41. Kent-Braun, J.A., Ng, A.V. & Young, K. Skeletal muscle contractile and 
noncontractile components in young and older women and men. J. Appl. Physiol. 
88, 662–8 (2000). 
42. Van Deursen, R.W. & Simoneau, G.G. Foot and ankle sensory neuropathy, 
proprioception, and postural stability. J. Orthop. Sports Phys. Ther. 29, 718–26 
(1999). 
43. Sreekumar, R., Halvatsiotis, P., Schimke, J.C. & Nair, K.S. Gene Expression 
Profile in Skeletal Muscle of Type 2 Diabetes and the Effect of Insulin Treatment 
Candidate genes for type 2 diabetes. Diabetes. 51, 1913–1920 (2002). 
44. Armstrong, R.B., Gollnick, P.D. & Ianuzzo, C.D. Histochemical properties of 
skeletal muscle fibers in streptozotocin-diabetic rats. Cell Tissue Res. 162, 387–94 
(1975). 
45. Mårin, P., Andersson, B., Krotkiewski, M. & Björntorp, P. Muscle fiber 
composition and capillary density in women and men with NIDDM. Diabetes 
Care 17, 382–6 (1994). 
46. Simoneau, J. & Kelley, D. Altered glycolytic and oxidative capacities of skeletal 
muscle contribute to insulin resistance in NIDDM. J. Appl. Physiol. 166–171 
(1997). 
47. Pagel-Langenickel, I., Bao, J., Pang, L. & Sack, M.N. The role of mitochondria in 
the pathophysiology of skeletal muscle insulin resistance. Endocr. Rev. 31, 25–51 
(2010). 
48. Buller, A., Eccles, J. & Eccles, R. Interactions between motoneurones and muscles 
in respect of the characteristic speeds of their responses. J. Physiol. 417–439 
(1960). 
49. Hamada, T., Sale, D.G., MacDougall, J.D. & Tarnopolsky, M. a. Interaction of 
fibre type, potentiation and fatigue in human knee extensor muscles. Acta Physiol. 
Scand. 178, 165–73 (2003). 
120 
 
 
 
50. Nakagawa, M. & Kobayashi, S. Kimura, I., Kimura, M. Diabetic state-induced 
modification of Ca, Mg, Fe and Zn content of skeletal, cardiac and smooth 
muscles. Endocrinol. Japon. 36, 795-807 (1989).  
51. Benders, A.A., Oosterhof, A., Wevers, R.A., Veerkamp, J.H. Excitation-
contraction coupling of cultured human skeletal muscle cells and the relation 
between basal cytosolic Ca 2+ and excitability. Cell Calcium 21, 81-91 (1997). 
52. González, E. & Delbono, O. Age-dependent fatigue in single intact fast- and slow 
fibers from mouse EDL and soleus skeletal muscles. Mech. Ageing Dev. 122, 
1019–32 (2001). 
53. Ganguly, P.K., Mathur, S., Gupta, M.P., Beamish, R.E. & Dhalla, N.S. Calcium 
pump activity of sarcoplasmic reticulum in diabetic rat skeletal muscle. Am. J. 
Physiol. 251, E515–23 (1986). 
54. Lieber, R.L. & Friden, J. Functional and clinical significance of skeletal muscle 
architecture. Muscle Nerve 1647–1666 (2000).  
55. Grant, W.P., Sullivan, R., Sonenshine, D.E., Adam, M., Slusser, J.H., Carson, 
K.A., Vinik, A.I. Electron microscopic investigation of the effects of diabetes 
mellitus on the Achilles tendon. J. Foot Ankle Surg. 36, 272–278 (1997). 
56. Hamlin, C.R., Kohn, R. R. & Luschin, J.H. Apparent accelerated aging of human 
collagen in diabetes mellitus. Diabetes 24, 902–4 (1975). 
57. Andreassen, T., Seyer-Hansen, K. & Bailey, A. Thermal stability, mechanical 
properties and reducible cross-links of rat tail tendon in experimental diabetes. 
Biochim. Biophys. Acta. 677, 313–317 (1981). 
58. Reid, K.F. & Fielding, R.A. Skeletal muscle power: a critical determinant of 
physical functioning in older adults. Exerc. Sport Sci. Rev. 40, 4–12 (2012). 
59. D’Antona, G., Pellegrino, M.A., Carlizzi, C.N. & Bottinelli, R. Deterioration of 
contractile properties of muscle fibres in elderly subjects is modulated by the level 
of physical activity. Eur. J. Appl. Physiol. 100, 603–11 (2007). 
60. Meier, M.R., Desrosiers, J., Bourassa, P. & Blaszczyk, J. Effect of type II diabetic 
peripheral neuropathy on gait termination in the elderly. Diabetologia 44, 585–92 
(2001). 
61. Simmons, R.W. & Richardson, C. The effects of muscle activation on postural 
stability in diabetes mellitus patients with cutaneous sensory deficit in the foot. 
Diabetes Res. Clin. Pract. 53, 25–32 (2001). 
62. Resnick, H., Stansberry, K., Harris, T.B., Tirivedi, M., Smith, K., Morgan, P., 
Vinik, A.I. Diabetes, peripheral neuropathy, and old age disability. Muscle Nerve. 
43–50 (2002).  
121 
 
 
 
CHAPTER 6 
6 Increased fatigability associated with severe diabetic neuropathy is 
attributed partially to neuromuscular transmission failure
5
 
6.1 Introduction 
Diabetic polyneuropathy (DPN), a common complication of diabetes mellitus 
(DM), can be associated with dysfunction of the neuromuscular system. Some DPN-
related neuromuscular changes include: muscle atrophy
1
, weakness
2
, muscle contractile 
slowing
3
, reduced motor unit firing rates
4–6
, and motor unit loss
5,7,8
. However, at present, 
little is known regarding how these alterations may affect the performance of the 
neuromuscular system when its capacity is stressed during a fatiguing task and 
subsequent recovery. Challenging the compromised system will permit the identification 
and functional relevance of key underlying factors contributing to DPN.  
Neuromuscular fatigue can be defined as the loss of voluntary force-producing 
capacity during physical activity
9
. In the context of this investigation, this is 
differentiated from “experienced fatigue” which refers to a general sense of tiredness, 
lack of energy or chronic exhaustion often reported clinically
10,11
. Neuromuscular fatigue 
is well known to be task-dependent and can be affected by a wide array of factors 
including age
12
, physical training status
13
 and neurological disease
14
.  
One previous study that explored muscle fatigue in insulin dependent (type 1) 
DM, concluded DM patients have greater relative muscle endurance than controls during 
repeated, maximal isokinetic contractions of the ankle plantar and dorsiflexors
15
. 
However, in that report, the majority of DM patients either did not have symptoms of 
DPN or had a neuropathy with minimal motor involvement
15
. Additionally, no measure 
                                                 
5
 A version of this chapter has been submitted for publication. Used with permission from 
the American Physiological Society. 
 
Allen, M.D., Kimpinski, K., Doherty, T.J., Rice, C.L. Increased fatigability associated 
with severe diabetic neuropathy is attributed partially to neuromuscular transmission 
failure. J Appl Physiol (undergoing revision) 
122 
 
 
 
of voluntary activation was made, therefore it is not known whether participants were 
producing maximal efforts during their isokinetic contractions
15
. It has been shown 
previously that individuals with metabolic disease without neuropathy (e.g. type 1 DM)
16
, 
vascular disease (e.g. chronic heart failure)
17
, or nerve disease (e.g. amyotrophic lateral 
sclerosis [ALS])
18
, fatigue more quickly than controls.  
Greater fatiguability in various other clinical populations when compared with 
controls has been attributed to a range of factors including: insufficient blood flow
17
, 
impaired neuromuscular transmission
19
, and central activation failure
20
. Indeed, even 
during minimally fatiguing contractions (25% MVC for 30 seconds), neuromuscular 
conduction failure has been reported in DPN patients (Chapter 4). In contrast, healthy 
adult aging has been associated with greater resistance to fatigue in most isometric 
tasks
12,21
, but not all isometric tasks and muscle groups
22
. It is not entirely clear whether 
slowed contractile and metabolic functions often reported with aging necessarily provide 
greater endurance
23
, in any case, slowed contractile properties also have been reported in 
DPN patients which could theoretically impart the same effect on fatigability
3
. However, 
because DPN can involve concurrent pathophysiological changes to metabolism, 
vasculature, and nerve and muscle, the impact of altered contractile properties may be 
mitigated. Therefore, DPN provides an interesting model to study various factors 
contributing to fatigue as well as to improved understanding about the functional impact 
of DPN. 
Investigating the recovery of neuromuscular properties following fatigue also can 
provide insight into underlying physiological processes, although it is typically less well 
studied than fatigue per se. Metabolic disturbances
24
, blood flow impairments
25
 and 
dysfunction in myocellular processes related to clearing metabolites and restoring 
homeostasis
26,27
 could conceivably impair or delay recovery in DPN patients.  
The present study used a sustained, isometric dorsiflexion maximal voluntary 
contraction (MVC) to induce fatigue to a predetermined task termination point (i.e. 
60%MVC). Dorsiflexion was selected because the dorsiflexors (i.e. tibialis anterior) are 
known to be affected in DPN
3,5,7
, and participants are readily able to maximally activate 
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the dorsiflexors, with minimal familiarization or training
28
. A sustained, isometric MVC 
was selected to provide a relatively simple model that would substantially stress the 
neuromuscular system
29,30
. Finally, a pre-determined task termination point (60%MVC) 
was utilized to ensure all participants fatigued to the same degree relative to their 
maximal strength, thus providing an opportunity to assess recovery
30
.  
Thus the main objective of this study was to investigate neuromuscular fatigue in patients 
with DPN compared to age-matched controls using a sustained, dorsiflexion MVC. We 
also aimed to determine whether impairments in neuromuscular transmission or voluntary 
activation were associated with fatiguability in the DPN group. An additional objective 
was to assess the short-term (i.e. 2 minute) neuromuscular recovery of DPN patients 
compared to controls. We hypothesized individuals with DPN would fatigue more slowly 
than controls due to reduced absolute strength and slowed muscle contractile properties. 
Additionally we hypothesized both groups would be able to achieve near maximal 
voluntary activation (~95%) while fatiguing to 60% of MVC torque. Finally, we 
hypothesized DPN patients would recover more slowly than controls following the 
fatigue protocol due to DPN-related dysfunction in metabolite clearance and blood flow. 
 
6.2 Methods 
6.2.1 Participants 
Ten patients (6 males) with DPN (aged 64 ± 11 yrs) and ten age- and sex-matched 
controls (aged 62 ± 12 yrs) were recruited for participation in this study. All participants 
provided informed, written consent prior to participation. The study was approved by the 
local university’s Research Ethics Board and conformed to the Declaration of Helsinki. 
The patients with DPN met accepted clinical criteria for diagnosis of DM and DPN
31
. 
The presence of DPN was confirmed via clinical and electrophysiological examination 
performed by a trained neurologist, who also confirmed the absence of other causes of 
nerve injury or neuropathy. Data outlining some of the neuromuscular impacts of DPN 
(e.g. loss of motor units, muscle slowing, and neuromuscular transmission instability) in 
these patients have been previously reported elsewhere
3,5
. Patients with metabolic, 
124 
 
 
 
neurological or vascular conditions unrelated to DM or DPN were excluded from 
participation. Data regarding glycemic control were obtained through clinical chart 
review. Control participants were living independently in the community, free from 
medications and were screened by physicians (neurologists) to ensure they met inclusion 
criteria. Participants in both groups were not engaged in systematic physical exercise 
regimens. 
6.2.2 Evoked Contractile Properties and Maximal Strength of Dorsiflexors  
The experimental set-up has been described in detail in previous reports
3,5
. 
Participants were seated in a custom isometric dorsiflexion dynamometer to assess 
voluntary and electrically evoked properties of the dorsiflexor muscles
32
. In all 
participants the right leg was tested. The ankle was positioned at 30° of plantar flexion; 
both knee and hip angles were positioned at 90°. Hip joint movement was minimized by 
securing a padded, adjustable brace over the distal aspect of the right thigh. Inelastic 
straps were wrapped over the dorsum of the foot to secure it to the dynamometer
33
. The 
great toe was left uncovered by the straps to minimize torque contributions from extensor 
hallucis longus.  
Maximal evoked single twitch and compound muscle action potential (CMAP) 
responses from the dorsiflexors (tibialis anterior muscle) were obtained using 
supramaximal electrical stimulation of the fibular nerve just distal to the fibular head. 
Percutaneous nerve stimulation was performed using a bar electrode which transmitted 
the single, 100 µs square wave pulses triggered from a constant-voltage electrical 
stimulator (Digitimer stimulator, model DS7AH; Digitimer Ltd., Welwyn Garden City, 
UK). Twitches were analyzed off-line for: peak twitch tension (Nm), time to peak tension 
(ms), and half-relaxation time (ms). From these data twitch contraction duration (CD 
[ms]; time to peak tension + half-relaxation time) and twitch rate of torque development 
(RTD (peak twitch tension/time to peak twitch tension)) were calculated. Accompanying 
CMAPs were analyzed for maximal peak to peak voltage (mV).  
At least 3 dorsiflexion, maximal voluntary contractions (MVCs), and no more 
than 5, were performed by each participant, and each MVC attempt was separated by at 
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least 3 minutes to minimize the development of any fatigue before the actual fatigue test. 
Participants were verbally instructed to perform their MVC as hard and as fast as possible 
to ensure maximal torque and rate of torque development were produced. MVCs were 
held for ~3-4 seconds during each attempt, during which strong verbal encouragement 
was given. Real time visual feedback of the torque signal was provided to the participant 
on a computer monitor throughout the experimental protocol. The interpolated twitch 
technique (ITT) was used to assess voluntary activation (VA) during the 2
nd
 and 3
rd
 MVC 
attempts to ensure adequate muscle activation was achieved
34
. The ITT involves 
supramaximal electrical stimulation of the fibular nerve before, during and immediately 
after a voluntary MVC. The amplitude of the interpolated torque electrically evoked 
during the plateau of the MVC was compared to the twitch elicited immediately 
following the MVC. VA% was calculated as: [1- (interpolated twitch /resting twitch)] x 
100. The peak torque measured during the 3 MVC attempts was recorded as the maximal 
torque for that participant. All torque signals were collected and sampled online at 500 
Hz using Spike2 software (Version 7.11; Cambridge Electronic Design Ltd., Cambridge, 
United Kingdom). Torque was later analyzed off-line to determine voluntary isometric 
torques (strength) and maximal voluntary rate of torque development (RTD (Nm/s)). 
Maximal RTD was obtained by transforming the torque signal into its first derivative and 
recording the peak value for a given contraction. 
 Throughout the experimental protocol surface electromyography (EMG) was 
recorded from the TA and soleus (SOL) muscles using self-adhering Ag-AgCl electrodes 
(1 cm X 3 cm; GE Healthcare, Helsinki, Finland). For the TA, the active electrode was 
placed over the motor point, approximately 7 cm distal to the tibial tuberosity and 2 cm 
lateral to the anterior border of the tibia; the reference electrode was placed distally over 
the tendon of the TA. For the SOL, the active electrode was placed 2 cm below the 
gastrocnemii border, along the longitudinal axis over the soleus; the reference electrode 
was placed distally over the tendocalcaneus. Minor adjustments to active electrode 
placement over the TA were made until the optimal CMAPs (greatest amplitude and 
fastest rate of rise) were obtained from percutaneous, supramaximal nerve stimulation. 
Ground electrodes were placed over the patella. Maximal SOL CMAPs were obtained by 
electrically stimulating the tibial nerve between the origins of the heads of the 
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gastrocnemeii muscles. Surface EMG signals were pre-amplified (x100), amplified (x2), 
bandpass filtered (10 Hz to 1 kHz), converted by a 12-bit analog-to-digital converter 
(Power 1401, Cambridge Electronic Design, Cambridge, UK), and sampled online at 
2,000 Hz.  
6.2.3 Fatigue Protocol 
 Following the assessment of maximal dorsiflexion strength participants rested for 
10 minutes to ensure any fatigue or post-activation potentiation had dissipated. The 
fatigue protocol in the present study involved a single, sustained, isometric dorsiflexion 
MVC. The MVC was maintained until the participant could no longer sustain 60% of 
their pre-fatigue MVC torque. For the fatigue protocol, participants were instructed to 
contract as hard and as fast as possible, and as long as possible. Additionally participants 
were instructed to minimize any extraneous movements or contractions aside from 
dorsiflexion; also they were asked to continue breathing throughout the fatigue protocol. 
During the fatigue task, participants were provided with continuous and strong verbal 
encouragement. Throughout the protocol visual feedback of their torque was provided on 
a computer monitor. In addition to torque output, the computer monitor displayed a 
horizontal lines demarcating 100% of MVC and 60% MVC. Task termination occurred 
when the torque dropped and remained below the 60% MVC level despite further verbal 
encouragement. Participants were not informed that the line on the computer monitor 
demarcating 60% of MVC torque represented their task termination point. Prior to 
instructing the participant to cease the fatiguing MVC, an interpolated twitch was applied 
to assess VA% at task termination.  
 Similar to baseline measures, fatigue protocol torque and EMG data were 
analyzed offline. Time to task termination was determined as the time from which the 
participant reached their maximal torque until they could no longer produce torque 
greater than 60% of their baseline MVC. Torque and TA EMG data from the fatigue 
protocol were subsequently binned into increments of 10% of their time to task 
termination (i.e. a fatigue protocol lasting 60 seconds would consist of 10 x 6 second 
bins). Average torque and TA RMS EMG data for these 10% bins were calculated for 
each participant. Binned torque and RMS EMG data were subsequently normalized to 
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MVC torque and maximum RMS EMG data, respectively. This served to provide profiles 
of torque output and neural activation of the TA over the course of the fatigue protocol. 
Antagonist (soleus) co-activation was quantified during the dorsiflexion MVC fatigue 
protocol in similar manner to TA activation, but was normalized to soleus RMS EMG 
during baseline MVCs. The area under the curve of the torque tracing was measured to 
assess the angular impulse (Nm x sec) for each participant. This served as an analogue for 
the parameter of work, which is often calculated for dynamic muscle contractions. VA% 
at the cessation of the fatigue protocol was calculated similarly to baseline MVCs, 
described above. A sample fatigue protocol is depicted in Figure 6.1. 
6.2.4 Assessment of Recovery 
Immediately (~1 second) following cessation of the fatigue protocol a 
supramaximal electrical stimulus was applied to the fibular nerve to help assess the 
degree of central and peripheral fatigue induced by the fatigue protocol. Subsequently, 
participants performed MVCs with ITT at 30 seconds and 2 minutes post-fatigue 
protocol. Prior to these MVCs, additional maximal dorsiflexion twitches were elicited to 
provide an assessment of recovery of the twitch and CMAP properties following fatigue. 
MVCs were assessed for VA% using the ITT technique. Recovery MVC torques and TA 
EMG data were analyzed similarly to baseline MVCs. 
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Figure 6.1 Raw torque and EMG tracings from fatigue and recovery protocol  
Sample torque, tibialis anterior root-mean-squared electromyography (RMS EMG) and plantar flexor RMS EMG during a sustained, 
isometric dorsiflexion maximal voluntary contraction (MVC) fatigue protocol, and subsequent recovery at 30 seconds and 2 minutes 
post-task termination.
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6.2.5 Statistical Analysis 
Mean values ± standard deviations are presented in the text, tables, and figures, 
except where noted. The level of significance was set at p ≤ 0.05 for all statistical tests. 
All baseline data, and time to task termination of the fatigue protocol were analyzed 
using a one-way ANOVA (group). Binned torque and EMG values for fatigue data, as 
well as recovery data were analyzed using a mixed design (split-plot) ANOVA. For these 
mixed design ANOVAs the between-subjects factor was group (control or DPN patient), 
with repeated measures over time. Fatigue and recovery data were analyzed both as 
absolute values, as well as relative to baseline. Mauchly’s sphericity test and Levene’s 
test were used to ensure there were no violations of sphericity or homogeneity of variance 
assumptions, respectively. Main and interaction effects were determined by Pillai’s trace 
(p ≤ 0.05). Following each ANOVA in which a significant main effect or interaction was 
found, post-hoc analysis was performed using the modified Bonferroni correction 
method. Relationships among variables of interest were testing using Pearson’s Product 
Moment Correlation. Data analyses were performed using IBM SPSS Statistics software 
(Version 20.0; IBM SPSS, Arnock, New York, USA). 
 
6.3 Results 
6.3.1 Participant Characteristics and Baseline Measures 
Participant characteristics are presented in Table 6.1. No differences between 
groups were found for age (p>0.05), height (p>0.05), or weight (p>0.05). Baseline 
neuromuscular measures are presented in Table 6.2. DPN patients were found to have 
40% weaker (p<0.05) MVCs with 47% slower maximal RTD (p<0.05). Strength 
differences were not due to differences in VA% (p>0.05). Compared with controls, the 
DPN group twitches were ~36% smaller (p<0.05), and ~25% slower (i.e. longer 
contraction durations) (p<0.05) with ~40% smaller CMAP peak to peak amplitudes 
(p<0.05). 
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Participant Characteristic Controls (n=10) DPN Patients (n=10) 
Males/Females 6/4 6/4 
Age (years) 62.2 ± 12.1 64.7 ± 11.3 
Height (m) 1.6 ± 0.1 1.6 ± 0.1 
Weight (kg) 71.4 ± 5.6 78.9 ± 8.5 
HbA1c (%) - 7.5 ± 1.2 
 
Table 6.1 Participant Characteristics 
DPN – diabetic polyneuropathy 
 
 
 
Torque Parameter Controls DPN Patients % Difference 
MVC Torque (Nm) 33.7 ± 8.1 20.2 ± 9.2* -40% 
MVC RTD (Nm/s) 170.2 ± 41.5 89.1 ± 37.9* -47% 
Voluntary Activation 
(%) 
98.8 ± 2.1 97.2 ± 3.7 - 
Peak Twitch Torque 
(Nm) 
5.1 ± 1.7  3.2 ± 1.8* +36% 
Time to Peak Twitch 
(ms) 
106.2 ± 17.1 116.2 ± 28.6 - 
Twitch RTD (Nm/s) 45.0 ± 17.0 28.0 ± 14.0* -42% 
Half-Relaxation Time 
(ms) 
122.0 ± 15.0 170.2 ± 25.0* +40% 
Contraction Duration 
(ms) 
228.0 ± 23.0 286.0 ± 42.0* +25% 
EMG Parameter    
CMAP Negative Peak 
Amplitude (mV) 
6.6 ± 0.7 4.6 ± 1.1* -30% 
Table 6.2 Dorsiflexion neuromuscular parameters at baseline 
 
MVC – maximal voluntary contraction; RTD – rate of torque development; contraction 
duration = time to peak twitch + half-relaxation time; EMG – electromyography; CMAP 
– compound muscle action potential. * Denotes significant difference between groups 
(p<0.05). 
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6.3.2 Fatigue 
 Fatigue profiles of torque over time are presented as absolute values in Figure 6.2. 
The mean time to task termination of the fatigue protocol was ~21% shorter in DPN 
patients (56.4 ± 14.2 sec) compared to controls (71.1 ± 11.7 sec; p = 0.001). Additionally, 
DPN group angular impulse was ~50% less than controls (1637.4 ± 639.7 vs 852.4 ± 
410.5 Nm*s; p<0.05). There was a main effect for time (p<0.05) and an interaction effect 
for group and time (p<0.05) for the changes in relative torque calculated from the binned 
time intervals. Both groups featured decreases in torque output relative to their baseline 
MVCs over the course of the fatigue protocol (p<0.05). Pairwise comparisons between 
groups over binned time intervals showed the DPN group had lesser decreases in relative 
torque output from 50-90% of the time to task termination compared to controls (p<0.05). 
Just prior (1-2 s) to task termination VA% was >95% in both groups (p>0.05). No 
significant relationships were found between glycemic control (i.e. HbA1c %) or severity 
of neuropathy (i.e. TA CMAP amplitude) and time to fatigue.  
 In both groups over the course of the fatigue protocol, TA RMS EMG normalized 
to MVC RMS EMG values are expressed over 10% binned time intervals in Figure 6.3. 
For these variables a main effect of time (p<0.05) and an interaction effect between time 
and group (p<0.05) were detected. From 0-30% of the time to task termination, the DPN 
group featured less relative EMG activity from the TA compared with controls. For the 
remainder of the fatigue protocol no differences were detected in relative TA RMS EMG 
between groups (p>0.05). There were no group differences (p>0.05) in % antagonist 
soleus coactivation during the fatigue protocol, however there was an effect of time 
(p<0.05) with both groups featuring decreased % antagonist coactivation over the fatigue 
protocol (results not shown).  
6.3.3 Recovery  
 Absolute data pertaining to neuromuscular recovery following the fatiguing 
protocol are found in Table 6.3. At thirty seconds post-fatigue both DPN patients and 
control groups featured MVCs that were significantly weaker (~10%) compared to 
baseline (p<0.05; Table 6.3), but these relative changes were not different between 
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groups (p>0.05). At 2 minutes post-fatigue, the MVC for both had recovered to baseline 
levels (p>0.05). Similarly, MVC RTD was significantly reduced (~20%) in both groups 
30 seconds following fatigue (p<0.05; Table 6.3), however both groups were not 
significantly different from their respective baselines at 2 minutes post-fatigue (p>0.05). 
VA% was near maximal (>95%) in both groups during MVCs at 30 seconds and 2 
minutes post-fatigue (p>0.05). 
The twitch evoked immediately following task termination was 15-20% weaker in both 
groups relative to their respective baseline twitches (p<0.05; Table 6.3), however the 
relative changes were not different between groups (p>0.05; Figure 6.4A). Peak twitch 
torque recovered to baseline levels in both groups at 30 seconds post-fatigue (p>0.05). 
Twitch half-relaxation time (HRT) was prolonged ~20% compared to baseline in both 
groups immediately following the fatigue protocol (p<0.05; Table 6.3), and at 30 seconds 
post-fatigue twitch HRT recovered in both groups.  
Peak to peak CMAP amplitude was significantly reduced by ~12% in DPN 
patients immediately following the fatigue protocol (p<0.05; Figure 6.4B); whereas for 
controls there was no change (p>0.05; Figure 6.4B). By 30 seconds post-fatigue, the DPN 
group CMAPs had recovered to baseline (p<0.05).  
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Figure 6.2 Fatigue protocol: absolute torque over time  
Mean absolute dorsiflexion torque (Nm) produced during a sustained, isometric 
dorsiflexion maximal voluntary contraction (MVC) fatigue protocol in controls (open 
symbols; time to task termination = 71 s) and diabetic polyneuropathy (DPN) patients 
(closed symbols; time to task termination = 56 s). * denotes significant difference 
between groups in time to task termination (p<0.05). Controls produced significantly 
greater torque throughout the protocol (p<0.05). 
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 Baseline Immediate Post Fatigue 30 sec Post Fatigue 2 min Post Fatigue 
 Controls DPN 
Patients 
Controls DPN 
Patients 
Controls DPN Patients Controls DPN Patients 
Twitch 
Torque (Nm) 
5.1 ± 1.7 3.2 ± 1.8* 4.1 ± 1.3§ 2.8 ± 1.7*§ 4.6 ± 1.3 3.3 ± 1.9* 5.0 ± 1.6 3.3 ± 1.7* 
Twitch HRT 
(ms) 
122 ± 15 170 ± 25* 145 ± 21§ 203 ± 23*§ 120 ± 13 172 ± 29* 124 ± 18 184 ± 43* 
MVC (Nm) 33.0 ± 8.0 20.0 ± 9.0* - - 30.6 ± 9.4§ 17.6 ± 7.9*§ 32.9 ± 10.1 19.6 ± 9.0* 
MVC RTD 
(Nm/s) 
170.2 ± 41.5 89.0 ± 
37.9* 
- - 135.1 ± 50.1§ 65.8 ± 
26.9*§ 
166.4 ± 52.7 86.6 ± 30.9* 
CMAP Peak 
to Peak Amp 
(mV) 
6.6 ± 0.7 4.6 ± 0.9* 6.2 ± 0.7 4.0 ± 0.5*§ 6.2 ± 0.7 4.4 ± 0.6* 6.4 ± 0.8 4.4 ± 0.7* 
Table 6.3 Absolute recovery of maximal twitch, MVC and CMAP 
DPN – diabetic polyneuropathy; HRT – half-relaxation time; MVC – maximal voluntary contraction; RTD – rate of torque 
development; CMAP – compound muscle action potential. * denotes significant difference between groups; § denotes significant 
difference from baseline (p<0.05)      
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Figure 6.3 Tibialis anterior electromyography activity during fatigue task  
Tibialis anterior relative root-mean-squared electromyography (RMS EMG) during a sustained, isometric dorsiflexion maximal 
voluntary contraction (MVC) fatigue protocol in controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed 
symbols). * denotes significant difference between groups (p<0.05).
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Figure 6.4 Twitch torque and compound muscle action potentials following fatigue 
protocol  
Electrically evoked dorsiflexion relative twitch torques at baseline, immediately post-task 
termination, 30 seconds post-task termination and 2 minutes post-task termination in 
controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols). § 
denotes significant difference from baseline. (4B) Relative peak to peak compound 
muscle action potential (CMAP) amplitudes (mV) at baseline, immediately post-task 
termination, 30 seconds post-task termination and 2 minutes post-task termination in 
controls (open symbols) and diabetic polyneuropathy (DPN) patients (closed symbols). § 
denotes significant difference from baseline; * denotes significant difference between 
groups (p<0.05). 
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6.4 Discussion 
 The main findings of this study were: (1) during a sustained isometric dorsiflexion 
MVC, those with DPN had less endurance compared to controls; (2) the differences in 
fatiguability between groups did not appear to be due to deficiencies in VA%; (3) DPN 
patients featured evidence of possible neuromuscular transmission failure during and 
immediately following the fatiguing task, whereas controls did not; (4) at 2 minutes post-
fatigue, the maximal evoked and voluntary contractile properties of the dorsiflexors in 
both groups had recovered similarly to baseline levels. 
6.4.1 Increased Fatiguability in DPN 
 In agreement with other studies, baseline neuromuscular properties of the 
dorsiflexors related to strength (MVC, MVC RTD, twitch torque) and CMAP amplitude 
were decreased in patients with DPN compared to controls (Table 6.2)
3,5,35,36
. However 
novel to the present study, when tasked with maintaining a sustained, isometric 
dorsiflexion MVC, those with DPN fatigued significantly more quickly (~21%) 
compared to controls. Furthermore, the difference in fatigability between groups did not 
appear to be due to differences in VA, as both groups maintained greater than 95% VA 
(p>0.05) as measured via the interpolated twitch technique at task termination.  The time 
to task failure of the control group was similar to that reported previously using this same 
task and protocol (71 vs 85 s)
29
, but the greater endurance of the control group did not 
seem to be due to any differences in voluntary activation, as both groups achieved >95% 
voluntary activation just prior to task termination. Moreover, the greater muscle 
endurance in the control group does not appear to be due to a pacing strategy as their 
RMS EMG indicates a maximal or near-maximal effort and follows the expected pattern 
for a sustained MVC (Figure 6.3).  
 DPN patients fatigued significantly more quickly (~21%; Figure 6.1), while 
producing lower absolute torques, and substantially lesser total angular impulse (~50%) 
compared to controls. However, our results stand in contrast to those previously reported 
in a study investigating fatigue in a mixed population of insulin-dependent (type 1) DM, 
with and without DPN in which DM patients had greater muscular endurance than 
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controls
15
. The divergent findings could be accounted for by several key differences in 
experimental design. Andersen (1998)
15
 investigated fatigue in a group of insulin-
dependent DM patients, many of whom reported no symptoms of DPN or featured a mild 
DPN with minimal motor involvement. The present study included non-insulin-
dependent DM patients (type 2 DM), all with substantial neuromuscular impairment of 
the dorsiflexors
3,5
. Moreover, there are important differences in the underlying alterations 
related to DPN and metabolism in insulin-dependent versus non-insulin-dependent DM
37
. 
Additionally, the prior study used a metric of fatigue that combined plantar and 
dorsiflexor performance which may have affected the results given the greater resistance 
of the plantar flexors to DPN-related changes relative to the dorsiflexors. Finally, the 
previous work used repeated isokinetic contractions which are difficult to assess in terms 
of voluntary activation and their intermittent nature could attenuate the development of 
any substantive neuromuscular transmission failure. 
 There are several possible mechanisms underlying the increased fatiguability 
observed in DPN patients, which are not mutually exclusive. One possible mechanism is 
the presence of neuromuscular transmission failure, which may occur at the motor axon, 
neuromuscular junction or muscle fibre membrane. Evidence supporting transmission 
failure is reflected by the decreased relative surface EMG activity during fatigue in the 
DPN group compared to controls (Figure 6.3), and a reduction in CMAP size 
immediately following fatigue in DPN but not in controls (Figure 6.4B). Failure to 
propagate action potentials at any point in the neuromuscular system would fail to cause 
contractions of the associated muscle fibres, thus limiting the system’s force generating 
capacity. Demyelination or axonal damage could lead to a reduced safety factor and 
action potential propagation failure in the motor axon in a manner similar to frequency 
dependent conduction block observed in other demyelinating neuropathies
38,39
. 
Furthermore, given the significant reduction in motor units in DPN patients
5,7,8
 any 
neuromuscular transmission failure occurring at the level of the motor axon may have 
exacerbated decrements in force production compared to other demyelinative conditions 
because each remaining motor unit innervates a greater relative proportion of muscle 
fibres following motor unit loss and subsequent collateral reinnervation. DPN-related 
pathological alterations at the neuromuscular junction (e.g. reduced numbers of synaptic 
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vesicles) or muscle fibre (e.g. T-tubule disruption) levels could also contribute to failed 
neuromuscular transmission
40
. In addition, dysfunctional axonal Na+/K+ pumps
27,41
 and 
myocellular Ca
2+
 channels
42,43
 may contribute to any conduction failure in DPN, as 
previously postulated
41
. Moreover, neuromuscular transmission failure has been 
previously reported in DPN during sustained (i.e. 30 seconds) low intensity (25% MVC) 
contractions (Chapter 4). Thus it is possible the sustained maximal contraction used in the 
present study could result in equal or greater transmission failure, reducing force 
generation capacity in DPN patients more quickly than controls during a sustained 
contraction. 
Another potential cause underlying the increased fatiguability in DPN observed in 
the present study is related to abnormal muscle energy metabolism. A previous report has 
documented that myocellular PCr loss and pH decrease occur significantly faster during 
low intensity plantar flexion exercise, in skeletal muscle of type 2 DM compared to 
healthy controls
24
. Additionally, deoxygenation during exercise occurred more quickly in 
type 2 DM than controls
24
. Greater PCr loss, increased myocellular inorganic phosphate 
concentrations and decreased pH in DPN patients compared to controls could lead to an 
earlier reduction in actomyosin cross-bridge force production during a sustained effort 
(see Westerblad et al 1998 for review
44
). However, it is important to note that the 
aforementioned report discussing skeletal muscle energetics in DM during exercise used 
repeated dynamic contractions during a protocol that lasted ~7 minutes
24
, which is a very 
different exercise duration and contraction type compared to the present study. Indeed, 
the task-dependent nature of fatigue has been well-described (see Enoka and Duchateau 
2008 for review
45
) therefore it is not completely clear how these previous findings may 
relate to the results presented here.  
An additional consideration regarding DPN and skeletal muscle endurance is 
related to blood supply. Adequate blood flow is necessary to engage in oxidative 
metabolism, and if this blood flow is insufficient during muscular contraction, 
metabolism and the ability to remove metabolic by-products which inhibit force 
production are limited
44
. It has been reported that DM and DPN are associated with 
dysfunction in the macro- and microvasculature
25,46–49
, as well as oxygen kinetics during 
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exercise
50,51
. Although blood flow to the dorsiflexors may not present a major limitation 
to force production in healthy individuals
52
, it should be noted that an impaired ability to 
deliver oxygen and clear metabolites from contracting muscle could contribute to 
increased fatiguability in DPN patients. 
6.4.2 Neuromuscular Recovery Post-Fatigue in DPN 
DPN patients performed a fatigue protocol of shorter duration (~21%; Figure 6.2), 
at lower absolute levels of torque output (~40%; Figure 6.2), and therefore markedly less 
total angular impulse (~50% less angular impulse) compared to controls. Two minutes 
following fatigue evoked twitch and MVC properties had returned to baseline values in 
both groups. However, immediately following the fatigue protocol, DPN patients and 
controls both featured evoked twitch responses that were similarly weaker than their 
respective baseline twitches (Figure 6.4A). Additionally, 30 s post-task termination both 
groups had similar deficits in MVC torque (~10%) and MVC maximal RTD (~20%). The 
similar recovery profiles between patients and controls are surprising giving the 
substantial disparity in total angular impulse (i.e. work), and it may be interesting to test 
these groups with tasks of equal total angular impulse. Notwithstanding, whereas fatigue 
induced a similar relative change in twitch torque across groups, it appears that the 
reasons underlying the weaker twitch responses may be different. DPN patients featured 
a smaller CMAP compared to baseline, whereas the mean CMAP from the control group 
was unchanged immediately following fatigue (Figure 6.4B). This finding could indicate, 
as mentioned earlier, neuromuscular transmission failure may have occurred in DPN 
patients contributing to a decrease in strength; whereas twitch torque depression in 
controls is likely primarily due to accumulation of force depressing metabolites (e.g. 
inorganic phosphate, H+ ions). Another consideration is DPN patients have been shown 
to potentiate to a lesser relative extent (~-40%) compared to healthy controls
3
, which may 
be related to muscle atrophy
53
 or changes in fibre type composition
54
. As individuals with 
DPN benefit less from post-activation potentiation, they may be more subject to the 
force-depressing effects of fatigue without gaining as much from the competing force-
increasing effects of potentiation during recovery
55
. In summary, to recover from a 
maximal, sustained fatiguing contraction of short duration, it seems DPN patients may 
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need to regain both neuromuscular transmission fidelity, as well as the clearance of 
metabolites, as evidenced by prolonged half-relaxation times.  
6.4.3 Summary 
 The present study reports an increased susceptibility to neuromuscular fatigue in 
patients with diabetic neuropathy compared to controls, during sustained maximal 
contractions. Given our results, we propose this DPN-related greater fatiguability may be 
partially attributed to neuromuscular transmission failure and possibly pathological 
alterations in muscle metabolism affecting cross-bridge force production. Although the 
DPN group performed approximately 50% less angular impulse (an isometric analogue of 
work) than controls, post-fatigue, evoked and voluntary muscle strength properties 
recovered in both groups similarly. These findings may have functional relevance 
underlying abnormal gait and increased fall risk in patients with DPN
56,57
. Finally, DPN-
related fatiguability may warrant consideration for the design and implementation of 
exercise-based rehabilitation strategies for this patient population. 
 
 
 
 
 
 
 
 
 
 
142 
 
 
 
References 
1. Andersen, H., Gadeberg, P.C., Brock, B. & Jakobsen, J. Muscular atrophy in 
diabetic neuropathy: a stereological magnetic resonance imaging study. 
Diabetologia 40, 1062–9 (1997). 
2. Andreassen, C., Jakobsen, J. & Andersen, H. Muscle weakness a progressive late 
complication in diabetic distal symmetric polyneuropathy. Diabetes 806–812 
(2006).  
3. Allen, M.D., Major, B., Kimpinski, K., Doherty, T.J. & Rice, C.L. Skeletal muscle 
morphology and contractile function in relation to muscle denervation in diabetic 
neuropathy. J. Appl. Physiol. 116, 545–52 (2014). 
4. Watanabe, K. Gazzoni, M., Holobar, A., Miyamoto, T., Fukuda, K., Merletti, R., 
Moritani, T. Motor unit firing pattern of vastus lateralis muscle in type 2 diabetes 
mellitus patients. Muscle Nerve 48, 806–13 (2013). 
5. Allen, M.D., Kimpinski, K., Doherty, T.J. & Rice, C.L. Length dependent loss of 
motor axons and altered motor unit properties in human diabetic polyneuropathy. 
Clin. Neurophysiol. 125, 836–43 (2014). 
6. Almeida, S., Riddell, M. C. & Cafarelli, E. Slower conduction velocity and motor 
unit discharge frequency are associated with muscle fatigue during isometric 
exercise in type 1 diabetes mellitus. Muscle Nerve 37, 231–40 (2008). 
7. Allen, M.D., Choi, I.H., Kimpinski, K., Doherty, T.J. & Rice, C.L. Motor unit loss 
and weakness in association with diabetic neuropathy in humans. Muscle Nerve 
48, 298–300 (2013). 
8. Hansen, S. & Ballantyne, J.P. Axonal dysfunction in the neuropathy of diabetes 
mellitus: a quantitative electrophysiological study. J. Neurol. Neurosurg. 
Psychiatry 40, 555–64 (1977). 
9. Bigland-Ritchie, B., Jones, D.A., Hosking, G.P., Edwards, R.H. Central and 
peripheral fatigue in sustained maximum voluntary contractions of human 
quadriceps muscle. Clin Sci Mol Med  54, 609-14 (1978).  
10. Kluger, B., Krupp, L. & Enoka, R. Fatigue and fatigability in neurologic illnesses 
Proposal for a unified taxonomy. Neurology 409–416 (2013).  
11. Friedman, J. & Friedman, H. Fatigue in Parkinson’s disease. Neurology 43, 2016-8 
(1993).  
143 
 
 
 
12. Allman, B.L. & Rice, C.L. Neuromuscular fatigue and aging: central and 
peripheral factors. Muscle Nerve 25, 785–96 (2002). 
13. Pääsuke, M., Ereline, J. & Gapeyeva, H. Neuromuscular fatigue during repeated 
exhaustive submaximal static contractions of knee extensor muscles in endurance-
trained, power-trained and untrained men. Acta Physiol. Scand. 166, 319–26 
(1999). 
14. Chaudhuri, A. & Behan, P.O. Fatigue in neurological disorders. Lancet 363, 978–
88 (2004). 
15. Andersen, H. Muscular endurance in long-term IDDM patients. Diabetes Care 21, 
604–9 (1998). 
16. Almeida, S., Riddell, M.C. & Cafarelli, E. Slower conduction velocity and motor 
unit discharge frequency are associated with muscle fatigue during isometric 
exercise in type 1 diabetes mellitus. Muscle Nerve 37, 231–40 (2008). 
17. Buller, N. P., Jones, D.A. & Poole-Wilson, P.A. Direct measurement of skeletal 
muscle fatigue in patients with chronic heart failure. Br. Heart J. 65, 20–4 (1991). 
18. Sharma, K.R., Kent-Braun, J.A., Majumdar, S., Huang, Y., Mynhier, M., Weiner, 
M.W., Miller, R.G. Physiology of fatigue in amyotrophic lateral sclerosis. 
Neurology 45, 733–40 (1995). 
19. Zwarts, M. J. & Van Weerden, T. W. Transient Paresis in Myotonic Syndromes. 
Brain 112, 665–680 (1989). 
20. Schillings, M.L., Kalkman, J.S., Janssen, H.M., van Engelen, B.G., Bleijenberg, 
G., Zwarts, M.J. Experienced and physiological fatigue in neuromuscular 
disorders. Clin. Neurophysiol. 118, 292–300 (2007). 
21. Christie, A., Snook, E.M. & Kent-Braun, J.A. Systematic review and meta-
analysis of skeletal muscle fatigue in old age. Med. Sci. Sports Exerc. 43, 568–77 
(2011). 
22. Justice, J.N., Mani, D., Pierpoint, L.A & Enoka, R.M. Fatigability of the 
dorsiflexors and associations among multiple domains of motor function in young 
and old adults. Exp. Gerontol. 55, 92–101 (2014). 
23. Kent-Braun, J.A. Skeletal muscle fatigue in old age: whose advantage? Exerc. 
Sport Sci. Rev. 37, 3–9 (2009). 
144 
 
 
 
24. Scheuermann-Freestone, M., Madsen, P.L., Manners, D., Blamire, A.M., 
Buckingham, R.E., Styles, P., Radda, G.K., Neubauer, S., Clarke, K. Abnormal 
cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. 
Circulation 107, 3040–6 (2003). 
25. Edmonds, M., Roberts, V. & Watkins, P. Blood flow in the diabetic neuropathic 
foot. Diabetologia 22, 9–15 (1982). 
26. Kelley, D.E., He, J., Menshikova, E.V., & Ritov, V.B. Dysfunction of 
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51, 2944–50 
(2002). 
27. Kjeldsen, K., Braendgaard, H., Sidenius, P., Larsen, J.S. & Nørgaard, A. Diabetes 
decreases Na+-K+ pump concentration in skeletal muscles, heart ventricular 
muscle, and peripheral nerves of rat. Diabetes 36, 842–8 (1987). 
28. Belanger, A.Y. & McComas, A.J. Extent of motor unit activation during effort. J. 
Appl. Physiol. 51, 1131–5 (1981). 
29. Kent-Braun, J.A. Central and peripheral contributions to muscle fatigue in humans 
during sustained maximal effort. Eur. J. Appl. Physiol. Occup. Physiol. 80, 57–63 
(1999). 
30. Minotti, J.R., Pillay, P., Chang, L., Wells, L. & Massie, B.M. Neurophysiological 
assessment of skeletal muscle fatigue in patients with congestive heart failure. 
Circulation 86, 903–908 (1992). 
31. Dyck, P.J. and the Toronto Expert Panel on Diabetic Neuropathy. Diabetic 
polyneuropathies : update on research definition , diagnostic criteria and estimation 
of severity. 620–628 (2011). doi:10.1002/dmrr 
32. Marsh, E., Sale, D., McComas, A.J. & Quinlan, J. Influence of joint position on 
ankle dorsiflexion in humans. J. Appl. Physiol. 51, 160–7 (1981). 
33. McNeil, C.J., Doherty, T.J., Stashuk, D.W. & Rice, C.L. The effect of contraction 
intensity on motor unit number estimates of the tibialis anterior. Clin. 
Neurophysiol. 116, 1342–7 (2005). 
34. Todd, G., Taylor, J.L. & Gandevia, S.C. Measurement of voluntary activation of 
fresh and fatigued human muscles using transcranial magnetic stimulation. 661–
671 (2008).  
145 
 
 
 
35. Andersen, H., Stålberg, E., Gjerstad, M.D. & Jakobsen, J. Association of muscle 
strength and electrophysiological measures of reinnervation in diabetic 
neuropathy. Muscle Nerve 21, 1647–54 (1998). 
36. Martinelli, A.R. Mantovani, A.M., Nozabieli, A.J., Ferreira, D.M., Barela, J.A., 
Camargo, M.R., Fregonesi, C.E. Muscle strength and ankle mobility for the gait 
parameters in diabetic neuropathies. Foot (Edinb). 23, 17–21 (2013). 
37. Callaghan, B.C., Hur, J. & Feldman, E.L. Diabetic neuropathy: one disease or 
two? Curr. Opin. Neurol. 25, 536–41 (2012). 
38. Kaji, R. Physiology of conduction block in multifocal motor neuropathy and other 
demyelinating neuropathies. Muscle Nerve 27, 285–296 (2003).  
39. Watson, B.V., Brown, W.F. & Doherty, T.J. Frequency-dependent conduction 
block in carpal tunnel syndrome. Muscle Nerve 33, 619–26 (2006). 
40. Fahim, M.A., Hasan, M.Y. & Alshuaib, W.B. Early morphological remodeling of 
neuromuscular junction in a murine model of diabetes. J. Appl. Physiol. 89, 2235–
40 (2000). 
41. Krishnan, A.V, Lin, C.S.Y. & Kiernan, M.C. Activity-dependent excitability 
changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain 131, 
1209–16 (2008). 
42. Nakagawa, M. & Kobayashi, S. Kimura, I., Kimura, M. Diabetic state-induced 
modification of Ca, Mg, Fe and Zn content of skeletal, cardiac and smooth 
muscles. Endocrinol. Japon. 36, 795-807 (1989). 
43. Nobe, S., Aomine, M., Arita, M., Ito, S. & Takaki, R. Chronic diabetes mellitus 
prolongs action potential duration of rat ventricular muscles: circumstantial 
evidence for impaired Ca2+ channel. Cardiovasc. Res. 24, 381–9 (1990). 
44. Westerblad, H., Allen, D.G., Bruton, J. D., Andrade, F.H. & Lännergren, J. 
Mechanisms underlying the reduction of isometric force in skeletal muscle fatigue. 
Acta Physiol. Scand. 162, 253–60 (1998). 
45. Enoka, R. M. & Duchateau, J. Muscle fatigue: what, why and how it influences 
muscle function. J. Physiol. 586, 11–23 (2008). 
46. Bauer, T. & Reusch, J. Skeletal muscle deoxygenation after the onset of moderate 
exercise suggests slowed microvascular blood flow kinetics in type 2 diabetes. 
Diabetes 30, 2880-85 (2007). 
146 
 
 
 
47. Greenman, R., Khaodhiar, L. & Lima, C. Foot small muscle atrophy is present 
before the detection of clinical neuropathy. Diabetes 28, 1425-30 (2005). 
48. Williams, S.B., Cusco, J.A., Roddy, M.A, Johnstone, M.T. & Creager, M.A. 
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent 
diabetes mellitus. J. Am. Coll. Cardiol. 27, 567–74 (1996). 
49. Laakso, M., Edelman, S.V, Brechtel, G. & Baron, A.D. Impaired insulin-mediated 
skeletal muscle blood flow in patients with NIDDM. Diabetes 41, 1076–83 (1992). 
50. Regensteiner, J.G., Bauer, T.A., Reusch, J.E., Brandenburg, S.L., Sippel, J.M., 
Vogelsong, A.M., Smith, S., Wolfel, E.E., Eckel, R.H., and Hiatt, W.R. Abnormal 
oxygen uptake kinetic responses in women with type II diabetes mellitus skeletal 
muscle contracting at moderate intensity J. Appl. Physiol. 85, 310–17 (1998). 
51. Regensteiner, J.G. Sippel, J., McFarling, E.T., Wolfel, E.E., Hiatt, W.R. Effects of 
non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. 
Sci. Sport. Exerc. 27(6): 875-81 (1995). 
52. Wigmore, D. M., Propert, K. & Kent-Braun, J.A. Blood flow does not limit 
skeletal muscle force production during incremental isometric contractions. Eur. J. 
Appl. Physiol. 96, 370–8 (2006). 
53. Tubman, L.A, Rassier, D. E. & MacIntosh, B. R. Attenuation of myosin light chain 
phosphorylation and posttetanic potentiation in atrophied skeletal muscle. Pflugers 
Arch. 434, 848–51 (1997). 
54. Hamada, T., Sale, D.G., MacDougall, J.D. & Tarnopolsky, M.A. Interaction of 
fibre type, potentiation and fatigue in human knee extensor muscles. Acta Physiol. 
Scand. 178, 165–73 (2003). 
55. Rassier, D.E. & Macintosh, B.R. Coexistence of potentiation and fatigue in 
skeletal muscle. Braz. J. Med. Biol. Res. 33, 499–508 (2000). 
56. Resnick, H., Stansberry, K., Harris, T.B., Tirivedi, M., Smith, K., Morgan, P., 
Vinik, A.I. Diabetes, peripheral neuropathy, and old age disability. Muscle Nerve 
25, 43–50 (2002).  
57. Volpato, S., Bianchi, L. & Lauretani, F. Role of muscle mass and muscle quality in 
the association between diabetes and gait speed. Diabetes 35, 1672-1679 (2012). 
 
147 
 
 
 
CHAPTER 7 
7 General Discussion and Summary  
7.1 General Discussion 
 
This thesis provided substantial novel experimental evidence regarding the effects 
of diabetic polyneuropathy (DPN) on the neuromuscular system in humans. The first half 
of this thesis focused on DPN-related changes at the motor axon and neuromuscular 
signal transmission level. Indeed, my results support the concept of a DPN-related loss of 
motor units (Chapters 2 & 3) and neuromuscular transmission instability with intermittent 
signal propagation failure (Chapter 4). Moreover, the second half of this thesis 
investigated how these alterations at the motor axon and neuromuscular transmission 
levels affect skeletal muscle properties and function. I reported the degree of motor unit 
loss is related to increased non-contractile intramuscular tissue and muscle slowing 
(Chapter 5); and DPN is associated with increased fatiguability in the context of a 
sustained maximal contraction, which may be related to neuromuscular transmission 
failure (Chapter 6). These findings (1) build upon the understanding of how DPN may 
impact the neuromuscular system; (2) help explain DPN-related functional limitations; 
and (3) eventually may prove useful in the diagnosis and progressive assessment of DPN-
motor system involvement in clinically or rehabilitative settings. 
The studies included in this thesis confirm and extend the understanding of how 
DPN may affect the neuromuscular system. It has long been understood that DPN can 
cause neuromuscular dysfunction, and it has been presumed part of this dysfunction was 
due to neuromuscular remodeling and the loss of motor axons
1,2
. Indeed, this notion 
forms the basis for using compound muscle action potential (CMAP) amplitude, and 
needle electromyography (EMG)-detected motor unit potential (MUP) parameters as 
electrophysiological markers of neuropathy in DPN patients
1,3,4
. Moreover, one previous 
study reported DPN may be associated with motor unit loss in the extensor digitorum 
brevis (EDB), an intrinsic muscle of the foot
2
. In this thesis, the results in Chapters 2 and 
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3 extend the concept of motor unit loss in DPN by exhibiting reduced MUNEs in the 
tibialis anterior (TA) in DPN patients versus controls. This finding is important as it 
shows DPN can impact motor unit numbers in a more proximal muscle, with a more 
fundamental functional role, compared to EDB. Also, studying the TA rather than EDB is 
warranted because it may be difficult to ascertain whether EDB motor units are damaged 
due to neuropathic stressors or mechanical damage caused by the altered gait associated 
with DPN
5,6
. Furthermore, the results presented in Chapter 3 indicate DPN-related motor 
unit loss and remodeling may follow a similar distal to proximal pattern of progression as 
other aspects of DPN
7
.  
This thesis also builds upon previous work suggesting DPN patients could be 
susceptible to neuromuscular transmission failure (Chapter 4). Various studies using 
animal models of DPN have found dysfunction in motor axons, the neuromuscular 
junction, and muscle fibres, all of which may contribute to failed action potential 
propagation
8–11
. Additionally, in humans, Na+/K+ pump dysfunction and reductions in 
nodal Na+ currents have been suggested as having the potential to trigger conduction 
failure
12,13
. In Chapter 4 of this thesis, I report intermittent conduction failure in the form 
of % blocking, as well as unstable neuromuscular transmission, supporting the concept 
that transmission failure may occur in patients with DPN. Moreover, this susceptibility to 
transmission failure could have functional implications, specifically with regards to a 
reduced capacity to sustain intense efforts, as presented in Chapter 6. 
The effect, if any, of DM or DPN on motor unit or muscle fibre type composition 
is not clear
14–18
. Previous studies have suggested there is an increase in the relative 
proportion of type II or fast motor units in animal models or patients with DM
14,15,18
. 
However those results may not reflect the chronic effect of DPN, but rather the physical 
inactivity associated with the development of diabetes mellitus (DM). Additionally those 
studies may have been influenced by technical limitations associated with the procedures 
used to assess muscle fibre type
19
. The results in Chapter 4 of this thesis indicate the 
sensible possibility that DPN preferentially targets type II motor units. This is evidenced 
by: slowed evoked contractile properties, reduced voluntary rates of torque development, 
and reduced motor unit firing rates compared to controls (Chapter 4). This can be 
149 
 
 
 
interpreted to indicate that in terms of neuromuscular changes, DPN acts like an 
accelerated form of human aging
20
. However, these aforementioned DPN-related 
alternations could be caused by a host of other factors (e.g. reduced numbers of 
sarcomeres in series or increased tendon compliance reducing muscle speed), and further 
study is required to parse out the physiological causes underlying these results. 
DPN patients often feature various functional limitations which may affect their 
ability to live independently, and decrease their quality of life. These can include: altered 
or slowed gait
5,21,22
, impaired standing and dynamic balance
23
, increased fall risk
29
, 
increased risk of injurious falls
24
, an inability to do housework
25
, and difficulty climbing 
stairs
25
. These functional limitations have been associated with the presence and severity 
of neuropathy
26
, however it is important to consider that dysfunction in the different 
compartments of the nervous system may have inter-related, synergistic effects. For 
example, lower limb muscle weakness (secondary to motor unit loss)
2,7
, in conjunction 
with loss of sensation
27
 and deficits in proprioception
28
 likely all play contributing roles 
in altered gait patterns and increased prevalence of falls
29
. Furthermore, patients with 
DPN with substantial dorsiflexor weakness and impaired sensation are at increased risk 
of developing ‘foot drop’5,6,21 and their foot drop is more likely to cause them to trip and 
fall
29–31
. As outlined in this thesis, the notion that DPN is associated with reduced muscle 
speed
16,32
, and hence reduced muscle power
32,33
, may further exacerbate the impaired 
functional capacity of DPN patients, beyond strength loss alone
34
. Additionally, the 
increased susceptibility to neuromuscular fatigue may impact the ability of this group to 
engage in sustained or repeated activity (i.e. climbing up many flights of stairs, engaging 
in an exercise-based rehabilitation or training program)
35,36
. For example, some of the 
findings described in this thesis, particularly loss of muscle strength, speed and 
endurance, should be taken into consideration when developing or managing preventative 
and rehabilitative training programs. For example, in terms of rehabilitative strategy, a 
training program for those with DPN may feature a greater emphasis on maintaining both 
muscle mass and muscle power to help prevent the functional decline outlined above
34,37–
40
.  
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Given the nature and extent of the potential DPN-related impacts on the 
neuromuscular system, early diagnosis may be integral to forming the optimal plan for 
treatment and prevention. Some of the findings presented in this thesis may prove helpful 
in contributing to the early identification and longitudinal assessment of DPN, especially 
in the context of neuromuscular involvement
7
 (Chapters 2-4). In Chapters 2 and 3, DPN 
was shown to be associated with a loss of motor units, which was correlated with a loss 
of strength
41
. Interestingly, the majority of patients with DPN included in these studies 
had CMAPs greater than 4.0 mV and thus would not have met the electrophysiological 
clinical threshold for pathological motor involvement of the TA. However, when 
examining individual TA MUNEs in this group compared to healthy age matched 
controls, the DPN group generally appeared to possess substantially fewer motor units 
despite maintaining a clinically ‘normal’ or ‘healthy’ sized CMAP. Between groups, TA 
MUNEs had a larger magnitude of effect (or effect size) than CMAPs or needle EMG-
derived measures of neuromuscular pathology (Chapter 3). Additionally, the NF MUP 
parameters introduced in Chapter 4 may prove useful in an EMG clinic setting, 
particularly when higher intensity contractions are performed during a clinical needle 
EMG study, which may be desirable to allow for a MUNE calculation. However, it is 
important to note the comparisons performed in Chapters 3 and 4 between MUNE, NF 
MUP parameters and more standard electrophysiological markers of disease are 
somewhat limited and biased. The results used to represent standard MUP parameters, for 
example, were not obtained using the same protocol that would be used in the EMG 
clinic. Additionally, the DPN patient group studied throughout this thesis featured a more 
severe neuropathy, with a more drastic motor component, than what would be expected 
in patients in the very early stages of DPN
3,42,43
. Thus further study is warranted to better 
evaluate the novel electrodiagnostic parameters described herein to determine their 
potential diagnostic and prognostic utility. 
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7.2 Limitations  
Many of the conclusions throughout this thesis were made based upon results 
obtained using electrophysiological methods, particularly analysis of DQEMG. Some of 
these conclusions could have been better supported or confirmed had I included muscle 
biopsies in my studies. For example, the analysis of muscle biopsies could have: 
supported the idea of neuromuscular remodeling (via fibre type grouping)
44
; given insight 
into any shift of muscle fibre type predominance
19,20
; or provided greater understanding 
of muscle quality (via the assessment of single myofibre properties)
45,46
. However, the 
inclusion of muscle biopsies was not practical for these experiments. Moreover, the 
majority of my projects focused on the dorsiflexor muscle group, especially the TA, 
which is not considered a convenient muscle to biopsy compared with the knee extensors, 
for example. Obtaining and analyzing vastus laterali biopsies would provide a specious 
and spurious means for comparison with the TA, given the length-dependent nature of 
DPN, and the different properties and functions of these muscle groups. Additional 
methodologies that could have added further insight into these studies are magnetic 
resonance spectroscopy (MRS) or near-infrared spectroscopy (NIRS). The use of MRS or 
NIRS would have been particularly helpful in Chapter 6, the study of DPN and fatigue, as 
these might have elucidated the accumulation of metabolites
47
 (inorganic phosphate, H+ 
ions etc) and level of deoxygenation
48
 throughout the fatigue and recovery protocols. 
However, the inclusion of these techniques was not a practical or feasible addition with 
the design of these original studies.   
Habitual physical activity levels play important roles in muscle strength, muscle 
speed
49,50
, and perhaps the age-related rate of neuromuscular remodeling and motor unit 
loss
51,52
. The DPN patient and control groups discussed in this thesis were not matched 
for physical activity levels, nor was physical activity level quantified using 
questionnaires, accelerometers or some other method. This must be considered when 
interpreting any of the results presented herein. If the control group was substantially 
more physically active than the DPN group, this difference could conceivably contribute 
to some of the divergence between the groups with respect to their neuromuscular 
properties and health. However, if the DPN group was substantially less active than the 
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controls, one would likely expect to find faster evoked muscle twitch properties in the 
DPN group often reported in models of disuse
53,54
 (Chapter 5). Rather, the twitch 
responses of the DPN patients were significantly slower than the controls (Chapter 5). 
Furthermore, anecdotally, the majority of patients with DPN appeared to maintain 
relatively ‘average’ physical activity levels for their age. Finally, although the control 
group may have engaged in more physical activity on a day-to-day basis than the DPN 
group, they were not engaged in systematic physical training and their activity levels 
likely were not so high as to cause a notable effect on neuromuscular properties. 
Additionally, the mean participant ages were approximately 65 years old. The 
effects of natural adult aging on the neuromuscular system are thought to manifest 
detectably in most individuals in the 7
th
 decade of life
55
. Thus, the majority of those in the 
DPN group studied in this thesis would not only be expressing DPN-related changes but 
also age-related changes to the neuromuscular system. This may affect the 
generalizability of the results obtained in this thesis, as DPN may differentially affect 
humans as they age, versus how DPN may affect a group of homogenously young 
participants. Furthermore, both experimental groups included similar equal numbers of 
males and females. Although the two groups were sex matched, the inclusion of both 
sexes may have introduced greater heterogeneity into our dataset. Unfortunately due to 
challenges with subject accrual, an insufficient number of DPN patients of both sexes in 
these studies precludes an examination of any sex-based differences in the effects of DPN 
on the neuromuscular system.  
As mentioned earlier in this section, my conclusions regarding physiological 
mechanisms are generally derived from obligatory indirect measurements, including 
EMG, electrically evoked muscle properties, MRI, and dynamometry. In forming 
conclusions regarding DPN-related underlying changes to the neuromuscular system, 
such indirect measures are not necessarily ideal. However, although the specific 
mechanisms cannot be obtained with certainty using these techniques, this does not 
invalidate them or prevent their interpretation in the context of previous studies using 
animal models, reduced preparations or more invasive means in humans. Moreover, it 
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may emphasize the need for, and influence the direction of future studies which 
ultimately need to be explored in the human model. 
 
7.3 Future Directions  
There are a plethora of interesting and viable avenues for future research 
concerning the impacts of DPN on the neuromuscular system, the description of which 
will be necessarily somewhat limited in this section. Future studies may build upon my 
conclusion that DPN causes reduced motor unit firing rates and muscle slowing by 
recording maximal motor unit firing rates. This could be accomplished by recording 
motor unit firing rates intramuscularly using tungsten needle electrodes. Furthermore, 
tests of the force-velocity relationship, maximal contractile velocity and isotonic muscle 
power generation might greatly add to the understanding of DPN-related impacts on 
muscle function. This could be carried out using the isokinetic or, preferably, isotonic 
modes of a Cybex or Biodex multi-joint dynamometer. Additionally, such dynamic 
contractions used in the context of a fatigue protocol may allow for a better 
understanding of the limitations placed upon skeletal muscle affected by DPN. In 
conjunction with these measures, it would be helpful to include standard clinical 
measures of mobility or functional capacity, including sit-stand tests, shuttle walks, and 
tests of balance. Additionally, metrics, such as questionnaires, assessing physical activity 
history could provide useful information regarding the status of participants. Inclusion of 
such measures may help delineate the functional relevance of the various parameters 
tested in those with DPN in the neuromuscular laboratory.  
To help identify and quantify the presence of neuromuscular transmission failure 
it would interesting to apply single motor unit recordings during sustained and fatiguing 
contractions in DPN patients. Including this measure could provide a more robust 
indicator of intermittent transmission failure of individual motor units, which would be 
more persuasive than relying upon the analysis of surface EMG or post-contraction 
CMAPs alone. Furthermore, this technique may be used during sustained, ramped 
contractions providing insight into the recruitment and de-recruitment patterns of patients 
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with DPN compared to controls. Repetitive nerve stimulation could also be used to test 
for neuromuscular transmission failure at rest or during fatigue. 
Throughout this thesis, no limitations regarding voluntary activation during 
maximal efforts (including the fatigue protocol) were identified in controls or DPN 
patients. However, inclusion of transcranial magnetic stimulation (TMS) or 
cervicomedullary (CM) stimulation would provide further insight into any DPN-mediated 
changes at the supraspinal or spinal levels of excitability. Examining changes in the silent 
period following stimulation, or the amplitudes of motor evoked potentials (MEP) or 
cervicomedullary motor evoked potentials (CMEP) under various conditions would 
provide some insight into the influence of these important factors.  
Finally, a longitudinal study of patients with DPN, including the neuromuscular 
parameters outlined in this thesis, could provide greater insight into the progression of 
DPN-related neuromuscular dysfunction. Concurrent assessments of the sensory and 
autonomic nervous system also would be helpful in determining how neuropathy 
progresses in the different aspects of the nervous system. Perhaps most interestingly, a 
longitudinal study would provide an opportunity to assess the ameliorative, restorative or 
preventative effects of exercise training. Previous studies have investigated the effects of 
resistance and/or aerobic training on other aspects of DM or DPN: including glycemic 
control
56
, vascular function
57
, development of neuropathy
58
, autonomic dysfunction
59,60
 
and balance and gait
61
. However, the effects of training on neuromuscular impacts of 
DPN are less well understood, thus specifically it would be fascinating to assess how 
different training modalities and intensities affect the motor progression of DPN. In this 
context, to investigate how a resistance training regimen focused on training and 
restoring speed and power, in addition to strength, compares to a more traditional 
approach to exercise in DPN could be interesting. And finally, the potential 
neuroprotective effects of chronic exercise
51,52
 in DPN patients should be assessed.  
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7.4 Summary  
 
Diabetic polyneuropathy (DPN) may cause many impactful physiological and 
functional alterations to the human neuromuscular system. My thesis consists of an 
integrated collection of novel and foundational studies concerning DPN. Specifically, it 
provides support for the importance of the progressive and accelerated loss of motor units 
underlying muscle atrophy and weakness in patients with DPN (Chapters 2 and 3). 
Indeed the accelerated loss of motor units is associated with the development of 
intramuscular non-contractile tissue, the loss of contractile muscle mass, and the slowing 
of muscle contraction (Chapter 5). In addition to the loss of motor units, my thesis 
indicates there is a loss of fidelity or stability in those motor units that remain (Chapter 
4). This DPN-related neuromuscular instability may be associated with, and perhaps a 
precursor to, neuromuscular transmission failure during intense, sustained bouts of effort 
(Chapter 6). Overall these foundational explorations may help direct further useful 
studies and strategies to understand, and influence clinical support in those with DPN. 
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Appendix B  
 
 
 
 
 
 
Custom-built hand apparatus used to study neuromuscular properties of the first dorsal 
interosseus muscle. 
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magnetic resonance imaging techniques. In preparation for: Muscle and Nerve 
(Manuscript Preparation) 
 
1. Allen MD, Doherty TJ, Rice CL, Kimpinski K (2014) Physiology in Medicine: 
Neuromuscular consequences of diabetic neuropathy in humans. In preparation for: 
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Academic and Professional Experience: 
 
 
Teaching Assistantships 
 
KIN 2203Q: Kinesiology Canoe Activity Course (Fall 2007, 2008, 2009, 2012, 
2013) 
School of Kinesiology, The University of Western Ontario 
Duties: Assist in teaching canoe skills and leading week-long canoe trip in 
Northern Ontario with approximately 30 Kinesiology undergraduate students 
 
KIN 4430F/KIN 9430A: Exercise Physiology: Muscle Function and Metabolism     
(Fall 2011, 2013) 
School of Kinesiology, The University of Western Ontario 
Duties: Grading of assignments, providing teaching support after lectures and 
during office hours for undergraduate and graduate students 
 
KIN 2230B: Introductory Exercise Physiology (Winter 2008, 2009) 
School of Kinesiology, The University of Western Ontario 
Duties: Instructing and supervising exercise physiology lab sections for 
undergraduate students; grading exams 
 
 
Academic Presentations 
 
2. Allen MD (2014) Impacts of diabetic neuropathy on the human neuromuscular system. 
PhD Public Lecture. University of Western Ontario, July 28
th
, 2014, London, ON, 
Canada 
 
1. Allen MD (2014) Nerves, muscles, aging and exercise: Are you fitter than a 95 year 
old? Bioscience Seminar, School of Kinesiology, University of Western Ontario, March 
24
th
, 2014, London, ON, Canada 
 
Invited Academic Presentations 
4. Allen MD (2012) Motor unit loss, instability and remodeling in human diabetic 
neuropathy. McGill University, Department of Kinesiology and Physical Education, 
November 28
th
, 2012, Montreal, QC, Canada 
3. Allen MD (2012) Changes in properties of the neuromuscular system associated with 
coronary artery disease in humans. NERVE Research Team Annual Meeting 2012 (CIHR 
Team Grant #PAF-107514) November 21st, 2012, London, ON, Canada 
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2. Allen MD (2012) Effects of diabetes and exercise on motor nervous system 
dysfunction and changes in neuronal molecular processes in rodents. NERVE Research 
Team Annual Meeting 2012 (CIHR Team Grant #PAF-107514) November 20th, 2012, 
London, ON, Canada 
1. Allen MD (2011) Impacts of vascular disease and exercise interventions on the 
neuromuscular system in humans. NERVE Research Team Annual Meeting 2011 (CIHR 
Team Grant #PAF-107514) November 29th, 2011, London, ON, Canada 
 
Research Assistantships 
  
Canadian Comprehensive Pain Program research assistant (2010 – 2014) 
Toronto Western Hospital, University Health Network, Toronto, ON 
Supervisor: Dr. Angela Mailis-Gagnon 
Duties: Collected data through chart review; performed data analysis; assisted in 
writing of manuscripts 
 
Musculoskeletal Imaging Lab research assistant (2010 – 2011) 
Department of Medical Biophysics, University of Western Ontario, London, ON 
Supervisor: Dr. Gregory D. Marsh 
Duties: Analyzed MRI data; led writing of associated manuscripts 
 
Neuromuscular Physiology research assistant (Winter/Spring 2011) 
School of Kinesiology, University of Western Ontario, London, ON 
Supervisor: Dr. Charles L. Rice 
Duties: Assist senior PhD students in collecting data, led preparation and writing 
of manuscripts 
 
Clinical Neuromuscular Physiology research assistant (Summer 2008) 
Department of Clinical Neurological Sciences, London Health Sciences Centre, 
London, ON  
Supervisor: Dr. Timothy J. Doherty 
Duties: Troubleshoot malfunctioning equipment, recruit research participants, and 
collect data using electromyography and dynamometry techniques 
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External Research Consultations 
 
McGill University Muscle Aging Diagnostics Laboratory (Fall 2012 – Summer 
2013) 
 Primary Investigators: Dr. Russell Hepple and Dr. Tanja Taivassalo 
 Department of Kinesiology, McGill University, Montreal, QC 
Duties: Perform advanced electrophysiological techniques (DQEMG) on special 
populations (older adults and older world class athletes); assist in synthesizing 
results with other data, writing relevant manuscripts 
 
UWO Molecular Biology and Exercise Laboratory (Summer 2012) 
Primary Investigators: Dr. Kevin Shoemaker and Dr. Earl Noble 
School of Kinesiology, University of Western Ontario, London, ON 
Duties: Perform motor nerve conduction studies on rodents to assess the impact of 
diabetes and exercise on nerve health 
  
 UWO NeuroBehavioral Laboratory (Winter 2011 – 2012) 
 Primary Investigator: Dr. Matthew Heath 
 School of Kinesiology, University of Western Ontario, London, ON 
Duties: Assist electrical engineering graduate student (Ahmed Ali) in the 
development of a custom-designed electromyography system using MATLAB 
software and pre-amplified electrodes 
 
University Hospital – LHSC: Clinical Neuromuscular Physiology Laboratory 
(Winter 2011 – Spring 2012) 
 Primary Investigators: Dr. Tim Doherty and Dr. Tom Overend 
 School of Physical Therapy, University of Western Ontario, London, ON 
Duties: Instruct PhD candidate (Anuradha Sawant) in the application of clinical 
electrophysiological techniques and dynamometry in patients on dialysis 
 
 
Professional Service: 
 
Editor Positions  
 
Managing Editor (News Department): Canadian Health Sciences Inquiry, 2011 – 2013  
Duties: Led selection of News Department staff (~12 personnel); 
coordinated news article topic selection with Reporters; provided writing 
assistance and held ultimate editorial discretion on all news articles 
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Journal Peer Reviewer  
Muscle and Nerve, since 2010 (6 manuscripts to date) 
 
 Clinical Neurophysiology, since 2014 (1 manuscript to date) 
  
American Journal of Physical Medicine and Rehabilitation, since 2014 (1 
manuscript to date) 
 
Physiotherapy, since 2014 (1 manuscript to date) 
 
Physiotherapy Canada, since 2012 (1 manuscript to date) 
 
 
 
Elected Positions  
 
 Society of Graduate Studies Student Councillor (2008-2009, 2011-2012, 2012-
2013) 
Duties: Lead the interests of Kinesiology students to the SOGS University 
council and to discuss issues and aid in decision-making that affect 
graduate students across the University 
 
Graduate Teaching Assistant (GTA) Union Representative (2011-2012) 
Duties: Represent graduate student teaching assistants and address their 
concerns through their union (Public Service Alliance of Canada Local 
610) 
 
 
Committee Memberships 
 
Society of Graduate Studies Academic Committee (2008-2009, 2011-2012, 2012-2013) 
School of Graduate and Post-Doctoral Studies, University of Western 
Ontario 
Duties: Organized and helped run UWO’s annual multi-disciplinary 
research forum (Western Research Forum); led fundraising for the 
Western Research Forum (secured ScotiaBank as a sponsor) 
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Professional and Academic Society Memberships 
 
 Ontario Medical Association (OMA) 
  Student Member (2014 – present) 
 
 Canadian Medical Association (CMA) 
  Student Member (2014 – present) 
 
 Canadian Association of Physical Medicine & Rehabilitation (CAPM&R) 
  Student Member (2014 – present)  
 
 American Physiological Society (APS) 
  Student Member (2013 – present) 
 
 Society for Neuroscience (SfN) 
  Student Member (2013 – present) 
  
 Peripheral Nerve Society (PNS) 
  Trainee Member (2012 – 2014) 
  
 American College of Sports Medicine (ACSM) 
  Student Member (2011 – 2013)  
 
 Canadian Society of Exercise Physiology (CSEP) 
  Graduate Student Member (2011 – present)  
 
